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Spider venoms are a rich source of bioactive compounds with potential biotechnological 
applications. The overall aim of this project was to isolate and characterise novel spider-
venom peptides (SVPs) with potential in two key areas: (1) insect control using orally 
active insecticidal peptides; (2) improvement of human health with peptide modulators that 
target acid-sensing ion channels (ASICs).  
 
Insect pests are a worldwide problem as they threaten crop yields and spread a multitude 
of insect-borne diseases. Unfortunately, the armament of commercially available chemical 
insecticides is rapidly diminishing due to the emergence of insecticide-resistant insect 
strains as well as deregistrations and use restrictions by regulatory authorities due to 
environmental and health concerns. This has created an unmet need for new eco-friendly 
insecticides. Spiders are highly efficient insect predators that utilise venom to rapidly 
incapacitate prey. As such, many SVPs have potent insecticidal properties. However, as 
SVPs are injected by the spider, they are generally perceived to lack sufficient oral efficacy 
to be of practical agrochemical use. Recently, several orally-active insecticidal peptides 
(OAIP 1–5) were isolated from the venom of the Australian tarantula, Selenotypus 
plumipes, and shown to be lethal when fed to the termites. Chapter 2 describes the 
characterisation and structure determination of one of these peptides, OAIP3. The peptide 
was produced using an efficient E. coli periplasmic expression system that promotes 
disulfide bond formation in vivo. The insecticidal activity of the recombinant peptide was 
tested in mealworms, while the structure of the peptide was solved using heteronuclear 
nuclear magnetic resonance spectroscopy. Structural studies indicated that OAIP3 
contains a canonical inhibitor cystine knot motif commonly found in spider venom peptides. 
In comparison to its native form, recombinant OAIP3 is markedly less potent in 
mealworms, with ~53% moribund at a dose of 7.6 nmol/g. Sequence and structural 
homologies with other spider venom peptides indicated that OAIP3 is likely to target insect 
voltage-gated sodium channels.  
 
Spider venoms are a rich source of peptides that target therapeutically-relevant ion 
channels such as ASICs. Chapter 3 describes the isolation and characterisation of a novel 
ASIC1a modulator, Hm3a, isolated from spider venom. ASICs are proton-gated ion 
channels that respond to acidosis. Since their initial discovery more than a decade ago, 
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they have been implicated in many neurodegenerative diseases, neuronal damage 
resulting form ischemia, and pain. Given that spider venoms are a rich source of ion 
channel modulators, we screened a panel of 30 spider venoms for inhibitory activity on 
ASIC1a. Through an assay-guided fractionation using reverse-phase high performance 
liquid chromatography, we isolated a peptide modulator of ASIC1a from the venom of the 
tarantula Heteroscodra maculata. Recombinant peptide was produced and characterised 
using two-electrode voltage-clamp electrophysiology studies of ASICs expressed in 
Xenopus laevis oocytes. The peptide, named π-TRTX-Hm3a (Hm3a), is highly selective 
for ASIC1a over other ASIC subtypes. Hm3a is a close homolog of PcTx1, sharing similar 
electrophysiological effects on ASICs, but it proved to be more resistant to high 
temperatures as well as proteolytic degradation by human serum and cerebrospinal fluid. 
An engineered variant of Hm3a resulted in improved potency and efficacy on ASIC1a.  
 
Since the population of ASIC1a that is therapeutically relevant is located in the brain, an 
efficient method of administration is needed to deliver the peptide across the blood-brain 
barrier. Invasive methods are often required to deliver drugs into the brain. An alternative 
approach is intranasal administration that bypasses the blood-brain barrier and allows 
direct delivery to the brain via the olfactory bulb. Thus, we hypothesised that intranasal 
administration may also be an effective method for delivery of ASIC1a modulators into the 
CNS. As described in Chapter 4, several engineered variants of the prototypical ASIC1a 
modulator, PcTx1, were produced recombinantly or chemical synthesised. These peptides 
were then conjugated to moieties for PET, MRI and optical imaging in vivo. The addition of 
various imaging moieties at the N-terminal of PcTx1 had minimal effect on its activity on 
ASICs. A pharmacokinetics and biodistribution study of PcTx1 was performed using in vivo 
PET/CT imaging and traditional ex vivo tissue sampling after intravenous and intranasal 
administration. We show that brain delivery of PcTx1 in mice can be achieved through 
intranasal but not intravenous administration.  
 
In summary, the work presented in this thesis demonstrates that spider venoms provide a 
diverse library of peptides with potential biotechnological applications. In addition, we show 
that unconventional intranasal delivery is a plausible route for delivering peptide drugs to 
target sites in the CNS. 
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Literature Review: Biotechnological application of spider venoms 
1.1 Animal venoms in biotechnology  
Biotechnology, simply defined, is the manipulation of microorganisms or biological 
substances to develop or improve products for the benefit of human lives or the 
environment. Since early civilisation, humans have harnessed the biotechnological 
potential of animal venoms for varied and seemingly contradictory purposes. Indigenous 
people lace weapons with venoms or poisonous secretions from animals to improve the 
efficiency of their hunting. Conversely, animal venoms have been prescribed for millennia 
in traditional medicines to treat many diseases and ailments. Interestingly, the detailed 
study of animal venoms in the last century has identified many bioactive components that 
may indeed be beneficial for the treatment of pain and other ailments. My thesis covers the 
potential biotechnological potential of venoms with a focus on use of spider-venom 
peptides (SVPs) as bioinsecticides and pharmacological tools (with a view to therapeutic 
agent development). This thesis also addresses issues that may limit the use of SVPs for 
their intended purpose as well as potential solutions to overcome these limitations.  
 
1.2 Venom diversity and composition  
Over the course of evolution (Fig. 1.1), animals have developed venoms for predation, 
defence and competitor deterrence1. The ability to use venom is clearly advantageous, as 
indicated by the diverse range of animals that have independently developed venom 
systems. Venoms are typically injected directly into tissues through various apparatuses 
such as fangs, stingers and harpoons. Venoms contain a cocktail of biologically active 
compounds such as proteins (> 10 kDa), peptides (3−10 kDa), small organic molecules 
(< 1 kDa), and inorganic compounds2. The combination of advanced separation and 
sequencing technologies employed in proteomics and transcriptomics analyses have 
highlighted the complexity of these animal venoms3. Venom peptides have evolved to be 
target specific molecular targets with high levels of potency and selectivity4-5. The 
incredible pharmacological diversity, complexity and potency of animal venoms has led to 
an explosion of venomics-based research and discovery programs for biotechnological 
applications such as the development of bioinsecticides and therapeutic agents6-10.  
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1.3 Spider venoms as a source for novel peptides  
Based on their vast species diversity and the wide range of habitats in which they reside, 
spiders are the most successful group of venomous animals (Fig. 1.1) with highly complex 
venoms containing up to a thousand distinct peptides2, 11. The majority of SVPs are small 
(3–8 kDa) and contain disulfide-rich scaffolds that provide excellent chemical, thermal and 
proteolytic stability2, 11-12. The most common SVP structural scaffold is the inhibitor cystine 
knot (ICK) motif that is comprised of two antiparallel β-strands connected by a network of 
three disulfide bonds. Two of the disulfide bonds and the intervening sections of the 
peptide backbone form a ring while the third disulfide bond pierces the ring to form a 
pseudo-knot that stabilises the peptide structure13. Due to their relatively small molecular 
weight, potency and structural stability, spider venoms are a rich source of compounds 
with impressive biotechnological potential9-10.  
	
 
Figure 1.1: Evolutionary timeline of selected venomous animals (figure modified from Ref. 7). 
 
1.4 The need for new insecticides 
Food security is a major global issue as the world’s population is projected to reach nine 
billion by 205014. With rapid urbanisation and diminishing availability of arable land, it is 
important to increase crop yields to support the growing population14. Unfortunately, the 
effects of global warming have an immense negative influence on crop yields15, causing an 
increased occurrence of crop failures and global movement of insects from warm to what 
were previously cooler regions16-17. Although only a small minority of insects are 
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considered pests, it is estimated that herbivorous insects destroy one-fifth of the world’s 
total crop production annually18. 
 
The expansion of insects to colder regions has also led to increased reliance on 
insecticides and the escalating emergence of insecticide-resistant strains16, 19-20. Besides 
threatening our food security, insect pests also pose a significant risk to human health as 
they are highly mobile vectors of a variety of human and animal pathogens21-22. 
Mosquitoes cause more suffering than any other organisms as they transmit a variety of 
disease-causing parasites and viruses23. A classic example is Anopheles gambiae, the 
major vector of the malarial parasite Plasmodium falciparum. According to a 2015 World 
Health Organisation (WHO) report, there were an estimated 214 million cases of malaria in 
2015 leading to an estimated 438,000 deaths. The majority of the cases occurred in sub-
Saharan Africa with children under the age of 5 being the most susceptible (see WHO 
report at www.who.int/malaria/media/world-malaria-report-2015/en/). Tropical fevers such 
as dengue fever, Chikungunya and Zika fever caused by flaviviruses are transmitted by 
Aedes sp. mosquitoes23. The outbreak of Zika virus infection in Brazil was linked to a spike 
in cases of babies born with microcephaly and Guillain-Barre syndrome that affects the 
nervous system (see WHO report at www.who.int/emergencies/zika-
virus/articles/mosquito-control/en/). In the absence of effective antiviral therapies, vector 
control using chemical insecticides remains the most effective way to decrease disease 
transmission. Unfortunately, insecticide-resistant strains of mosquito have been identified 
in multiple countries, increasing the difficulty of pest control24-25. 
 
1.5 Problems with current insecticides 
Despite the increasing use of transgenic crops and other biological measures, chemical 
insecticides remain the primary method of insect pest control26. Prolonged and widespread 
use of insecticides has promoted the evolution of insecticide resistance, with more than 
600 arthropod species now resistant to one or more chemical insecticides10, 27 (Fig. 1.2). 
With selection pressure, it was shown that insecticide resistance could be acquired in as 
little as 22 generations with relatively few mutations in the gene to maintain the overall 
function and survivability28-29. Superficially, there appear to be a vast array of chemical 
insecticides but there are actually only five major insecticide targets: glutamate- and γ-
aminobutyric acid (GABA)-gated chloride channels, insect voltage-gated sodium (NaV) 
channels, nicotinic acetylcholine receptors (nAChRs), and acetylcholinesterase24, 30. 
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Insensitivity to pyrethroid or dichlorodiphenyltrichloroethane (DDT) is acquired by a single 
point mutation of leucine to phenylalanine (L1014F) in housefly (Musca domestica) NaV 
channels, resulting in 10–20-fold decrease in sensitivity. Resistance is further enhanced (> 
500-fold) by a methionine (Met) to threonine substitution (M918T) in insect NaV channels31. 
Similarly, an alanine to serine substitution (A302S) in the GABA receptor of the fruit fly 
Drosophila melanogaster confers resistance to cyclodienes32, while there are four point 
mutations in acetylcholinesterase (G265A, F330Y, G368A, and I1161V) associated with 
insensitivity to acetycholinesterase inhibitors. These latter mutations individually or in 
combination conferred varying degrees of resistance in fruit fly33.  
 
 
Figure 1.2: Total number of insecticide resistance cases grouped according to molecular target. The four 
main targets of insecticides are acetylcholinesterase (blue), GABA/glutamate-gated chloride channels (red), 
NaV channels (green), and nAChRs (purple) (figure from Ref.34). 
 
In addition to issues related to the development of insecticide resistance, there are safety 
and environmental concerns regarding the use of certain chemical insecticides. 
Acetylcholinesterase inhibitors such as organophosphates pose ecological and health 
risks due to high toxicity and poor species selectivity. Exposure to organophosphates has 
been shown to have adverse effects on reproduction, development and cancer onset35-37. 
Some insecticides such as organochlorines are persistent organic pollutants that resist 
degradation leading to detrimental environment effects and bioaccumulation38-39. Due to 
health, safety and environmental concerns, the USA Environmental Protection Agency 
(EPA) deregistered 169 chemical insecticides between the years 2006 to 2009, while only 
nine new insecticides were approved during this period10. 
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1.6 Natural products as bioinsecticides  
Due to the problems of chemical insecticides mentioned above, there is an urgent need to 
develop new, eco-friendly insecticides. In recent years, there has been a paradigm shift 
towards natural product-derived bioinsecticides as opposed to synthetic chemical 
insecticides. Pyrethrins, from which the synthetic pyrethroid insecticides are derived, are 
found in the seeds of Chrysanthemum cinerariaefolium; they are effective against many 
insects and have low toxicity in mammals40. Azadirachtin, a Neem-seed extract, can be 
used as an insect repellent, anti-feedant and growth regulator with low non-target effects41. 
Bacterial products such as spinosad and avermectin which target the insect nervous 
system are also commonly employed to control insect pest populations42-43. However, a 
major downside with some natural insecticides is their relatively low efficiency, often 
requiring several days and repeated applications. An alternative approach is the use of 
potent insecticidal proteins or peptides that can be produced recombinantly or engineered 
into plants or enthomopathogens. The best-known example of this approach is the use of 
pore-forming toxins secreted by the gram-positive soil bacterium, Bacillus thuringiensis 
(Bt)44. When ingested, the alkaline and proteolytic environment of an insect gut liberates 
the virulent factor from Bt toxins enabling it to bind to the gut epithelium. The binding 
causes pore formation leading to the eventual death of the insect from starvation and 
septicaemia45. However, increasing resistance towards Bt transgenic crops had been 
reported in 5 of 14 major pest species46. Moreover, Bt crops are resistant to a limited 
range of pests (primarily lepidopterans) as Bt is ineffective against sap-sucking pests such 
as aphids, which are a major agricultural pest47. Thus alternative sources of bioinsecticides 
are constantly being assessed, of which arthropod venoms show great promise. 
 
1.7 Venom peptides as bioinsecticides 
Arthropods such as spiders, scorpions and centipedes are master insect predators. Based 
on a conservative estimate from ArachnoServer (www.arachnoserver.org) approximately 
70% of SVPs are predicted to have insecticidal activity48. These peptides typically target 
the nervous system causing rapid incapacitation or paralysis, and they can be highly insect 
selective. Some peptides isolated from Australian funnel-web spiders are lethal to multiple 
insect genera (Coleoptera, Orthopetera, Lepidoptera and Diptera) but harmless when 
injected into mice49-51. Recently, a SVP was approved by the EPA for sale as a 
bioinsecticide in the United States (see www.vestaron.com/epa-approval/). Although 
  
	 	 Chapter One 		 	
7 
venoms are typically injected and not thought to be orally active, several SVPs isolated 
from an Australian tarantula were found to be insecticidal when fed to termites 
(Coptotermes acinaciformis), mealworm beetle (Tenebrio molitor) larvae and ticks 
(Amblyomma americanu), further highlighting the potential of SVPs as bioinsecticides52-53. 
 
1.8 Venom peptides as therapeutic leads 
Venomous animals have unintentionally become medicinal chemists. Their venoms 
contain numerous highly specific and potent peptides, many of which target vertebrate ion 
channels. The use of animal venoms as therapeutics is clearly evident in multiple 
traditional medicines across varied cultures. Many oriental medicines featured the use of 
animal venoms or poisonous secretions from bees or toads (Venenum Bufonis) for their 
touted pain relieving and anti-inflammatory properties54-55. Ayurveda (traditional Indian 
medicine) uses snake venoms to prolong life and treat arthritis and gastrointestinal 
problems7. The use of venoms in traditional medicines has been based on folklore and 
empirical observations rather than an understanding of the pharmacological basis of their 
effects. Recent advances in the molecular identification and functional understanding of 
ion channels and their roles in various diseases (channelopathies) has ignited interest in 
the discovery of ion channel modulators as research tools and potential therapeutic leads. 
This trend is exemplified by the increasing number of venom-derived drugs approved by 
the Food Drug Authority (FDA) and the many venom peptides currently in preclinical 
development and clinical trials (Table 1.1).  
 
The current suite of drugs on the market can be broadly grouped into two main 
categories—traditional “small molecule” drugs (< 500 Da) that are generally administered 
orally and “biologics” (> 5 kDa), which are typically injected56. Due to their small size, small 
molecule drugs have favourable pharmacokinetic properties, but often have poor target 
selectivity leading to undesirable side-effect profiles. In contrast, biologics are more 
selective but have low bioavailability, poor membrane permeability, and are metabolically 
unstable56. A third and growing class of drugs, peptides (5–50 amino acid residues), may 
address some of the shortcomings from both drug categories57. Peptide drugs can provide 
the selectivity and potency of biologics but with better bioavailability, lower immunogenicity 
and lower cost of production58. They can also be made to be more stable and orally 
available using specific chemical modifications58. Peptides have traditionally been 
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considered poor drug candidates due to their poor oral bioavailability. However, with 
recent advances in drug delivery, oral efficacy is often not a limiting factor for drug 
development and design59 and has led to a revival of interest in peptidic drugs in recent 
years. There are now more than 34 peptide-based drugs available and 24 in various 
phases of clinical trial60. In 2014 alone, 41 new molecular entities were approved by the 
FDA, of which one-tenth were peptide-based61. 
 
Table 1.1: Venom-derived compounds in clinical trials or approved by the FDA7, 62-64. 
Compound Status Source Molecular Target Indication 
Captopril Approved Arrowhead viper 
angiotensin-converting enzyme 
(ACE) inhibitor Hypertension 
Tirofban Approved Saw-scaled viper glycoprotein Iib/IIIa inhibitor Acute coronary syndrome 
Eptifibatide Approved Pygmy rattlesnake glycoprotein Iib/IIIa inhibitor Acute coronary syndrome 
Bivalirudin Approved Leech thrombin inhibitor Anticoagulant 
Ziconoitide Approved Cone snail 
inhibitor of voltage-gated 
calcium channel CaV2.2 Chronic pain 
Exenatide Approved Gila monster glucagon-like peptide-1 agonist Type 2 diabetes 
Batroxobin Approved Lancehead snake Fibrinogen protease Haemostatic agent 
Dalazatide Phase IIa Sea anemone 
Inhibitor of voltage-gated 
potassium channel KV1.3 Autoimmune diseases 
Cenderitide Phase II Green mamba natriuretic peptide receptor Chronic heart failure 
Tumour Paint 
(BLZ-100) Phase I 
Death stalker 
scorpion 
Chloride channels, matrix 
metalloprotease 2, annexin A2 Tumour imaging 
 
 
1.9 Acid-Sensing Ion Channels (ASICs) 
Acid-sensing ion channels are the primary acid sensors in mammals65. As acidosis is a 
key feature of many pathological conditions, ASICs are promising molecular targets for the 
treatment of various pathological conditions such as trauma, ischemia, tumours, pain and 
inflammation66. ASICs are proton-gated, cation-permeable (mainly Na+) ion channels that 
belong to the degenerin/epithelial sodium channel (DEG/EnaC) superfamily67. Six ASIC 
subtypes (ASIC1a/b, ASIC2a/b, ASIC3 and ASIC4) assemble as homotrimeric (ASIC1a/b, 
ASIC2a and ASIC3 only) or heterotrimeric channels that are widely distributed in both the 
central and peripheral nervous system68-70 (Table 1.2). The combination of various 
subunits in a trimeric channel affords different channel characteristics such as cation 
permeability, proton sensitivity, and activation/inactivation kinetics71-76. The first ASIC 
(ASIC2a) was cloned from human brain and named Brain Sodium (Na+) channel (BnaC1) 
as it was found to conduct Na+ ions77. It was also cloned separately by another group and 
named mammalian degenerin 1 (MDEG1) based on sequence similarity with the 
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C. elegans degenerin channel78. It was later found that these channels are proton-gated 
after the cloning of a homologous channel, ASIC1a (previously known as ASIC), with 67% 
similarity to ASIC2a79. Subsequently, several homologous, proton-gated, Na+-permeable 
channels and splice variants were cloned from brain and dorsal root ganglia of human, 
rodents and other high-order vertebrates. The group of channels were collectively 
renamed as acid-sensing ion channels (ASICs) (Table 1.2). ASIC1a is the most abundant 
ASIC subunit in the central nervous system of rodents and humans. Unlike other ASICs, 
ASIC1a is also slightly permeable to calcium (Ca2+) and protons (H+)74, 80. ASIC1a has 
been implicated in a variety of pathophysiological conditions such as inflammatory and 
neuropathic pain, psychiatric illness, multiple sclerosis, epileptic seizures, and ischemic 
stroke, and hence it is considered a promising therapeutic target66, 81. 
 
Table 1.2: Summary of ASIC subtypes71, 77-79, 82-87. 
Subtype Alias Gene pH  range Distribution 
ASIC 1a ASIC-α/ BnaC2 ACCN2 5.8–6.8 CNS, PNS1 
ASIC 1b ASIC-β ACCN2 6.1–6.2 PNS 
ASIC 2a BnaC1/ MDEG1 ACCN1 4.5–4.9 CNS, PNS 
ASIC 2b MDEG2 ACCN1 NA CNS, PNS 
ASIC 3 DRASIC ACCN3 6.4–6.6 PNS, Brain 
ASIC 4 SPASIC ACCN4 NA CNS, PNS 
1CNS = central nervous system. PNS = peripheral nervous system. 
 
1.10 Overall electrophysiological properties and structure of ASICs 
As their name suggests, ASICs are highly sensitive to acidic environments (i.e. acidosis) 
and are activated upon rapid protonation. Combinations of various ASIC subunits exhibit 
characteristic electrophysiological profiles and sensitivities to protons, allowing a wide 
dynamic range for sensing perturbations to pH (Fig. 1.3A). As proposed by Gründer and 
Pusch (2015), ASICs exist as three distinct conformational states. At physiological proton 
concentrations (~pH 7.4), they exist in the resting state, in which they do not conduct ions. 
The channels are activated upon protonation of the channel (pH50 for activation of ASIC1a 
is ~6.5), resulting in a conformational change from the resting state to an “open” state, 
allowing an influx of ions (mainly Na+) in the cell. Following activation (within 6–13 ms), the 
channels then promptly enter a desensitised state in which there is no further influx of ions 
despite the continuous presence of protons. ASICs can also become desensitised (a 
process known as steady-state desensitisation, SSD) without an apparent initial activation 
(pH50 for SSD of ASIC1a is ~7.2). During SSD, the probability of proton binding is low and 
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thus channel activation is disorganised (hence accounting for the lack of apparent channel 
activation in electrophysiology experiment). The slow recovery time for SSD (~70 s) 
means that most channels exist in the desensitised conformation (i.e. they do not conduct 
ions). Some ASICs modulators, such as the spider toxin PcTx1, binds preferentially to the 
desensitised state of ASIC1a, induces SSD at physiological pH (Fig. 1.3B)65. 
 
The structure of ASIC1 was first solved using a non-functional, truncated version of the 
chicken ASIC1 (cASIC1) channel69. A short time later, the structure of a functional, less 
truncated cASIC1 was obtained88. As both structures were obtained at low pH, it is 
presumed that these crystal structures represent the desensitised state of the channel69, 88. 
Overall, the two structures are highly similar and thus provide a definitive overview of ASIC 
structure. Three ASIC subunits combine to form a trimer with threefold symmetry; the 
channel has a large extracellular domain and a smaller transmembrane I domain 
comprised of two TM helices from each subunit69, 88. A dominant feature of the surface of 
the extracellular domain is an acidic pocket, defined by the high density and close 
proximity of acidic residues Arg191, Glu220, Asp238, Glu239, Glu243, Gln271, Asp346, 
Asp350 and Asp408. The acidic pocket is important for proton sensing and thereby gating 
of the channel (Fig. 1.3B). Specifically, the acidic pocket contains three pairs of negatively 
charged residues (Asp238–Asp350, Glu239–Asp346 and Glu220–Asp408) that form 
carboxyl-carboxylate interactions69, 88. The short distance between carboxyl-carboxylate 
pair suggested binding of protons at these sites69. This was verified using mutagenesis of 
residues at the proposed protonation sites (Asp238Ala and Glu239Ala), which resulted in a 
significant shift in the pH-dependence of activation of ASIC1a to higher proton 
concentrations (EC50 6.42 for wild-type compared to EC50 3.92 for the double mutant)89. 
Thus, the acidic pocket plays a vital role in pH sensing and is responsible for inducing the 
conformational changes which lead to activation of the channel90. Peptide modulators such 
as PcTx1 bind at the acidic pocket (Fig. 1.3B) of ASIC1a, thereby inducing SSD at 
physiological pH91-92. In contrast, some modulators such as MitTx preferentially bind to the 
open state, resulting in channel activation93. 
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Figure 1.3. Properties of ASICs. (A) Electrophysiological profiles of ASICs: shown are sodium currents 
following a drop in pH to pH 5.081. (B) Surface representation of cASIC1 channel. The acidic pocket is shown 
in red while one of the functionally critical residues for PcTx1 activity, Phe350, is highlighted in yellow.  
 
1.11 Modulation of ASICs 
The known modulators of ASICs can be broadly categorised as metal ions, small 
molecules, inflammatory mediators and venom peptides94. Although there are several 
small-molecule modulators of ASICs, none of them has the high specificity and potency of 
ASIC modulators that have been isolated from animal venoms94. 
 
Divalent and trivalent ions (including but not limited to zinc, calcium and gadolinium) are 
able to modulate channel activity. Zinc inhibits homomeric ASIC1a and heteromeric 
ASIC1a/2a at nanomolar concentrations95. However, at higher (micromolar) 
concentrations, it potentiates ASIC1a/2a currents95. Calcium inhibits ASIC3 but has a dual 
effect on ASIC1a96-97. potentiating the channel at low concentration but inhibiting the 
channel at high concentration96. Gadolinium inhibits homomeric ASIC2a with an IC50 of ~ 
1 mM and heteromeric ASIC2a/3 with IC50 ~ 40 µM76. 
 
There are several small molecule drugs that inhibit ASICs. Amiloride, a commonly used 
diuretic drug, non-specifically inhibits all ASICs as well as members of the EnaC/DEG 
superfamily and Na+/H+ and Na+/Ca2+ exchangers with an IC50 ranging from 10 to 50 µM79. 
Recent pilot studies revealed that treatment with amiloride reduced aura and headache 
symptoms in four of seven patients with otherwise intractable migraine98. A-317567 is a 
novel small molecule that is more potent and selective for ASICs as compared to 
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amiloride99. Animal studies indicated that A-317567 is useful for reducing post-operative 
and chronic inflammatory pain99. Non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen, diclofenac, salicylic acid and aspirin are also non-selective inhibitors of ASIC1a 
and ASIC3 (IC50 90–250 µM)100. An NSAID-derived small molecule, CHF5074 was shown 
to inhibit acid-evoked ASIC currents in hippocampal pyramidal neurons (IC50 ~50 nM) and 
demonstrated neuroprotection against in vitro ischemia-induced cell death101. The small 
molecule 2-guanidine-4-methylquinazoline (GMQ) was found to induce sustained 
activation of ASIC3 (EC50 ~ 0.06–3.34 mM) dependent on the dose as well as proton and 
Ca2+ concentrations102. 
 
In addition, there are many endogenous modulators that are known to potentiate (increase 
or enhance current amplitude or duration) or increase pH sensitivity. These modulators 
include neuropeptides such as dynorphins and Phe-Met-Arg-Phe (FMRF) amide; 
polyamines such as spermine and agamatine; inflammatory mediators such as arachidonic 
acid (AA), lactate and nitric oxide (NO); neurotransmitters such as serotonin; and 
adenosine triphosphate66. 
 
To date, the most potent and selective ASIC modulators have been isolated from animal 
venoms (Table 1.3). Psalmotoxin 1 (PcTx1 or π-theraphotoxin-Pc1a) was the first 
described venom peptide modulator of ASICs. It was isolated from the venom of the South 
American tarantula Psalmopoeus cambridgei103. PcTx1 consists of 40 amino acid residues 
with six cysteines, and it forms an ICK fold104. It is the most potent and specific inhibitor of 
homomeric ASIC1a and heteromeric ASIC1a/2b (IC50 of ~ 0.7 and 2.6 nM, respectively) 
and it has become an indispensible pharmacological tool for the study of ASIC1a 
function94, 103, 105. PcTx1 increases the apparent affinity of ASIC1a to protons and stabilises 
ASIC1a in its desensitised state, preventing acid-induced currents at physiological pH106-
107. Subsequently, it was found that PcTx1 also binds to ASIC1b, however, it appears to 
stabilise ASIC1b in its open state instead, thereby producing a potentiating or agonistic 
effect (albeit only at high concentrations) as opposed to its inhibitory effect on ASIC1a107. 
Studies of the interaction of PcTx1 on chimeric channels indicated that PcTx1 binds to the 
thumb and palm domains of ASIC1a in the region of the acidic pocket108; this suggestion 
was supported by several docking studies104, 109) and finally confirmed upon co-
crystallisation of truncated cASIC1 and PcTx191-92. Molecular dynamics and mutagenesis 
studies based on the co-crystal structure further refined our knowledge on the interaction 
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of PcTx1 with ASIC1a by identifying all the peptide residues that are important for 
functional activity110. 
 
APETx2 is a 42-residue peptide isolated from the sea anemone Anthopleura elegantissima 
that inhibits homomeric ASIC3 with an IC50 of 63 nM as well as the heteromeric ASIC3-
containing channels ASIC2b/3, ASIC1b/3 and ASIC1a/3 with an IC50 of 117 nM, 0.9 µM, 
2 µM, respectively 111. At higher concentrations, APETx2 has also been shown to inhibit 
non-ASIC channels including NaV channels and the voltage-gated potassium (KV) channel 
KV11.1 (also known as hERG)112-114. 
 
Several other sea anemone toxins have been reported to inhibit ASICs. These include 
Ugr-9-1 (π-AnmTxUgr 9a-1) from Urticina grebelnyi, which inhibits ASIC3 with an IC50 of 
~10 µM115, and PhcrTx1 from Phymanthus crucifer which partially inhibits native ASIC 
currents in sensory neurons (IC50 ~100 nM). At micromolar concentrations, PhcrTx1 also 
inhibits KV channels116.  
 
Mambalgins are a family of homologous three-finger toxins (57-residue peptides) isolated 
from venom of black mamba (Dendroaspis polylepis) and green mamba (Dendroaspis 
angusticeps) snakes117-118 They have similar pharmacological profiles, inhibiting both 
ASIC1a and ASIC1b-containing channels with IC50 values ranging from 11 to 252 nM117. 
As such, mambalgins inhibit a greater proportion of native ASIC currents (~60% inhibition) 
in rodent central neurons than PcTx1 (~40% inhibition)117. Mambalgins also appear to bind 
near the acidic pocket of ASIC1a119-120; however, unlike PcTx1, they decrease the 
apparent affinity for protons, thereby inducing a shift in the pH-dependence activation of 
ASIC1a to lower pH, making the channel more resistant to acidosis117. 
 
MitTx is a heterodimeric peptide complex isolated from the venom of the Texas coral 
snake (Micrurus tener tener)93. It strongly activate ASICs, particularly ASIC1a, ASIC1b and 
ASIC3 with EC50 values of ~9, 23 and 830 nM, respectively. Co-crystallisation of MitTx 
with cASIC1a revealed that it binds mostly to the thumb domain (overlapping with the 
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Table 1.3: Summary of ASIC modulators isolated from animal venoms122 
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1.12 ASICs as analgesic target  
Pain, as defined by the International Association for the Study of Pain (IASP), is “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage”. Under normal conditions, pain acts as a 
warning signal for the bearer; however, its functionality is lost if it becomes a chronic 
occurrence (> 3 months) and it can be detrimental to one’s health both physically and 
psychologically. The IASP reported that one-fifth of the world’s population suffers from 
chronic pain. It was estimated that the total economic cost of chronic pain in the USA in 
2008 was about USD $600 billion, more than the combined economic cost of cancer, heart 
disease and diabetes123. Pain-related disabilities remain a problem as current painkillers 
are often inadequate in providing sufficient pain relief and/or have undesirable dose-
limiting side-effects that limit their usage124. 
 
Pain is initiated following a noxious stimulus at nociceptors located at the peripheral 
terminal of primary afferent sensory neurons125. Ion channels and receptors located at the 
nerve terminal are temporarily activated, allowing an influx of ions into the cell which 
causes membrane depolarisation and generation of small receptor potentials125. 
Amplification of these receptor potentials by downstream channels (e.g. by voltage-gated 
sodium (NaV) channels) leads to action potentials that are transmitted along the afferent 
nerve fibres, via their cell bodies in the dorsal root ganglion (DRG), to the spinal cord 
where they synapse with ascending secondary sensory neurons that transmit the signal to 
the brain where it is perceived as pain125. As depicted in Fig. 1.4, there are a variety of ion 
channels and receptors located at the peripheral terminal of nociceptors and along the 
nerve axon. They respond to different stimuli such as noxious temperature, mechanical 
trauma, changes in pH, and chemicals. ASICs are highly expressed along the nociceptive 
pathway (including the nociceptors, DRG, spinal cord neurons and many brain regions) 
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and are involved in nociception and pain processing (Fig. 1.4), responding specifically to 
acidosis and causing acidosis-related pain126-127. 
 
 
Figure 1.4. Schematic of the pain signalling pathway in humans. Noxious stimuli activate peripheral 
nociceptors, which leads to action potentials that are conveyed via the DRG to the spinal cord. These signals 
are then transmitted to the brain via ascending secondary sensory neurons. The intensity and duration of the 
nociceptive input can then be modulated by descending modulation from the brain. The peripheral terminals 
of nociceptors contain a variety of receptors and ion channels that respond to a wide range of noxious 
stimuli, as indicated in the inset at left. 
 
Several early studies indicated that ASICs may be the major sensors of acid-induced pain 
in humans. Administration of non-selective ASIC inhibitors such as amiloride and NSAIDs 
(diclofenac and ibuprofen) attenuated pain induced by the application of acidic solutions in 
healthy human volunteers128-129. A more recent clinical study showed that the non-
selective ASIC inhibitor amiloride was able to mitigate migraine pain in patients with an 
intractable form of the condition98. The analgesic potential of ASIC inhibition has been 
better studied in animal models using more selective peptide modulators from animal 
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venoms. Analgesic effects were observed following introduction of PcTx1 into the CNS for 
both acute and neuropathic pain models as a result of ASIC1a inhibition and downstream 
effects mediated by the endogenous enkephalin pathway130. It was shown that 
upregulation of ASIC1a in rat spinal dorsal horn neurons contributed to inflammatory pain 
hypersensitivity and spinal neuron sensitisation131. Thermal and mechanical pain 
sensitivity was attenuated with either intrathecal administration of PcTx1 or genetic 
suppression of ASIC1a in a rat FCA (Freud’s complete adjuvant)-induced inflammatory 
pain model131. Mambalgin-1 produces antinociceptive effects when injected centrally 
(intrathecal) or peripherally (intraplantar) in mouse models of both thermal and 
inflammatory pain117. Inhibition of ASIC3 by in vivo knockdown using siRNA or APETx2 
induces potent analgesic effects against acute inflammatory hyperalgesia132. ASIC3 is also 
the main sensor for cardiac pain. Cardiac afferents produce large acid-evoked currents in 
response to extracellular acidification (pH 7.1 to pH 6.7) that match those of ASIC3127. 
Conversely, activation of ASIC1a, ASIC1b or ASIC3 via intraplantar injection of MitTx or 
GMQ elicited robust pain responses in mice93, 102. The effects were significantly reduced 
by disruption of ASIC1a, ASIC1b or ASIC393, 102.  
 
1.13 ASIC modulation for neuroprotection   
ASICs play a significant role in the excitotoxicity of neuronal cells following ischemia. 
Reduction in blood supply causes localised hypoxia and the subsequent conversion from 
aerobic to anaerobic metabolism. This results in accumulation of hydrogen ions (H+) and 
other acidic metabolites (e.g. lactate) causing acidosis and subsequent activation and 
potentiation of ASICs. The consequent overexcitation of the cell (culminating in 
intracellular Ca2+overload), initiates a cascade of downstream cytotoxic events and 
eventual cell death (i.e. excitotoxicity)133-134. Notably, inhibition of ASIC1a has been shown 
to afford neuroprotection in ischemic stroke, retinal ischemia, and traumatic spinal cord 
injury.  
 
Stroke is the second leading cause of mortality worldwide, claiming more than 6.2 million 
lives annually. It is also the leading cause of permanent disability in many developed 
countries such as Australia and the USA135-136. In the USA, there are an estimated 
700,000 cases of ischemic stroke each year, costing more than USD $70 billion to 
society137. Stroke is broadly categorised as ischemic or haemorrhagic137. Ischemic stroke 
occurs following an occlusion of blood supply to the brain while hemorrhagic stroke is 
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characterised by intracranial bleeding (e.g. from ruptured blood vessels)137. Ischemic 
stroke is by far the most prevalent type of stroke, accounting for ~87% of total stroke 
incidence in USA138. It was estimated that ~2 million neurons are lost with every minute of 
artery occlusion during ischemic stroke, equivalent to the amount of neuronal loss over 26 
years of normal ageing137. The only approved treatment for ischemic stroke involves rapid 
reperfusion of the affected area through surgical procedures (e.g. thrombectomy) or 
enzymatic thrombolysis137. Despite medical intervention for ischemic stroke, the mortality 
rate (~42%) and long-term disability remain high due to the narrow therapeutic window (3–
4.5 hours depending on patient eligibility) and potentially adverse side-effects (e.g. 
intracranial haemorrhage) with the use of thrombolytic agents such as tissue plasminogen 
activator (tPA)139-140. The limitations of current treatments has sparked immense interest in 
the development of better stroke therapeutics.  
 
Severe acidosis is observed following ischemic stroke with the pH in the ischemic core 
(brain tissue at the occlusion) and penumbral regions (brain tissues surrounding the 
occlusion) falling to as low as ~6, which is sufficient to robustly activate ASIC1a141. 
Multiple studies have shown that inhibition of ASIC1a through genetic knockout or acute 
pharmacological intervention (administration of “PcTX1 venom”, pure PcTx1 peptide or 
amiloride) after an occlusion of the cerebral artery (to simulate an ischemic stroke), 
reduced the infarct volume by ~60% in rodent models134, 141-142. Moreover, neurological 
assessments indicated that the administration of PcTx1 after ischemic stroke significantly 
reduces motor deficits in rats, indicating preservation of neurons and functionality142. 
 
Inhibition of ASIC1a results in a similar neuroprotective effect in retinal ganglion cells 
under ischemic stress. Retinal ischemia is a common cause of blindness arising from 
underlying retinal diseases such as glaucoma, diabetic retinopathy, and hypertensive 
vascular disease143. It was shown that ASIC1a is expressed in retinal ganglion cells 
(RGCs) and is important for retinal activity144. Retinal ganglion cells are highly sensitive to 
hypoxia; the loss of RGCs from hypoxic stress is the common etiology from these 
diseases leading to blindness143, 145. Treatment with amiloride or PcTx1 after hypoxic 
stress increased the survival rates of cultured RGCs compared to non-treated RGCs145.  
 
In addition to deleterious effects of low pH during stroke and retinal ischemia, acidosis 
plays a significant role in the severity of secondary injury following a traumatic spinal cord 
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injury (SCI)146. Multiple studies have suggested that the onset of secondary injury is 
mediated by events such as ischemia and inflammation after the initial trauma. This results 
in the production of inflammatory mediators (e.g. lactate and nitric oxide) which leads to 
the subsequent, enhanced activation of ASICs and cell death141. Elevated expression of 
ASIC1a, ASIC1a-mediated currents and Ca2+ influx in spinal neurons was observed in a 
rat model of thoracic spinal cord injury146. Importantly, genetic ablation or pharmacological 
inhibition of ASIC1a in this model resulted in reduced tissue damage and also promoted 
the recovery of neurological function after a traumatic spinal cord injury146. Thus, ASIC1a 
appears to be a promising target for neuroprotection of CNS and retinal neurons following 
ischemia. 
 
1.14 Targeting ASICs for the treatment of neurological diseases 
Currently, it is estimated that 48.4 million people worldwide are living with dementia, with 
an estimated economic burden of USD $818 billion147. The increasing life expectancy of 
the population is predicted to double this cost every 20 years, leading to an estimated cost 
of USD $2 trillion in 2030147. ASICs have been implicated in several neurological diseases 
such as Huntington’s disease148, Parkinson’s disease149, multiple sclerosis (MS)150 and 
spinocerebellar ataxia 1151 which can lead to the onset of dementia. Besides tissue 
acidosis, these diseases cause the release of chemicals such as lactate and 
neurotransmitters that can lead to enhanced activation of ASICs148. In many of these 
conditions, elevated expression of ASIC1a and acid-evoked currents are observed. MS is 
a chronic neuroinflammatory disease associated with axonal degradation and spinal cord 
acidosis150. Increased expression of ASIC1a was observed in MS lesions and genetic 
ablation of ASIC1a or pharmacological blockade of ASIC1a with amiloride or PcTx1 
attenuated axonal degradation, demyelination and reduced the clinical severity in mouse 
models of MS150, 152. Huntington’s disease and Parkinson’s disease are neurodegenerative 
diseases that currently have no cure. Patients with Huntington’s disease and Parkinson’s 
disease displayed elevated levels of lactate in their brains indicating tissue acidosis153. 
Parkinson’s disease is characterised by motor impairment and a loss of dopaminergic 
neurons which have also been shown to express ASIC1a154. The use of amiloride, 
benzamil and PcTx1 provided neuroprotection in mouse models of Huntington’s and 
Parkinson’s diseases148-149.  
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ASIC1a is highly expressed the amygdala, a region of the brain important for emotional 
behaviour such as anxiety and fear155. Characterisation of ASIC1a knockout mice revealed 
that expression of ASIC1a may be important for learning, synaptic plasticity and fear 
conditioning155-156. Overexpression of ASIC1a led to an increase in fear conditioning in 
animal studies157. Conversely, in preclinical studies, genetic ablation or pharmacological 
inhibition of ASIC1a produced antidepressant-like and anxiolytic-like effects158-159. Finally, 
inhibition of ASIC1a with amiloride or PcTx1 was found to reduce seizures and neuronal 
injury in an in vivo model of epilepsy160-161. Hence, ASICs may be novel molecular targets 
for antidepressants, antiepileptic drugs, and anxiolytics. 
 
1.15 ASICs as molecular target for cancer therapeutics 
Cancer is the leading cause of death worldwide with 8.2 million deaths and 14.1 million 
new cases identified in 2012 alone162. The microenvironment of solid tumours is often 
acidic as a result of poor vascularisation and high tumour cell metabolic rate, leading to 
hypoxia and lactate accumulation. This acidic environment has a strong influence on the 
progression, invasion, metastasis and responses of tumours to chemotherapy and 
radiation therapy163. The expression and activation of ASIC1a has been associated with 
disease progression in several cancer types. Glioblastoma multiforme (i.e. glioblastoma or 
grade IV astrocytoma) is the most common and aggressive form of adult brain cancer for 
which there is currently no cure164. Despite invasive treatment with resection surgery, 
radiotherapy and chemotherapy, the median prognosis for patient survival is 8.8–14.6 
months164. It was found that Glioblastoma multiforme display a constitutively active Na+ 
conductance due to a heteromeric ion channel consisting of ASIC1a, αENaC and γENaC 
subunits165-166. This Na+ current is not observed in normal astrocytes or low-grade 
gliomas165-167. Inhibition of the current by amiloride or PcTx1 was found to regulate cell 
migration and cell cycle progression thus implicating the ASIC1a subunit in glioma 
pathogenesis168-169.  
 
In addition to their involvement in cell migration and growth of gliomas, ASICs may also 
contribute to breast cancer tumorigenesis. Gupta and colleagues (2015) showed that 
several human breast cancer-derived cell lines had increased production of reactive 
oxygen species (ROS) when the cells were incubated at pH 6.5 as opposed to pH 7.4. 
This effect was significantly reduced in cells treated with amiloride or PcTx1 and in ASIC1a 
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knockdowns. Moreover, in vivo experiments in a mouse model of breast cancer revealed a 
reduction in acidosis-induced cell invasion, tumour growth and metastasis following 
ASIC1a inhibition170. Breast cancer is the most commonly diagnosed cancer and it is the 
leading cause of cancer death among women, accounting for 25% and 15% of all cancer 
cases and deaths, respectively162. Hence, ASIC1a appears to be a novel therapeutic 
target to reduce breast cancer tumorigenesis.  
 
1.16 Hurdle of CNS drug delivery — the blood-brain barrier 
Multiple studies have highlighted ASICs as promising therapeutic targets, in particular the 
neuroprotective effects of ASIC1a antagonists observed in rodent models of CNS diseases 
such as ischemic stroke and multiple sclerosis. Given that venom peptides (e.g. PcTx1) 
are currently the most potent and selective ASIC modulators known, there is immense 
interest in these ASICs ligands for drug development. An important consideration for drug 
development is the method of delivery. Oral administration is the easiest and therefore the 
most common method for drug delivery. However, the relatively high molecular weight of 
peptides, their polar chemical characteristics, and pre-systemic enzymatic degradation 
severely limits their oral bioavailability171. Therefore, peptide/protein drugs (e.g. insulin) are 
typically administered via parenteral routes. Drug delivery via parenteral routes often 
involves injection (e.g. intravenous, intramuscular or subcutaneous) which is painful, 
difficult to administer, and carries a risk of infection and more severe side-effects171. 
 
Additionally, the delivery of ASIC ligands to their intended site-of-action is a major hurdle 
for CNS diseases. Systemic delivery of therapeutics to the CNS is often challenging due to 
the blood–barrier barrier (BBB) which prevents the entry of >98% of small molecules and 
almost all large molecules172-173. Molecules that are small (< 600 Da), polar and lipophilic 
may be able to cross the BBB through passive transport (diffusion) across the tight 
junctions or endothelial cells. The movement of larger molecules are largely mediated 
through transport systems such as carrier-mediated transport, receptor-mediated transport 
or absorptive-mediated transport to cross the BBB (Fig. 1.5). However, in order to attain 
an effective drug concentration in the CNS, a substantially larger drug dose may be 
required, increasing the risk of systemic toxicity. Given the size and physicochemical 
properties of SVPs such as PcTx1, it is unlikely that such peptides would be able to cross 
the blood-brain barrier. Indeed, no brain uptake was observed following intravenous (IV) 
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administration of bovine serum albumin (66 kDa), demorphin (802 Da), chlorotoxin (4 kDa) 
or McoTI-II (3.3 kDa)174. Hence, an efficient method of drug delivery to the CNS is required 
to access the required site-of-action. 
 
 
Figure 1.5. Schematic of the BBB endothelium which separates the brain from circulating blood. The BBB 
endothelial cells are joined by tight junctions which restricts the flow of most molecules into the brain. The 
main transport pathways are shown. A small amount of water-soluble agents may cross the tight junctions 
through the paracellular aqueous pathway. The lipid membrane surfaces may provide a transcellular 
lipophilic pathway for the transport of lipid-soluble molecules. Molecules such as glucose, amino acids and 
nucleosides are transported across the BBB via their associated transport proteins. Other molecules such as 
insulin and transferrin are transported via specific receptor-mediated transcytosis. Cationization of plasma 
proteins such as albumin may enhance brain uptake through adsorptive transcytosis. (Figure from Ref.175). 
 
The BBB is a unique microvasculature system which segregates the interstitial fluid in the 
CNS (brain and spinal cord) from the circulating blood173. It consists of a single layer of 
endothelial cells sealed by intercellular tight junctions (TJs). BBB endothelial cells differ 
morphologically from their peripheral counterparts by a lack of fenestrations, and they 
have extremely low rates of transcytosis. Movement of molecules across the BBB is tightly 
regulated in order to maintain the homeostasis of the microenvironment and functioning of 
cells in the CNS176. Compromised BBB integrity can result in increased BBB permeability, 
leading to increased extravasation of immune cells and unregulated influx/efflux of 
molecules across the BBB. Disruption of BBB integrity is a common phenomenon in many 
neurological diseases such as stroke, MS, Alzheimer’s disease (AD), epilepsy, and 
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traumatic brain injuries, and this may therefore allow entry of therapeutics into the CNS. 
However, it remains uncertain if the disruption is a contributing causative effect or the 
resultant effect in some of these diseases176-177. In the case of ischemic stroke, BBB 
disruption occurs in a biphasic manner. The generation of excessive reactive oxygen 
species due to oxidative stress from ischemia and reperfusion leads to the first phase of 
BBB disruption. Subsequently, the compromised BBB allows infiltration of immune cells 
(e.g. neutrophils) which leads to the second phase of BBB disruption176. Despite 
observations of BBB disruption in many neurological diseases, delivery to the CNS 
remains a bottleneck for the development of CNS-targeted therapeutics. For example, in 
the case of ischemic stroke, opening of the BBB does not occur until around 10–12 h post 
stroke, and it would seem highly beneficial to be able to deliver a neuroprotective 
therapeutic to the CNS as early as possible. Thus, alternative routes for CNS drug delivery 
are needed.  
 
1.17 Methods to overcome the blood brain barrier  
Current methods of delivering drugs to the brain include invasive methods such as 
intracerebroventricular (ICV), intraparenchymal, intracerebral and intrathecal injections178. 
However, these delivery methods require high levels of technical expertise and carry the 
risk of infections and further tissue trauma and hence they are not practical for repeated 
dosing172. Moreover, the effectiveness of both routes is limited by the penetration and 
diffusion properties of the drug away from the injection site172. The use of convection 
enhanced diffusion (CED) may increase the diffusion zone by maintaining a pressure 
gradient during interstitial infusion of the drug, thereby generating flow through the brain179. 
 
Other methods of CNS drug delivery through the BBB are currently being investigated. 
BBB disruption methods (Table 1.4) are associated with side-effects such as severe 
vasculopathy, chronic neuropathologic changes, seizures and leakage of plasma proteins 
(e.g. albumin)177. Translocation of pharmaceutics through the BBB may also be achieved 
through receptor-mediated or absorptive-mediated transcytosis (Fig. 1.5) by coupling 
drugs with molecular ligands that act as a Trojan horse180.  
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Table 1.4. Summary of blood-brain barrier disruption strategies. 
BBB Disruption strategy Methodology 
Osmotic 
Use of hyperosmotic solution (e.g. mannitol) to induce shrinkage of 
cerebrovascular endothelial cells, disrupting the tight junctions.  
Biochemical 
Use of vasoactive compounds (e.g. bradykinin) to selectively 
increase permeability in brain capillaries in diseased tissue to 
enhance uptake. 
Ultrasound-mediated Use of ultrasonic waves for site-focused BBB disruption. 
 
1.18 Intransasal administration as alternative for CNS drug delivery  
Intranasal (IN) administration may provide a non-invasive route for CNS drug delivery that 
effectively bypasses the BBB. The feasibility of IN administration of peptides and proteins 
for CNS delivery has been assessed in multiple preclinical and clinical studies with 
promising results181. The pioneering study by Born and colleagues showed that IN 
administration of melanocortin (980 Da), arginine-vasopressin (1.1 kDa) and insulin 
(5.8 kDa) led to their detection in cerebrospinal fluid (CSF), but not blood plasma, 30 min 
after administration182. IN administration of iodine-125 radiolabeled insulin (125I-insulin) and 
insulin-like growth factor 1 (125I-IGF-I) (7.65 kDa) yielded high levels of radioactivity in the 
trigeminal nerve branches, trigeminal ganglion, pons, and olfactory bulbs in rodents183-184. 
Even larger proteins have been successfully delivered to the CNS via the IN route. 
Interferon-β1B (18.5 kDa), assessed as a treatment for MS in rodent and primate models, 
exhibited CNS uptake following IN administration as tracked via 125I-labelling185-186. 
Furthermore, IN administration of erythropoietin (34 kDa) was shown to protect the brain 
against stroke in animal models187-189. Notably, ICV and IN (but not intravenous) 
administration of P. cambridgei venom (from which PcTx1 was isolated) provided 
neuroprotection in rodent stroke models141.  
 
A search of active and completed clinical trials involving IN administration of drugs 
identified 751 studies of which 108 have been concluded with results (see 
https://clinicaltrials.gov). Some of these trials involve the study of the central effects of 
peptides such as insulin and oxytocin. Insulin acts as a neuromodulator important for 
cortical activity. Thus, IN administration was explored for direct CNS administration to 
minimise systemic exposure190. IN administration of insulin elicited beneficial central 
effects in patients with Alzheimer’s and Type 2 diabetes with minimal systemic side 
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effects191,190. Similarly, IN administration of the neuropeptide oxytocin (1 kDa) resulted in 
enhanced multiple positive “pro-social” behaviours192, 193: McRae-Clark, 2013 #265. 
 
1.19 Mechanisms of CNS delivery via IN administration  
Numerous studies on animals and humans have shown that IN administration provides a 
non-invasive method of bypassing the BBB to deliver peptide-based therapeutics to the 
CNS194. The nasal cavity extends from the nostrils to the nasopharynx, and can be broadly 
divided into the vestibule, respiratory and olfactory epithelium (Fig. 1.6A). The regular 
turnover of cells may facilitate the uptake of IN-administered molecules across the nasal 
epithelium, enabling access to the neuronal pathways located at the respiratory or 
olfactory epithelium (Fig. 1.6B) for transport to the CNS178.  
 
 
Figure 1.6. Anatomy of the human nasal cavity. (A) Sagittal section of the nasal cavity highlighting the 
vestibular (green), respiratory (red) and olfactory (blue) epithelial regions. (B) Lateral view showing 
innervations of the olfactory bulb (yellow) and trigeminal nerves (blue and green) in the nasal cavity. Figures 
adapted from http://teachmeanatomy.info/head/organs/the-nose/nasal-cavity/. 
 
There are several possible pathways for drug delivery to the CNS following IN 
administration as shown in Fig. 1.7. Following deposition in the nasal cavity, the drugs first 
cross the nasal epithelium to access the olfactory and trigeminal nerve pathways which 
extends to the olfactory bulb or brainstem. Transport of the drug along these nerve 
pathways to the brain may be achieved through intracellular transport mechanisms such 
as endocytosis or axonal transport. However, given that the vast majority of studies 
reported rapid delivery (within minutes to hour) of molecules in the brain, intracellular 
transport is unlikely to be the main mode of transport. Instead, the extracellular channels 
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such as the lymphatic, perivascular or perineural spaces associated with the nerve 
pathways is more likely to be the predominant mode of transport for molecules to the 
brain, following intranasal administration180, 194.  
 
    
Figure 1.7. A schematic of the pathways to CNS following intranasal administration. Figure of mouse brain 
obtained from http://www.clker.com/clipart-354921.html. 
 
The olfactory neuronal pathway is thought to be the major route involved in IN delivery to 
the CNS195. The olfactory epithelium is interspersed with olfactory sensory neurons 
(OSNs) with dendrites exposed at the mucosal surface extending through the cribriform 
plate and terminating at the olfactory bulb. The OSNs are enveloped by olfactory 
ensheathing cells (OECs) that creates fluid-filled, perineural channels along the olfactory 
nerve pathway. Molecules can travel along these channels via extracellular bulk flow 
mechanisms to reach the CNS rapidly181. As the OSNs are first-order neurons (i.e. no 
synapses), intracellular transport of molecules may also occur following endocytosis of the 
administered molecule181. 
 
The trigeminal pathway is another potential route to the CNS following IN delivery183, 185. 
Both the respiratory and olfactory epithelium are innervated with fibres from trigeminal 
nerves (mandibular and ophthalmic), with free nerve endings located near the surface. The 
trigeminal nerves run along the caudal and rostral regions of the brain, terminating in the 
brainstem. Biodistribution studies of IN administered radiolabelled proteins recorded 
radioactivity along the trigeminal nerves, trigeminal ganglion, medulla pons (part of the 
brainstem) and cerebellum, thereby indicating the plausibility of the trigeminal nerve 
delivery pathway183, 185.  
 
In summary, IN administration is a promising method for delivery of venom peptides, which 
are typically 3–5 kDa in size. Given the therapeutic potential of spider venom peptides, 
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exploration of different administrations routes for their administration and understanding of 
their in vivo pharmacokinetics and biodistribution will aid in the future development of 




Aims of PHD project 
 
Overall aim 
Spider venom peptides have immense biotechnological potential in both the agrichemical 
and therapeutic fields. Thus, the overall aim of this project is to isolate, characterise and 
develop SVPs with potential for biotechnological applications in two key areas: (1) insect 
control using orally active insecticidal peptides; (2) improvement of human health using 
peptides that target acid-sensing ion channels as therapeutic leads. 
 
Specific aims 
1. Characterisation of an Orally Active Insecticidal Peptide (OAIP3) isolated from the 
Australian featherleg tarantula, Selenotypus plumipes 
2. Isolation and pharmacological characterisation of a novel ASIC1a modulator from 
the venom of the tarantula Heteroscodra maculata 
3. Elucidation of the biodistribution and pharmacokinetics of PcTx1 following different 
routes of administration (IV and IN) using positron emission tomography (PET) and 
computed tomography (CT).  
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Functional and structural characterisation of an Orally Active 
Insecticidal Peptide 3 (OAIP3) isolated from the venom of the Australian 
featherleg tarantula, Selenotypus plumipes 
 
2.1 Introduction 
Insects are the largest and most widely distributed group of terrestrial animals. While only 
a small group of insects are considered pests, they are responsible for significant crop 
damage, economic losses, and human mortality10. Herbivorous insect pests reduce crop 
yields by 10–20% and damage ~20% of stored grains annually18, 196. They are also vectors 
for a multitude of human and animal pathogens — mosquitoes alone causes more than 
one million deaths worldwide each year23. Despite biological control measures such as the 
use of transgenic crops, chemical insecticides remained the dominant method for control 
of insect pests197. Unfortunately, the available arsenal of chemical insecticides is rapidly 
diminishing due to the increasing number of resistant insect strains resulting from long-
term use of chemical insecticides, as well deregistration of insecticides by regulatory 
authorities due to concerns about their detrimental effects on human health and the 
environment10. Together, these mounting problems have invigorated the search for novel 
and safer insecticidal compounds.  
 
Natural products are an excellent source of insecticidal compounds198. The success of 
transgenic crops expressing Bt toxins (orally active δ-endotoxins from Bacillus 
thuriengiensis) for insect pest control44 has fuelled interest in the discovery and 
development of insecticidal proteins (or peptides) as bioinsecticides. Spiders, being master 
insect predators, are an obvious starting point for such a search. Equipped with highly 
efficient venoms, they are able to achieve rapid incapacitation of prey through 
envenomation10. Spider venoms are a complex cocktail of small molecules, peptides and 
proteins. Spider-venom peptides are of particular interest as many are potently insecticidal 
and resilient to degradation51,12. Based on a “phyletic specificity” search on ArachnoServer 
(www.arachnoserver.org)48, more than 63% (234 of 368 identified toxins) are targeted 
towards insects. Interestingly, despite the lack of evolutionary drive (since venoms are 
typically injected), some spider venom peptides are also orally efficacious 53, 199. 
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A recently filed patent reported the discovery of several orally active insecticidal peptides 
(OAIPs 1-5) isolated from the venom of the Australian featherleg tarantula, Selenotypus 
plumipes200. The venom of S. plumipes was found to be potent on crickets (Acheta 
domesticus) and mealworms (larvae of Tenebrio molitor)  with LD50 values of ~69 and 
2 µg/g respectively201. The venom was fractionated using reversed-phase high-
performance liquid chromatography (RP-HPLC) and individual fractions were fed to 
termites to identify insecticidal components that are orally active199. This led to the isolation 
of five OAIPs. The potency, and more importantly, oral insecticidal activity in termites, has 
evoked strong commercial interest in these peptides as bioinsecticides. 
 
OAIP1 is the most potent orally active insecticidal peptide described in the literature to 
date, with an LD50 value of 104 pmol/g in the economically important cotton bollworm 
Helicoverpa armigera52. It was produced using solid-phase peptide synthesis (SPPS) as 
previous attempts at recombinant production were unsuccessful199. However, large-scale 
production of peptides by SPPS for commercial use (e.g. field spraying) is impractical 
given the quantity needed. 
 
OAIP3 was isolated from the same venom as OAIP1. It has a reported efficacy of 100% 
mortality in mealworms when injected at a dose of 3 nmol/g and ~50% mortality in termites 
when fed at 350 nmol/g199. A recombinant expression strategy was chosen for production 
of OAIP3. As there is low sequence homology between OAIP1 and OAIP3 (implying there 
may be significant structural differences), we used multidimensional heteronuclear nuclear 
magnetic resonance (NMR) spectroscopy for structural determination. The recombinant 
peptide was also tested in mealworms for functional studies.  
 
This chapter describes the recombinant production, insecticidal activity and solution 
structure of OAIP3. The functional and structural information obtained from this study may 
aid in the future development of peptide-based bioinsecticides as well as engineering of 
peptide drugs with oral efficacy and bioavailability. 
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2.2 Materials and Methods 
2.2.1 Bacterial transformation, recombinant expression and purification of OAIP3 
The gene sequence for OAIP3 was obtained by reverse translation of the peptide 
sequence, with optimisation of codons for E. coli expression. Gene construction and 
subcloning of the synthetic gene into the pLICC expression vector was performed by 
GENEARTTM (ThermoFisher Scientific, USA). The plasmid was transformed into 
competent E. coli BL21 (λDE3) by heat shock at 42oC then plated onto lysogeny broth (LB) 
agar containing 100 µg/mL ampicillin (Astral Scientific, Australia) for positive selection. The 
transformed colonies were expanded in LB media containing 100 µg/mL ampicillin (unless 
otherwise stated, all LB media were supplemented with 100 µg/mL ampicillin) until the 
OD600 reached ~2; the cell culture was then mixed 1:1 in 60% sterilised glycerol and stored 
at –80oC as glycerol stocks.   
 
Production of recombinant OAIP3 was based on a published protocol for recombinant 
production of disulfide-rich peptides202. Briefly, cultures were grown in LB media incubated 
at 37oC with constant agitation at 180 rpm until the OD600 reached ~1. For production of 
isotopically 13C/15N-labeled OAIP3, the culture was first incubated in 2 L LB media until the 
OD600 reached ~0.6, then cells were harvested by centrifugation at 3000 g for 15 min at 
4oC. The cell pellet was gently resuspended in 500 mL of minimal medium (22 mM 
KH2PO4, 90 mM Na2HPO4, 17 mM NaCl. 1.6 mM MgSO4. 80 nM CaCl2) supplemented 
with 13C6-D-glucose (22 mM) and 15NH4Cl (18 nM) (as the sole carbon and nitrogen 
sources, respectively), 0.5 mg thiamine and 0.002% vitamins (1.1 mg biotin, 1.1 mg folic 
acid, 110 mg para-aminobenzoic acid, 110 mg riboflavin, 220 mg pantothenic acid, 220 mg 
pyridoxine HCl, 220 mg thiamine HCl, 220 mg niacinamide in 50% ethanol/water). The 
culture was further incubated for 2 h at 37oC. Protein expression was induced with 0.5 mM 
isopropy-β-D-thiogalactopyranoside (IPTG) and the culture allowed to grow overnight at 
20oC.  
 
Cells were harvested the following day by centrifugation at 6000 g for 15 min at 4oC, then 
the cell pellet was resuspended in Equilibration Buffer (EB: 20 mM Tris, 200 mM NaCl, 
pH 8). The cells were then mechanically lysed using continuous flow cell disruption with a 
TS Series Constant Systems Cell Disruptor (Constant Systems Ltd, UK) at 28 kpsi. DNase 
(~1 µg/mL) was added to reduce the viscosity of the cell lysate. The soluble cell fraction 
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was then obtained by centrifuging the cell lysate at 16000 g for 20 min at 4oC. The His6-
containing fusion protein was captured on Ni-NTA Superflow resin (Qiagen, Germany) 
loaded into a gravitational flow column. Non-specifically bound components were removed 
with Wash Buffer (EB containing 10 mM imidazole) and then the fusion protein was eluted 
with Elution Buffer (EB containing 250 mM imidazole). The fusion protein was 
concentrated using a 30 kDa cut-off spin filter (Merck Millipore, USA), then diluted to 
10 mL with EB containing 3 mM reduced glutathione (GSH) and 0.3 mM oxidised 
glutathione (GSSG). Approximately 200 µg of tobacco etch virus (TEV) protease was 
added for each litre of bacterial culture purified. The cleavage reaction was allowed to 
proceed overnight at room temperature with gentle rocking.  
 
The cleavage mixture was acidified with 1% trifluoroacetic acid (TFA) then centrifuged at 
16000 g for 20 min at 4oC and filtered through a 0.22 µm syringe-driven polyvinylidene 
fluoride (PVDF) membrane filter. The liberated recombinant peptide was purified using RP-
HPLC on a Phenomenex C4 column (250 mm x 4.6 mm x 10 µm, 300 Å) at a flow rate of 
5 mL/min using a gradient of 15–45% Solvent B (0.043% TFA in 90% acetonitrile) in 
solvent A (0.05% TFA in water) over 30 min (gradient of 1% Solvent B/min). A secondary 
purification was performed using a XB-C18 column (Phenomenex Kinetex, 250 x 4.6 mm x 
5 µm, 100 Å). The purity and mass of the final product was verified using analytical RP-
HPLC and mass spectrometry. 
 
2.2.2 Structure determination  
Isotopically-labeled OAIP3 was reconstituted to a final concentration of 300 µM in 30 mM 
MES buffer, pH 6, constituted in 5% D2O. The sample was filtered using a Costar® Spin-
X® Centrifuge Tube Filters (0.22 µm pore size; Corning, USA), then 300 µL was added to 
a susceptibility-matched 5 mm outer diameter microtube (Shigemi Inc., PA, USA). NMR 
spectra were collected at 25˚C on a 900 MHz NMR spectrometer (Bruker BioSpin, 
Germany) equipped with a cryogenically‐cooled triple resonance probe. Spectra collection, 
editing and data processing were performed by Dr Mehdi Mobli (CAI, The University of 
Queensland). 
 
3D and 4D spectra used for resonance assignments were acquired using non-uniform 
sampling. Sampling schedules that approximated the signal decay in each indirect 
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dimension were generated using sched3d203. Non-uniform sampling data were processed 
using the Rowland NMR toolkit (www.rowland.org/rnmrtk/toolkit.html) and maximum 
entropy parameters were automatically selected as previously described.13C- and 15N-
edited HSQC-NOESY spectra (mixing time of 200 ms) were acquired using uniform 
sampling. Separate 13C-edited HSQC-NOESY spectra were acquired for the aliphatic and 
aromatic regions of the carbon spectrum. 
 
Dihedral angles were derived from TALOS+ chemical shift analysis204 and the restraint 
range for structure calculations was set to twice the estimated standard deviation. NOESY 
spectra were manually peak picked and integrated, peak lists were then automatically 
assigned, distance restraints extracted, and an ensemble of structures calculated using 
the torsion angle dynamics package with CYANA 3.0205. The tolerances used for CYANA 
were 0.02 ppm in the direct 1H dimension, 0.04 ppm in the indirect 1H dimension, and 
0.4 ppm for the heteronucleus (13C/15N). During the automated NOESY 
assignment/structure calculation process, CYANA assigned 92% of all NOESY peaks 
(1447 of 1566). The disulfide bonds were assigned on the basis of preliminary structure 
calculations; subsequent calculations included distance restraints for these disulfide bonds 
as described previously206.  
 
2.2.3 Insecticidal assay  
Mealworms were purchased from Pisces Enterprises (Kenmore, QLD, Australia). Insects 
between 3rd and 4th instar (mass 162–168 mg) were used. For each mealworm, 2.6 µL of 
toxin diluted in ultrapure water was injected into the metathoracic pleurite. Injections were 
performed using a 29.5 gauge insulin syringe (B–D Ultra-Fine, Terumo Medical 
Corporation, Elkton, MD) needle fitted to an Arnold hand micro-applicator (Burkard 
Manufacturing Co. Ltd., England). Three replicates of five insects were used for each toxin 
concentration. After injection, the mealworms were housed in petri dishes and maintained 
with wet chicken feed. Effects were monitored over 48 h. Mealworms that did not respond 
to gentle provocation were considered moribund (dead or paralysed); this assay was 
performed by Dr Volker Herzig (IMB, The University of Queensland). Means and standard 
deviations were calculated using Graphpad Prism 6.0 (La Jolla, USA).  
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2.2.4 Mass spectrometry 
Peptide masses were determined using matrix-assisted laser desorption/ionisation time-of-
flight (MALDI-TOF) mass spectrometry (MS) on a 4700 Proteomics Bioanalyser (Applied 
Biosystems, Carlsbad, CA, USA). Fractions were spotted 1:1  (v/v) with α-cyano-4 
hydroxycinnamic acid (CHCA) matrix (7 mg/mL in 50% acetonitrile/water, 0.1% formic 
acid). All masses reported are for monoisotopic [M+H]+ ions, using positive reflector mode, 
or average mass using linear mode. 
 
2.3 Results  
2.3.1 Recombinant expression of OAIP3  
Recombinant OAIP3 was produced using an E. coli periplasmic expression system 
optimised for production and purification of disulfide-rich venom peptides202. The IPTG-
inducible plasmid encodes a MalE signal sequence for translocation of the fusion protein 
from the cytoplasm to the periplasm, an N-terminal His6 tag for purification using nickel 
affinity chromatography, followed by a maltose-binding protein (MBP) fusion tag to 
enhance solubility of the expressed protein, a TEV protease recognition site for liberation 
of fusion tags, and finally the OAIP3 peptide sequence  (Fig. 2.1A). The recombinant 
OAIP3 sequence contains a non-native N-terminal glycine residue as the N-terminal 
residue of native OAIP3 is glutamic acid, a non-favoured residue for the P' position of the 
TEV protease recognition site207. The cystine pairings in OAIP3 determined using NMR 
(see below) matched the ICK framework commonly seen in SVPs (Fig. 2.1B).  
 
The expression and purification of OAIP3 is illustrated in Fig. 2.1C; comparison of lanes 2 
and 3 in Fig. 2.1C reveals overexpression of the His6-MBP-OAIP3 fusion protein after 
IPTG induction. The fusion protein is highly soluble as most of the His6-MBP-OAIP3 fusion 
protein was found in the soluble fraction following cell lysis (compare lanes 4 and 5 in Fig. 
2.1C). None of the His6-MBP-OAIP3 fusion was lost during application of the soluble cell 
fraction to a Ni-NTA column (Fig. 2.1C, lane 6) or during a subsequent wash step with 5 
mM imidazole (Fig. 2.1C, lane 7). A large amount of His6-MBP-OAIP3 fusion protein was 
eluted from the column with 300 mM imidazole (Fig. 2.1C, lane 8). Most of the fusion 
protein could be successfully cleaved with TEV protease to liberate free OAIP3 (compare 
lanes 9 and 10 in Fig. 2.1C). The OAIP3 liberated by TEV protease cleavage of the fusion 
protein was purified via RP-HPLC to obtain a single major peak (Fig. 2.1D). The purity 
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(>95%) of the peak collected was verified on analytical RP-HPLC (Fig. 2.1D, inset showing 
chromatogram). The asterisk in Fig. 2.1D denotes the peak with mass corresponding to 
the theoretical mass of OAIP3 (Fig 2.1D inset showing MS spectrum).  
 
Figure 2.1. Expression and purification of recombinant OAIP3. (A) Schematic of the plasmid vector used for 
OAIP3 expression in E. coli. Important elements of the vector are shown (not to scale), including the 
ribosome binding site (RBS) and promoter and operator regions. (B) Amino acid sequence of recombinant 
OAIP3; lines above the sequence indicate disulfide bonds as determined from NMR analysis. (C) SDS-
PAGE gel showing various stages in the expression and purification of recombinant OAIP3. The lanes (from 
left to right) are as follows: (1) molecular weight markers; (2) whole-cell extract before IPTG induction; (3) 
whole-cell extract after IPTG induction; (4) insoluble fraction after lysis of induced cells; (5) soluble fraction 
after lysis of induced cells; (6) flow-through from loading of soluble cell fraction onto Ni-NTA column; (7) 
eluate from wash of Ni-NTA column with 15 mM imidazole; (8) eluate from wash of Ni-NTA column with 250 
mM imidazole; (9) eluted MBP-OAIP3 fusion protein prior to TEV protease cleavage; (10) MBP-OAIP3 fusion 
protein sample after TEV protease cleavage. (D) Chromatograms showing RP-HPLC purification of 
recombinant OAIP3. Asterisk denotes peak with mass corresponding to OAIP3 (3686.5 Da), as indicated by 
the mass spectrum shown in the inset. 
 
Using the periplasmic expression system, a substantial quantity of recombinant OAIP3 
was successfully produced which enabled characterisation of the peptide. The fusion 
protein was the major cellular product formed following IPTG induction, indicated by the 
single major protein band observed at ~43 kDa (Fig. 2.1C, compare lanes 2 and 3). The 
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majority of the fusion protein was found in the soluble fraction of the crude cell lysate 
(Fig. 2.1C, compare lanes 4 and 5). The His6 tag allowed efficient purification of the fusion 
protein using nickel affinity chromatography, with minimal loss (Fig. 2.1C, lanes 6 and 7). 
Elution with 250 mM imidazole resulted in release of fusion protein from the Ni-NTA resin 
(Fig. 2.1C, lane 8) which was further concentrated with a 30 kDa molecular weight filter 
(Fig. 2.1C, lane 9). Liberation of OAIP3 from the fusion protein with TEV protease was 
~90% efficient (Fig. 2.1C, lane 10). Both RP-HPLC and mass spectrometry confirmed the 
production of recombinant OAIP3 which eluted as a major peak in the RP-HPLC 
chromatogram with a mass that matched the theoretical oxidised mass of OAIP3 
(Fig. 2.1D). The same approach was successfully employed to produce uniformly 13C/15N-
labelled OAIP3 for NMR structure determination. Using this system, approximately 0.5 mg 
of pure recombinant peptide was obtained per litre of culture. 
 
2.3.2  NMR structure determination  
The structural integrity of recombinant 15N-labelled OAIP3 was examined by acquiring a 
2D 1H-15N heteronuclear single quantum coherence (HSQC) spectrum (Fig. 2.2). Spectra 
were acquired at 25˚C on a Bruker 900 MHz spectrometer. The NMR spectrum revealed 
the expected number of backbone 1H-15N connectivities as well as peaks for the sidechain 
amide groups of the two Trp residues (boxed and labelled “W-SC” in Fig. 2.2), sidechain 
1H-15N connectivities for the single Asn residue (connected by a dashed line and labelled 
“N-SC” in Fig. 2.2) and a single (folded) peak for the sidechain amide group of the Arg 
residue (labelled “R-SC” in Fig. 2.2). The excellent chemical shift dispersion in both the 1H 
and 15N frequency dimensions is characteristic of a protein with a stable tertiary fold.  
 
The structure of OAIP3 was determined using heteronuclear NMR spectroscopy with 
13C/15N-labelled peptide. 1HN, 15N, 13Cα, 13Cβ, and 13C′ resonance assignments were 
obtained from analysis of amide-proton strips in 3D HNCACB, CBCA(CO)NH, and HNCO 
spectra. Sidechains assignments were based on 4D HCC(CO)NH-TOCSY, 3D 15N-HSQC 
NOESY and 3D 13C-HSQC NOESY spectra, with sidechain 1H and 13C chemical shifts 
obtained primarily from 3D H(CC)(CO)NH-TOCSY and (H)CC(CO)NH-TOCSY spectra, 
respectively. 1H–1H distances were determined from signal intensities in 3D NOESY 
spectra. A long-range HNCO experiment was acquired to identify hydrogen bonds. All 
spectra were analysed using XEasy208. Backbone φ and Ψ dihedral angle restraints were 
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generated from analysis of chemical shifts using TALOS+204. These dihedral-angle 
restraints were used in conjunction with interproton distance restraints derived from 
NOESY spectra, hydrogen-bond restraints from the HNCO experiment, and disulfide-bond 
restraints for structural calculations using CYANA 3.0205.  
 
Three hundred structures were calculated from random starting conformations, then the 20 
conformers with highest stereochemical quality as judged by MolProbity209 were selected 
to represent the solution structure of OAIP3 (Fig 2.3A). The structural ensemble has very 
high stereochemical quality as indicated with MolProbity209, with very few steric clashes 
(as indicated by the low clashscore: 8.7 ± 2.1%), low percentage of Ramachandran 
outliers (5.0 ± 1.4%), and a low percentage of unfavorable sidechain rotamers (16.4 ± 
4.2%) (Table 2.1). The final ensemble of 20 structures is precisely defined with RMSDs for 
the backbone and heavy atoms of 0.56 Å and 1.05 Å, respectively, over residues 2–33. 
The average MolProbity score of 3.09 places the ensemble in the 89th percentile (100th 
being the best) of structures in the MolProbity database (Table 2.1).   
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Figure 2.2. 2D 1H-15N HSQC spectrum of OAIP3 acquired at 900 MHz. Peaks are labelled according to the 
residue number of OAIP3. 
 
The structure comprises three disulfide bonds that form a classical inhibitor cystine knot 
(ICK) motif in which the Cys2–Cys17 and Cys10–Cys22 disulfide bonds and the 
intervening sections of polypeptide backbone forms a ring that is bisected by the Cys17–
Cys30 disulfide bond (Fig. 2.3B, left). The structure comprises two antiparallel β-strands 
formed by residues 23–26 and 29–32. Eight hydrophobic residues are clustered on one 
face of the molecule to form a hydrophobic patch while four cationic residues are arranged 





  G ECGGLMTRCDGKTTFCCSGMNCSPTWKWCVYAP 
34 residues 
G = 5 
P = 2 
R = 1 
N/Q = 1 
W = 2  
=> 31 BB NH 
=> 5 SC NH 
  
	 	 Chapter Two 		 	
39 
 
Figure 2.3. NMR solution structure of OAIP3. (A) Stereoview of the ensemble of 20 OAIP3 structures. The 
N- and C-termini are labelled, β-strands are shown in yellow, and disulfide bonds are magenta. (B). Left: 
Ribbon representation of OAIP3 structure. β-Strands are shown in yellow and disulfide bonds are magenta. 
Right: Molecular surface of rOAIP3. Hydrophobic, anionic, and cationic residues are shown in grey, red, and 
blue respectively. 
 
2.3.3 Sequence and structural homologs of OAIP3 
A BLAST search of the OAIP3 sequence against the ArachnoServer database identified 
several SVPs with high sequence similarity (Fig. 2.4). OAIP3 is 72% identical to U1-TRTX-
Cg1d, a spider toxin identified through analysis of a venom-gland transcriptome from the 
Chinese fawn tarantula Chilobrachys guangxiensis210. However, there is no activity 
information available for U1-TRTX-Cg1d. Given the high level of sequence identity it can 
be predicted that U1-TRTX-Cg1d is likely to be insecticidal. The next closest match with 
known activity is ω-TRTX-Asp2a, an inhibitor of CaV channels in rat cerebellar granule 
cells, isolated from the tarantula Aphonopelma sp.211. OAIP3 is 41% identical to U2-TRTX-
Hs1a and U2-TRTX-Hs1b, two homologous SVPs from the Chinese bird spider 
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Table 2.1. Statistics for the OAIP3 structure. 
 
 
A search for structural homologs of OAIP3 using the online DALI server 
(http://ekhidna.biocenter.helsinki.fi/dali/)213 revealed a remarkable 47 structural matches 
with a statistically significant z score > 2. The best six matches are as shown in Fig. 2.5; 
five of these are NaV channel modulators isolated from spider venoms. The closest 
matches were µ-TRTX-Hs2a, a potent inhibitor of neuronal tetrodotoxin (TTX)-sensitive 
NaV channels, and NaV channel targeting peptides isolated from Agelenopsis aperta 
(Western grass spider) and Haplopelma hainanum (Chinese Black Earth Tiger tarantula). 
Interestingly, there is a good overlay between the OAIP3 structure and the pharmacophore 
region of µ-TRTX-Hs2a214. The structural similarities between OAIP3 and several NaV 
toxins suggest that the molecular target of OAIP3 is likely to be insect NaV channels. 
Interestingly, it is also structurally similar to M-TRTX-Gr1a, isolated from Grammostola 
rosea (Chilean rose tarantula). M-TRTX-Gr1a was initially identified as a blocker of 
mechanosensitive ion channels 215, but more recently it has been shown to also inhibit NaV 
channels216. 
  




Figure 2.4. Sequence alignment of OAIP3 with orthologs from other spider venoms 
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Figure 2.5. Structural homologs of OAIP3. Alignment of the structure of OAIP3 (green) with the top six 
structural homologs (pink) as ranked by the Dali server213. The molecular target of each structural homolog is 
indicated, as is the Z score and RMSD of the alignment. Disulfide bonds are shown as solid tubes (red) and 
the N- and C-termini are labelled.  
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2.3.4  Insecticidal activity of recombinant OAIP3  
The insecticidal activity of native OAIPs was previously assessed using mealworms and 
termites199.100% mortality was observed for OAIP1 and OAIP3 while OAIP2 caused ~25% 
mortality and OAIP4 ~50% mortality when injected into mealworms199. All OAIPs, except 
OAIP2, were less potent when fed to termites. Initial testing of native OAIP3 yielded potent 
insecticidal activity when it was injected in mealworms, with 100% mortality at a dose of 
~3 pmol/g, and when fed to termites with >70% mortality at a dose of ~350 pmol/g (Fig. 
2.6A). 
 
When injected at a dose of 0.4 nmol/g, recombinant OAIP3 caused ~26% of mealworms 
to become moribund after 48 h, but this was not a significantly higher level than seen in 
controls (Fig. 2.6B). The number of affected insects increased to ~53% at a dose of 7.6 
nmol/g (Fig. 2.6B), but this is still significantly lower activity than observed for the native 
peptide. The reduced potency observed for recombinant OAIP3 suggests that the C-
terminal amidation present in the native peptide is crucial for activity and/or addition of a 
non-native glycine residue at the N-terminus of the recombinant peptide deleteriously 
affects peptide activity. Future structure-activity relationship studies will be required to 
ascertain the reasons for the reduced potency of the recombinant OAIP3. 
 
 
Figure 2.6. Insecticidal activity of OAIPs in mealworms and termites. (A) Activity of native OAIP 1-5 when 
injected into mealworms (3 pmol/g) and when fed to termites (350 pmol/g). Data from Ref. 199. (B) 
Percentage of moribund mealworms (dead or paralysed) 48 h after injection of recombinant OAIP3 (n = 5, in 
triplicates, mean ± SD) (one-way ANOVA, p = 0.2187, n.s.). Assays were performed by Dr Volker Herzig 
(IMB, University of Queensland). 
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2.4 Discussion 
2.4.1 Production of recombinant OAIP3 
Detailed structure-function characterisation of peptides requires a substantial quantity of 
material, especially for structure determination using NMR. Thus, I used an efficient E. coli 
periplasmic expression system for production of recombinant OAIP3, and used this system 
to produce isotopically-labelled peptide for determination of its solution structure using 
NMR spectroscopy. Functional characterisation was also carried out to determine the 
potency of the recombinant peptide. 
 
The presence of multiple disulfide bonds in SVPs is often challenging for SPPS and 
recombinant peptide production. Peptide synthesis requires technical expertise and 
specialised equipment as it involves potentially dangerous chemicals such as TFA or 
hydrofluoric acid (HF). Moreover, syntheses involving long-chain amino acid are often 
challenging due to steric hindrance and unwanted side-reactions such as premature 
termination. Lastly, extensive optimisation of folding conditions is often required to obtain 
correctly folded synthetic peptide217.  
 
An alternative to SPPS is recombinant production of SVPs in bacteria. E. coli is often the 
bacterium of choice for recombinant protein expression due to its fast doubling time 
(~20 min), ability to grow in high density, and scalability to large-scale fermenters for 
increasing production yields; this translates into higher yields at lower cost of production 
and therefore better economic returns. Recombinant expression also allows low-cost 
production of isotopically-labelled peptides for high-resolution structure determination 
using NMR202.  
 
However, production of cysteine-rich peptides is difficult as the reducing cytoplasmic 
environment is prohibitive for the formation of disulfide bonds. In contrast, the E. coli 
periplasm contains the endogenous cellular machinery for disulfide-bond formation218. 
Hence we used an expression vector containing a signal peptide sequence that allowed 
export of the OAIP3 fusion protein into the E. coli periplasm. This lead to the production of 
a single, oxidised isoform of recombinant OAIP3, highlighting the success of this 
expression strategy.  
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The successful production of OAIP3 in bacteria indicates that it might be possible to 
engineer genetically-modified (GM) crops that express OAIP3 for improved resistance 
against insect pests. This strategy has been used for ω-hexatoxin-Hv1a (Hv1a), an SVP 
isolated from the funnel-web spider Hadronyche versuta that is potently insecticidal49, but 
which lacks oral efficacy219. To overcome this problem, Hv1a was fused to snowdrop lectin 
(GNA) which enabled movement of the fusion protein across the insect gut into the 
hemolymph, allowing it to reach its targeted site in the insect nervous system and thereby 
enhancing its oral potency220, Transgenic Arabidopsis expressing the GNA/Hv1a fusion 
protein displayed markedly improved resistance against the green peach aphid (Myzus 
persicae 221. In contrast with Hv1a, the intrinsic oral efficacy of OAIP3 makes it a potential 
candidate for generation of GM-crops without the need for fusion to a carrier protein.  
 
2.4.2 Determination of the 3D structure of OAIP3 
Isotopically-labelled OAIP3 was produced for structure determination using NMR. The 
NMR experiments enabled assignment of the chemical shifts of all NMR-observable proton 
(1H), nitrogen (15N) and carbon (13C) atoms, which typically allows a higher-resolution 
structure to be obtained than is possible with 2D homonuclear NMR techniques222. The 
NMR studies revealed that OIAP3 has a canonical ICK fold with the C1–C4 and C2–C5 
disulfide bonds and the intervening sections of polypeptide backbone forming a loop that is 
pierced by the C3–C6 disulfide bond. ICK peptides are known to be highly resistant to 
thermal, chemical and proteolytic degradation12, 52. Intrinsic resistance to proteases, which 
remains to be proven experimentally, may contribute to the oral efficacy of native OAIP3. 
However, the alkaline environment of some insect guts (mostly lepidopterans) is 
unfavourable for the stability of ICK peptides due to the possibility of disulfide-bond 
shuffling12, and this will need to be investigated in future experiments with OAIP3. 
 
The search for structural homologs of OAIP3 using the DALI server identified many 
homologs. Remarkably, the top six hits are all spider-venom peptides that are known to 
modulate the activity of insect or vertebrate NaV channels. However, recombinant OAIP3, 
at concentrations up to 1 µM, had no effect on currents mediated by the BgNaV1 from the 
German cockroach Blattella germanica heterologously expressed in Xenopus oocytes 
(electrophysiology experiments performed by Dr Frank Bosmans, Johns Hopkins 
University, USA; results not shown). This does not necessarily imply that insect NaV 
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channels are not the target of OAIP3; as discussed in Section 2.3.4 above, the lack of C-
terminal amidation and the additional non-native N-terminal glycine residue may have 
contributed to the reduced in vivo potency of OAIP3 and the lack of activity on the BgNaV1 
channel. It has been shown in many cases that C-terminal amidation is required for 
maintaining the biological activity of neuropeptides and ion channel modulators214, 223. The 
C-terminal amide was shown to be critical for µ-TRTX-Hh2a activity against the human 
NaV1.7 channel. Recombinant µ-TRTX-Hh2a (with C-terminal acid, IC50 ~727 nM) was 66-
fold less potent against hNaV1.7 compared to synthetic peptide with a C-terminal amide 
(IC50 ~11 nM). Interestingly, the activity of the recombinant peptide was partly recovered 
(IC50 ~190 nM) by a one-residue (glycine) extension at the C-terminus to mimic the native 
C-terminal amide224.  
 
A marked difference in insecticidal activity between close homologs was also observed in 
U2-TRTX-Hs1b and U2-TRTX-Hs1a225, isolated from Haplopelma schmidti with 42% 
sequence identity to OAIP3 (Fig. 2.4). U2-TRTX-Hs1a weakly inhibits insect NaV channels 
in cockroach dorsal unpaired median (DUM) neurons with an IC50 of ~1.1 µM and causes 
reversible paralysis in cockroaches with a PD50 of ~50 nmol/g 225. In comparison, U2-
TRTX-Hs1b, which differs by a single C-terminal residue truncation and amidation, had no 
effect on cockroaches (up to 109 nmol/g)225. 
 
The addition of an N-terminal glycine to OAIP3 sequence (to aid TEV protease cleavage) 
may result in deleterious effects on activity. However, we have routinely produced 
recombinant peptides with a non-native serine or glycine without observing loss of activity. 
Hence, the stark differences in potency observed in native and recombinant OAIP3 may 
indicate that C-terminal amidation is crucial for OAIP3 activity.   
 
2.5 Conclusions  
In summary, this chapter described the production and characterisation of an insecticidal 
peptide, OAIP3, isolated from the venom of S. plumipes. Recombinant OAIP3 was 
produced in high yield as a single isoform using a bacterial periplasmic expression system. 
Structure determination using NMR indicated that OAIP3 has a canonical ICK fold 
commonly observed in spider-venom peptides. The search for structural homologs of 
OAIP3 identified several structurally related NaV channel modulators from other spider 
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venoms. Both sequence and structural alignments suggest that OAIP3 is likely to target 
insect NaV sodium channels. The insecticidal activity of recombinant OAIP3 was 
significantly less than native OAIP3, which we attribute to the loss of C-terminal amidation 
in the recombinant peptide. Overall, the structure-function characterisation of OAIP3 has 
provided informative insights for the development of bioinsecticides from spider venoms. 
 
 
 Chapter Three 
 
 
NB. This chapter is presented as a finalised manuscript and formatted as per required for 
submission to ACS Chemical Biology  
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ABSTRACT 
Acute pharmacological inhibition of acid-sensing ion channel 1a (ASIC1a) is efficacious in 
rodent models of neurological diseases such as stroke and multiple sclerosis. Thus, 
ASIC1a is a promising therapeutic target and selective ligands that modulate it are 
invaluable research tools and potential therapeutic leads. Spider venoms have provided an 
abundance of voltage-gated ion channel modulators, however, only one ASIC modulator 
(PcTx1) has so far been isolated from this source. Here we report the discovery, 
characterization, and chemical stability of a second spider venom peptide that potently 
modulates ASIC1a and 1b and investigate the molecular basis for its subtype selectivity. p-
TRTX-Hm3a is a 37-amino acid peptide isolated from Togo starburst spider (Heteroscodra 
maculate) venom with substantial sequence similarity to PcTx1, albeit three residues 
shorter at the C-terminus. Hm3a pH-dependently inhibited ASIC1a with an IC50 of 1–2 nM 
and potentiated ASIC1b with an EC50 of 50 nM similar to PcTx1. Using ASIC1a to ASIC1b 
point mutants in rat ASIC1a revealed that E177 and R175 in the palm region opposite a-
helix 5 play an important role in the Hm3a-ASIC1 interaction and contribute to the subtype-
dependent effects of the peptide. Despite the high sequence similarity with PcTx1, Hm3a 
showed higher levels of thermal, serum, and cerebrospinal fluid stability over 48 hours. 
Overall, Hm3a represents a potent, highly stable tool for the study of ASICs and use in 
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Growing knowledge on the molecular basis of various channelopathies and neurological 
disorders had sparked intense interest in the discovery and development of ion channel 
modulators as therapeutics and pharmacological tools1-2. Spiders, in particular, have 
proved to be a rich source of such modulators. Their venoms contain numerous 
biologically active peptides that potently target a variety of ion channels3-4. As such, 
peptides isolated from spider venoms have been widely used to dissect the molecular 
mechanisms of channel function and their role in biological processes and have been 
instrumental for improving our understanding of ion channels5-7. In this respect, the acid-
sensing ion channels (ASICs) are no different with a spider venom peptide being the first, 
and still the most potent, selective modulator known for ASICs. 
ASICs are chordate-specific members of the degenerin/epithelial sodium channel family 
that are widely distributed in the nervous system and many non-neuronal cells8. They are 
primary mammalian acid sensors and as such are activated by protonation9. Six ASIC 
subtypes are known (ASIC1a/b, ASIC2a/b, ASIC3 and ASIC4), which can assemble as 
functional homotrimeric (ASIC1a/b, ASIC2a and ASIC3 only) or heterotrimeric channels10. 
Each subunit consists of a large extracellular domain, two transmembrane helices, and 
short intracellular N- and C-termini. The combination of subunits in each channel affects 
the pH sensitivity, pharmacology, and kinetics of activation and desensitization10. ASIC1a 
is the most abundant ASIC subunit in the mammalian central nervous system. Unlike other 
ASICs, ASIC1a is also permeable to Ca2+, a property that has been associated with 
ASIC1a’s role in acidosis-induced neuronal injury11-12. ASICs have been implicated with a 
variety of pathophysiological conditions such as inflammatory and neuropathic pain13-15, 
psychiatric illness16, multiple sclerosis17, epileptic seizure termination18 and ischemic 
stroke19, hence are considered promising therapeutic targets11, 20. 
Although several small molecules have been demonstrated to modulate ASIC activity, 
they lack subtype specificity and potency, and thus are limited in their usefulness as 
pharmacological tools. In contrast, venom peptides are often extremely potent and can 
have very high selectivity for neuronal targets3. To date, six ligands targeting various ASIC 
subtypes have been isolated from animal venoms21. The prototypical and therefore most 
studied ASIC ligand is the spider venom peptide, PcTx1 from the spider Psalmopoeus 
cambridgei22. PcTx1 inhibits homomeric ASIC1a with an IC50 of ~0.9 nM, and stabilises the 
open state of ASIC1b. More recently it has been shown to also inhibit heteromeric 
ASIC1a/2b and ASIC1a/2a channels23-24. The only other inhibitory peptide ligands of 
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ASIC1 include the mamblagins, from the Mamba snakes (Dendroaspis spp.), which have 
been shown to inhibit ASIC1a and ASIC1b containing channels with IC50 values between 
11 and 300 nM21, 25.  
From a panel of spider venoms, we observed ASIC1a inhibitory activity from the venom 
of the Toga starburst spider (Heteroscodra maculata). Here, we describe the isolation, 
recombinant expression and characterisation of a second potent inhibitor of ASIC1a from 
venom of Heteroscodra maculata. This venom-peptide, named π-theraphotoxin-Hm3a 
(hereafter Hm3a), was pharmacologically characterized to determine its ASIC subtype-
selectivity, binding site, mechanism of action and stability in biological fluids. 
 
RESULTS AND DISCUSSION 
ASIC1 has been associated with many pathophysiological conditions as a result of 
acidosis and has been shown to be a promising drug target20. However, the current array 
of ASIC1 modulatory ligands available as selective pharmacological tools and therapeutic 
leads is extremely limited. The difficulty in developing more selective small molecule ASIC 
inhibitors as therapeutic leads is illustrated by a series of classical medicinal chemistry 
studies by Merck. Three studies using different starting scaffolds all resulted in more 
potent molecules, however, all had significant off-target effects resulting in substantial 
sedation in animal studies26-28. Based on the discovery of PcTx1 in a spider venom22 we 
hypothesized that spider venoms should be a valuable source of additional novel ASIC 
modulators. Discovery of novel ligands, and understanding the molecular basis for 
differences in their biological properties (such as structural and chemical stability) and 
functions provides valuable insight to develop improved ligands.  
 
Identification and Purification of Hm3a 
A panel of spider venoms were screened for activity on rat ASIC1a channels expressed 
in Xenopus laevis oocytes using two-electrode voltage-clamp (TEVC) electrophysiology. 
Venom from Heteroscodra maculata (1/1000-fold dilution) resulted in robust (>90%) 
inhibition of ASIC1a. Fractionation of the crude venom using reversed-phase (RP) HPLC 
yielded 44 fractions, indicating the high complexity of H. maculata venom. Assay-guided 
fractionation led to the identification of a minor, early-eluting peak, Fraction 12, that 
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inhibited rASIC1a currents (Fig. 3.1A). Subsequent purification of Fraction 12 led to 
isolation of a single peptide, with an observed monoisotopic M+H+ of 4285.05 (Fig. 3.1B). 
The peptide was named p-TRTX-Hm3a, hereafter Hm3a, according to a rational 
nomenclature system for naming peptide toxins from venomous animals29. 
The full-length amino acid sequence of Hm3a was determined by a combination of N-
terminal Edman degradation and tandem mass spectrometry. The theoretical oxidized 
monoisotopic m/z (M+H+ = 4285.03) of the Hm3a sequence matched the observed 
monoisotopic mass suggesting the presence of a free carboxylic acid at the C-terminus 
and three disulfide bonds. A BLAST search on the ArachnoServer database 30 revealed 
that Hm3a shares 82% identity with PcTx1, the prototypical ASIC1a inhibitor from 
Psalmopoeus cambridgei venom (Fig. 3.1C). Hm3a differs from PcTx1 by five point 
mutations and a three residue C-terminal truncation. Native Hm3a is highly potent on 
rASIC1a, inhibiting acid-evoked currents with an IC50 of 2.6 ± 1.3 nM when applied at pH 
7.45 (Fig. 3.1D). Due to the high sequence identity, conserved cysteine framework, and 
similar pharmacology between Hm3a and the inhibitor cysteine knot (ICK) fold peptide 
PcTx1 (PDB: 2KNI), it is highly likely that Hm3a also conforms to the ICK fold (Fig. 3.1E). 
Despite being identified 15 years ago, PcTx1 remained the only known peptide isolated 
from spider venom that targets ASICs. Moreover, the relatively small molecular weight of 
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Figure 3.1.  Isolation of Hm3a from H. maculata venom. (A) RP-HPLC chromatogram of crude H. maculata 
venom. The asterisk denotes the Hm3a containing fraction. Inset shows the effect of Fraction 12 on rASIC1a 
expressed in Xenopus oocytes. (B) Chromatogram showing the final purification step of native Hm3a and 
MALDI-TOF MS spectrum showing a monoisotopic mass, M+H+ of 4285.05. (C) Full amino acid sequence of 
Hm3a aligned with PcTx1 (non-conserved residues are in bold, cysteine residues are shown in red). (D) 
Concentration-effect curve for inhibition of rASIC1a by native Hm3a (n = 6; error bars denote SEM). Fitting 
the Hill equation to the data yielded an IC50 of 2.6 ± 1.3 nM. (E) Three-dimensional homology model of Hm3a 
based on PcTx1 (PDB:  2KNI). Disulfide bridges shown in red, N- and C- termini are as indicated. 
 
 
Recombinant Production of Hm3a 
In order to obtain sufficient material to carry out further pharmacological characterization 
of Hm3a, we used an Escherichia coli recombinant expression system that we have 
previously employed to produce many disulfide rich venom peptides including PcTx131-32. 
Following IPTG induction, the Hm3a-fusion protein was the dominant cellular protein 
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present (Fig. 3.2A). Cleavage from the fusion protein and purification using RP-HPLC 
resulted in a single peptide isoform, with a final yield of ~1 mg of correctly folded peptide 
per liter of bacterial culture at >98% purity (determined using RP-HPLC and MS) (Fig. 
3.2B). The observed M+H+ (4372.58) was in accordance with the calculated value 
(4372.06) for Hm3a with an additional N-terminal serine left from the TEV recognition site 
(Fig. 3.2B insert).  
 
Figure 3.2. Production and purification of recombinant Hm3a were performed by Mr Ben Cristofori-
Armstrong. (A) SDS-PAGE gel showing the expression, purification and TEV cleavage of the Hm3a-MBP 
fusion protein. The lanes are labeled as follows: Marker = 1 kDa protein molecular weight marker; Uninduced 
= whole-cell extraction before induction; Induced = whole-cell extract after induction; Insoluble = the insoluble 
fraction after cell lysis; Soluble = soluble fraction after cell lysis; flow-through = the flow-through after loading 
to Ni-NTA; Wash = the Ni-NTA flow-through after 15 mM imidazole wash; Elution = the Ni-NTA after 250 mM 
imidazole wash; Before TEV = concentrated sample before addition of TEV protease; After TEV = 
concentrated sample after addition of TEV protease. (B) RP-HPLC chromatogram of purified recombinant 
Hm3a. Inset is a MALDI-TOF mass spectrum showing the monoisotopic M+H+ (observed, 4372.58; 
calculated 4372.06).  
 
Effects of Hm3a on ASICs 
The potency and selectivity of Hm3a was assessed using TEVC electrophysiology on 
oocytes expressing homomeric rASIC1a, rASIC1b, rASIC2a, rASIC3, human ASIC1a, 
hASIC1b, and heteromeric rASIC1a/ASIC1b (Fig. 3.3A, 3.3B and 3.3C). Recombinant 
Hm3a was similarly potent to the native peptide, causing rapid and reversible inhibition of 
rASIC1a with an IC50 of 1.3 ± 0.2 nM (Fig. 3.3A) confirming that the identified sequence is 
indeed the active peptide and is folded correctly. Furthermore, it shows that the addition of 
an extra residue on the N-terminus (the serine from the TEV cleavage) has little effect on 
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the inhibitory activity of the peptide, consistent with the well tolerated addition of a Tyr to 
the N-terminus of PcTx133. Having ascertained the identity and structural conformation, the 
remaining characterization studies of Hm3a were performed using recombinant peptide. 
Hm3a is highly selective for ASIC1, with no observable effect on rASIC2a or rASIC3 when 
tested at concentrations up to 10 µM (Fig. 3.3A). In stark contrast, Hm3a strongly 
potentiated rASIC1b (~4-fold increase in amplitude) with an EC50 of 46.5 ± 6.2 nM (Fig. 
3.3B) as has previously been reported for PcTx134. The potentiating effect was also 
observed on heteromeric rASIC1a/ASIC1b channels with higher potency (EC50 of 17.4 ± 
0.5 nM), but lower efficacy (less than 2-fold increase in current amplitude) as compared to 
homomeric rASIC1b (Fig. 3.3B).  
We next assessed species–dependent effects of Hm3a on ASIC1. Similar to the rat 
isoforms, Hm3a also inhibited human ASIC1a and potentiated hASIC1b; however, was 
~30-fold, and ~3.8-fold less potent, respectively, than on the rat isoforms (Fig. 3.3C). The 
Hill coefficients from the concentration-effect curves of Hm3a on both rat and human 
ASIC1a and ASIC1b are 1.3–1.6, suggesting positively cooperative binding of more than 
one Hm3a peptide per ASIC1 trimer. This is consistent with the co-crystal structures of 
cASIC1 and PcTx1 that showed three PcTx1 peptides bound per channel35-36. 
In the study by Chen et al.34, that first demonstrated the potentiation of ASIC1b by 
PcTx1, they were unable to determine an accurate EC50 as a plateau in the PcTx1 induced 
potentiation effect was not reached (likely due to the high concentrations required and the 
high cost of commercially available peptides). Here, we were able to show a maximal 
response in Hm3a potentiation of both rat and human ASIC1b and determine a more 
robust EC50 value. PcTx1 has been shown to inhibit both ASIC1a homomers22 as well as 
rASIC1a/ASIC2b and rASIC1a/ASIC2a heteromers23-24, however no activity has been 
reported on rASIC1a/ASIC1b heteromers. Our results indicate that rASIC1a/ASIC1b 
heteromers are sensitive to Hm3a in the mid-nanomolar range. A better understanding of 
the interaction of these peptides with both ASIC1b and ASIC1a/1b heteromers is crucial 
when they are used as ASIC1a inhibitors in animal studies because both ASIC1a and 
ASIC1b are highly expressed in the peripheral nervous system in rodents37. Thus, the use 
of high concentrations of Hm3a or PcTx1 may lead to confounding results, and possible 
undesirable side-effects because inhibition of ASIC1b has caused analgesic effects on 
inflammatory and nociceptive pain models of ASIC1a-knockout mice, indicating the 
involvement of ASIC1b in pain25. 
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Despite the high sequence identity of Hm3a to PcTx1, Hm3a is slightly less potent on 
rASIC1a (~3-fold compared to PcTx1 in our previous studies) (Fig. 3.1D, 3.3A, 3.5C)32, 38.  
From our previous structure-activity studies on PcTx1, we have shown that truncation of 
the three C-terminal residues (Pro38Lys39Thr40) resulted in a ~4-fold decrease in 
activity38. Furthermore, a P38A mutation of PcTx1 was also ~4-fold less potent than wild-
type PcTx1, leading us to the conclusion that the interaction made by Pro38 in PcTx1 
could account for the slight loss in activity observed in these variants38. Being equivalent in 
length to the Δ3C variant of PcTx1, Hm3a also lacks a proline at position 38. Hence, we 
hypothesized that the potency of Hm3a on rASIC1a could be enhanced by the addition of 
a proline at the C-terminus (Hm3a_P38). A plasmid encoding the Hm3a_P38 variant was 
produced by site-directed mutagenesis and the peptide was recombinantly produced. 
Hm3a_P38 had an IC50 of 0.4 ± 0.11 nM (Fig. 3.3D) or a 3.25-fold increase in potency as 
compared to wild-type Hm3a, in complete agreement with our prediction.  
Extensive mutagenesis of PcTx132, 38, along with two co-crystal structures in complex 
with chicken ASIC135-36 have been instrumental in defining the PcTx1 pharmacophore. 
Three of the residue differences between PcTx1 and Hm3a (D2P, G9S, and E19A) were 
not identified as potential contacts in structural studies. As a result, the effect of these 
mutations in PcTx1 have not been studied, and here we show that these mutations do not 
appear to be crucial for activity at rASIC1a. Thr37 of PcTx1 was identified as a crystal 
contact, however a PcTx1_T37A mutant was shown to be equipotent with wild-type PcTx1 
38, in good agreement with the Hm3a potency (Thr37 is a Val in Hm3a, see Figure 1C). 
The only residue difference between Hm3a and PcTx1 that falls within the key 
pharmacophore residues was R28K. Arg28 makes multiple channel contacts and the 
PcTx1_R28A mutant had 14.5-fold lower activity on rASIC1a38. In the case of Hm3a, the 
conservative mutation of Arg to Lys at postion 28 appears to have little to no deleterious 
effect on peptide activity, thus the substitution is both functionally and structurally neutral. 
Although Lys has one less amino group, full retention of activity suggests that not all the 
interactions proposed in crystal studies are making energetically important contributions.  
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Figure 3.3. Concentration-effect curves of Hm3a for (A) homomeric rASIC1a, 2a, and 3 (n = 6–10), and (B) 
homomeric rASIC1b and heteromeric rASIC1a/ASIC1b channels (n = 6) (p = 0.052, F = 8.069). (C) 
Concentration-effect curves of Hm3a for homomeric hASIC1a and hASIC1b (n = 7) (p = 0.0029, F = 13.34). 
(D) Concentration-effect curves of wild-type Hm3a and Hm3a_P38 mutant on homomeric rASIC1a (p = 
0.029, F = 9.388). Data are mean ± SEM.  
 
The mechanism of action of Hm3a on ASIC1 
Given the sequence similarity of Hm3a and PcTx1, we hypothesized that Hm3a 
modulates ASIC1a in similar manner as PcTx1. Upon protonation, ASIC1 transitions from 
a resting state to an open state, then promptly enters a desensitized state in which the 
channel does not conduct current despite continued proton stimulus39. The mechanism of 
action of PcTx1 on ASIC1a inhibition is well established. PcTx1 mimics the binding of 
protons in the acidic pocket of ASIC1a. In this context, PcTx1 acts as an agonist to 
stabilize the desensitization state of ASIC1a at physiological pH, resulting in channel 
inhibition32, 34. 
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We assessed the effects of Hm3a on the SSD of rASIC1a by conditioning the channel 
with increasing proton concentrations in the presence and absence of 30 nM peptide (Fig. 
3.4A and 3.4B). The current amplitude at different proton concentrations was fitted to the 
Hill function to obtain the pH of half-maximal desensitisation (pH50 SSD) (Fig. 3.4C). The 
pH50 SSD of rASIC1a alone was 7.243 ± 0.003 (In good agreement with previous reports34). 
The presence of 30 nM Hm3a during conditioning induced a parallel alkaline shift in the 
pH50 SSD of rASIC1a by 0.362 pH units to 7.605 ± 0.024 (Fig. 3.4C). This parallel shift in 
SSD shows that when applied at conditioning pH 7.9, 30 nM Hm3a in insufficient to induce 
SSD of the channel (i.e. inhibition) thus channels are in the resting state but in the 
presence of peptide. This allows us to study the effect of the peptide on the pH-
dependence of channel activation.  
We next assessed the effects of Hm3a on pH-dependent activation of ASIC1a. A 
conditioning pH of 7.9 was used throughout these experiments to ensure that Hm3a did 
not inhibit channels as previously shown in the SSD experiment. In good agreement with a 
previous study on PcTx134, the pH50 of activation (pH50 ACT) of rASIC1a was 6.078 ± 0.039 
as compared to 6.284 ± 0.064 when 30 nM Hm3a was used. Thus Hm3a lowered the 
proton concentrations required for activation by 0.206 pH units. This also highlights that 
Hm3a can interact with the channel and the channel can still be activated with peptide 
bound at pH 7.9. 
The on- and off-rate of Hm3a on rASIC1a was examined by application of 30 nM 
peptide at pH 7.45 for increasing periods of time followed by activation at pH 6 (Fig. 3.4D). 
Fitting a single exponential function to the time course of inhibition data revealed a time to 
50% inhibition (t1/2) of ~16 s, with maximal inhibition reached after ~90 s (Fig. 3.4D). The 
slow onset of Hm3a inhibition may not be reflective of the actual binding on-rate for the 
peptide-channel interaction. Hm3a causes inhibition via inducing SSD of ASIC1a; 
however, the slow transition time required for conformational changes between the open 
state and desensitised may take longer than the actual on rate of the Hm3a. In agreement 
with this, we observed that application of 30 nM Hm3a for less than 10 s, led to 
potentiation of currents indicating the quick interaction between ASIC1a and Hm3a, similar 
to previously reported observations with PcTx1 on ASIC1a40. The on-rate of Hm3a was 
similar to PcTx1 as previously reported using oocyte electrophysiology. Full inhibition of 
ASIC1a induced by 30 nM PcTx1 was achieved ~150 s after peptide application, with a 
time constant (Tau) of 52 s34. Comparatively, on rate is slower with lower concentration of 
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PcTx1. With 1 nM PcTx1, maximum inhibition of ASIC1a expressed in COS-7 cells was 
achieved only after ~3 min33, indicating that the on rate of Hm3a is concentration-
dependent. Recovery of ASIC1a current after inhibition induced by a 180 s exposure to 30 
nM Hm3a for was slow, reaching maximum current amplitude after ~360 s of washout of 
peptide. Fitting a single exponential function to the data revealed a t1/2 of ~132 s (Fig. 
3.4E). ASIC1a recovers from the desensitised state over a time course of several seconds 
(time constant ~10 s)41, hence the slower recovery from Hm3a inhibition can be largely 
attributed to dissociation of the peptide from the channel rather than simply recovery from 
SSD.  
PcTx1 (and by similarity, Hm3a) was shown to preferentially bind and stabilize the open 
state of ASIC1b, resulting in channel potentiation34. In order to determine the mechanism 
of ASIC1b potentiation by Hm3a, we analyzed the decay time constants of inactivation 
from the ASIC1b data shown in Fig. 3.4F. Control ASIC1b currents elicited by a pH drop to 
5.0 decayed with a time constant, τ of 1.17 ± 0.10 ms. In good agreement with the EC50 of 
Hm3a for rASIC1b potentiation (Fig. 3.2B), Hm3a caused a concentration-dependent 
increase in the time constant of inactivation with an EC50 of 53 ± 2.54 nM and plateaued at 
~300 nM with a time constant of 2.18 ± 0.11 ms (Fig. 3.4E).  
  




Figure 3.4.  The mechanism of action of Hm3a on rASIC1. The effects of Hm3a on the pH-dependent 
steady-state desensitization, activation of ASIC1a and ASIC1b as well as the on-rates of Hm3a on ASIC1a 
were characterized by Mr Ben Cristofori-Armstrong. (A) Representative current traces in the absence (top) or 
presence (bottom) of 30 nM Hm3a, elicited by pH 6.0, following conditioning from pH 7.9 to 7.1. (B) 
Representative current traces in absence (top) or presence (bottom) of 30 nM Hm3a, elicited by pH 5.0 to 
6.0, following conditioning at pH 7.9. (C) The alkaline shift in steady-state desensitisation (p < 0.0001, F = 
379.1) and activation (p = 0.029, F = 5.526) of rASIC1a in the presence of 30 nM Hm3a (solid line, closed 
circle) as compared without Hm3a (dash line, open circles) (n = 6). (D) Time course of rASIC1a inhibition by 
30 nM Hm3a. The time constant (t1/2) for inhibition was calculated by fitting the data to a single-exponential 
decay function (n = 6). (E) Recovery from inhibition was assessed by applying 30 nM Hm3a for 180 s, then 
stimulating the channel after 0 s, 30 s, 60 s, and every 60 s thereafter until maximal recovery was reached. 
The time constant (t1/2) for recovery from inhibition was calculated by fitting the data to a single-exponential 
function (n = 6). Data are mean ± SEM. (F) The ratio of rASIC1b time constants of desensitization with 
varying concentrations of Hm3a against control conditions. Dashed line represents a fit of the Hill equation to 
the data and yielded an IC50 of 53 ± 0.4 nM (n = 5). 
 
Characterizing the molecular interactions involved in subtype and species 
selectivity of Hm3a on ASIC1 
The binding site of PcTx1 on ASIC1a has been extensively studied32, 35-36, 38 and 
comprises primarily α-helix5 at the bottom of the acidic pocket and palm of the adjacent 
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subunit. (Fig. 3.5A). The rASIC1a residue F350 (F352 in hASIC1a) on α-helix5 in the 
thumb domain is particularly important for interaction with the peptide42 making it 
diagnostic for this binding pocket. Given the similarity of Hm3a with PcTx1 in sequence 
and pharmacology we assume it will share the same biding site. However, in order to 
confirm this, the peptide was tested on the channel mutant rASIC1a_F350A. Hm3a did not 
inhibit rASIC1a_F350A, rather, at concentrations over 300 nM, Hm3a strongly potentiated 
currents (Fig. 3.5B). Previous studies using diluted Psalmopoeus cambridgei venom 
(containing PcTx1) on the rASIC1a_F350A or hASIC1a_F352L mutants showed a total 
lack of inhibition however, Sherwood 2009b43 did show evidence that PcTx1 could still bind 
to the mutant channel (i.e. pre-incubation with 200 nM PcTx1 prevented the action of 
bigdynorphin). Our studies with higher concentrations of Hm3a (up to 3 mM) show that not 
only can it still bind but can have functional effects. This suggests that in the absence of 
the large number of contacts (~6) made between F350 and PcTx1 (and by similarity, 
Hm3a)38 there are still sufficient residual contacts to mediate functional interaction.  
ASIC1b is highly expressed in peripheral sensory nerves and has been shown to play a 
key role in mediating acid-induced nociception, at least in rodents25, 44. Thus determining 
the molecular basis for Hm3a’s potentiation of ASIC1b is an important step to understand 
potential complications when interpreting in vivo data, and enable the design of more 
selective ASIC1 modulators. Thus, we further characterized the potential interactions sites 
of Hm3a on ASIC1. ASIC1a and ASIC1b are splice isoforms that only differ in the first third 
of the protein (identical from residue 186 of rASIC1a onwards). A series of chimeras of 
rASIC1a and rASIC1b identified the small region of residues 167–185 of rASIC1a (19 
residues N-terminal to the splice-site) to be sufficient to confer the inhibitory effect on 
rASIC1a in to rASIC1b34. Interestingly, the only residue difference between human and rat 
ASIC1a within the known PcTx1 binding site, Ala178 in the rat channel (Val in human 
ASIC1a, and a proline in rASIC1b) also resides in this small region. We examined this 
region in further detail to determine specific residues involved by testing the effects of 
Hm3a on the rASIC1a mutants A178V, R175C, and E177G (Fig. 3.5A), as it was predicted 
these residues could be responsible for the different subtype and species pharmacology of 
Hm3a and PcTx1 at ASIC1.   
The IC50 of Hm3a was only slightly increased on rASIC1a_A178V (~ 4 nM) (Fig. 3.5B), 
which does not account for the 30-fold difference in IC50 on rat and human ASIC1a, or the 
vastly different effects on rASIC1b, We concluded that Ala178 is not strongly involved in 
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channel–peptide interaction, consistent with MD predictions whereby the equivalent 
residue on cASIC1a, Gln179, does not form persistent interaction with Lys25 of PcTx138. 
In contrast, there was a profound decrease in Hm3a activity on both rASIC1a_R175C and 
rASIC1a_E177G, with IC50s of 72.5 nM and 117 nM, respectively (Fig. 3.5B). These 
mutations were made to make the rASIC1a-binding interface resemble that of rASIC1b. 
None of these mutations affected the channels sensitivity to protons (in the form of SSD 
and activation) (Supp. Fig. 3.1), thus, any loss in potency is likely due to a loss of 
important interactions between the peptide and channel, rather than changes in channel 
function. Consistent with this evidence, PcTx1:ASIC1a crystal structures and molecular 
dynamic studies35-36, 38 showed that Glu177 and Arg175 of rASIC1a (Glu178 and Arg176 in 
cASIC1a) make contact with Trp24 and Arg27 of PcTx1, respectively, both major 
pharmacophore residues32, 38. Although the interaction between PcTx1 and ASIC1a is well 
characterized, no study has so far demonstrated individual residues that determine 
subtype specificity between rASIC1a and rASIC1b. Here we show that Hm3a interacts with 
both ASIC1a and 1b with ~35-fold difference in potency (but different functional outcomes) 
and identified Arg175 and Glu177 of rASIC1a as two of the causative residues which can 
account for the subtype specificity of Hm3a, and most likely PcTx1. This improved 
understanding of the binding interaction between peptide and channel should the design of 
more specific analogues of these peptides.  










rASIC1a_R175C: IC50 = 46 nM
rASIC1a_E177G: IC50 = 126 nM
rASIC1a_A178V: IC50 = 2.3 nM
rASIC1a: IC50 = 1.3  nM
















Figure 3.5. Molecular interactions involved in species and subtype selectivity. Concentration-response 
curves of Hm3a on (A) rASIC1a_F350; (B) rASIC1a_E177G, rASIC1a_R175C, rASIC1a_A178V and wild-
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PcTx1: IC50 = 0.5 nM
Hm3a: IC50 = 1.2 nM
 
Supplementary figure 3.1. (Left) Current trace of rat ASIC1a stimulated with pH 6.0. Several control pH 
exposures were included due to the tachyphylaxis effect of protons on ASIC1a. Data were normalised to the 
peak current (Imax) after several exposures. (Right) Dose-response curves of PcTx1 (in blue) and Hm3a (in 
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Supplementary figure 3.2. The Act (Left) and SSD (Right) curves for channel mutants. (n = 6–7). 
Experiments were carried out by Mr Ben Cristofori-Armstrong. 
 
Stability of Hm3a and PcTx1 
Given the likely role of ASIC1a in a range of pathological conditions, and the need to 
use selective pharmacological tools for target validation in vivo, it is important to 
understand the thermal and biological stability of peptides such as Hm3a and PcTx1. 
Despite its extensive use a research tool in vivo, the stability of PcTx1 has never been 
reported. Therefore, we evaluated the stability of Hm3a and PcTx1 in comparison to the 
clinically used peptide oxytocin at 55oC (in aqueous buffer at pH 7.4), in human serum and 
in human cerebrospinal fluid (CSF) (Fig. 3.6A, 3.6B, and 3.6C). Hm3a proved to have 
high thermal stability with <10% loss after 48 h at 55oC. In contrast, both PcTx1 and 
oxytocin showed a near-linear breakdown over time, with ~44% of PcTx1 and ~50% of 
oxytocin remaining at 48 h. Similarly, Hm3a was largely unaffected in human serum with 
>90% intact peptide after 48 h. In comparison, there was an initial sharp decline in PcTx1 
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during the first few hours which then plateaued at ~76% over 48 h. An initial sharp decline 
was also observed for oxytocin, however, unlike PcTx1, degradation of oxytocin continued 
over time, with ~50% peptide remaining after 48 h. Hm3a and PcTx1 appear to be highly 
stable in human CSF with >90% intact after 48 h. Oxytocin was also relatively stable in 
hCSF (~81% intact at 48 h) while human atrial naturetic peptide was completely degraded 
by 12 h under these conditions.  
It is often claimed that peptides containing the ICK motif are highly stable and resistant 
to thermal, chemical and enzymatic degradation and this has been as demonstrated for 
several spider venom ICK peptides such as ω-Hv1a, ProTx-I, ProTx-II, GsMTx-4, and 
GTx1-15 45-46. Interestingly, despite the high degree of sequence similarity, Hm3a was 
more stable than PcTx1 when challenged with high temperature or human serum. The 
improved stability of Hm3a over PcTx1 may be due to Hm3a’s fewer charged residues 
(particularly lysines at the C-terminus), which are involved in the cleavage sites of many 
enzymes such as trypsin47. We conclude that the substantially higher biological stability of 
Hm3a as compared to PcTx1 makes it a more attractive tool for studying the role of ASICs 
in biological fluids and in in vivo studies.  
 
Figure 3.6. Comparative stability studies of Hm3a and PcTx1. (A) Thermal stability of Hm3a, PcTx1 and 
oxytocin at 55 °C (pH 7.4). (B) Serum stability of Hm3a, PcTx1 and oxytocin at 37 °C. (C) Cerebrospinal fluid 
stability of Hm3a, PcTx1, oxytocin and human atrial naturetic peptide (hANP) at 37 °C (CSF stability of Hm3a 
and hANP were carried out by Mr Ben Cristofori-Armstrong). The percentage of peptide remaining for all 
conditions was quantified using RP-HPLC. Data are mean ± SEM. 
 
Spider venom peptides are known to be gating modifiers of voltage-gated ion channels, 
hence Hm3a was also tested on therapeutically-relevant off-targets including the voltage-
gated sodium channel subtype 1.2  (NaV1.2) and the voltage-gated potassium channel 
subtypes 10.1 (KV10.1) and 11.1 (KV11.1). NaV1.2 is predominantly expressed in the 
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central nervous system; prolonged opening of the channel were implicated with onset of 
epileptic disorders48. KV10.1 is implicated in a variety of cellular processes including cell 
proliferation and tumour progression49 whereas KV11.1 is vital for proper cardiac 
functioning49. At 10 uM, Hm3a had no effect on the voltage-dependence activation of 
these channels (Supp. Fig. 3.2), further iterating the high selectivity of Hm3a towards 
ASIC1.  































Supplementary figure 3.3: The effect of 10 mM Hm3a on the voltage dependence of activation of several 
human voltage gated ion channels off-targets, (from left to right) NaV1.2, KV10.1 and KV11.1.Experiments 
were performed by Mr Ben Cristofori-Armstrong.  
 
 
Supplementary figure 3.4: HPLC profile of PcTx1 following incubation in human serum at 0 h (black), 24 h 
(blue) and 48 h (pink).  
 
Conclusion. We have identified and characterized a new potent peptide modulator of 
ASIC1 from the venom of H. maculata, and suspect that spider venoms harbour more, 
potent and selective peptide inhibitors of ASICs. Despite the high sequence and 
pharmacological similarity of Hm3a and PcTx1, Hm3a appears to be superior in terms of 
stability. Furthermore, through rational engineering of Hm3a, we produced a more potent 
variant of the peptide making its ASIC1a inhibitory potency on par with PcTx1. We also 
identified several determinant residues in rASIC1a for ASIC1a/1b selectivity studies. The 
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distinct differences between the subtypes and species selectivity will contribute to the 
rational engineering and development of ASIC modulators with improved subtype 
selectivity. Overall, the discovery of new ASIC1 modulators will improve our knowledge of 
ASIC function and facilitate the development of novel ASIC-targeting therapeutic leads and 
research tools.  
 
METHODS 
Venom Peptide Purification and Characterization 
Heteroscodra maculata venom was purchased from Spider Pharm (Yarnell, AZ, USA). 
The lyophilized venom was dissolved in water (1:10 dilution from original venom volume) 
and stored at –20oC until required. A total of 50 µL of the diluted venom was fractionated 
using RP-HPLC on a C18 column (Phenomenex Kinetex, 250 x 4.6 mm, 100 Å) using a 
gradient of solvent A (0.05% trifluoroacetic acid (TFA) in H2O) and solvent B (90% 
acetonitrile, 0.043% TFA in H2O) as follows: 5% solvent B for 5 min, 5–20% solvent B for 
10 min, 20–50% solvent B for 30 min, 50–80% solvent for 5 min, at a flow rate of 1 
mL/min. Fractions were collected by monitoring eluent absorption at 214 and 280 nm and 
lyophilized. The dried fractions were dissolved in water and aliquots of each fraction were 
assayed for activity against rASIC1a expressed in Xenopus oocytes. A second RP-HPLC 
purification was carried out on the active fraction using a C18 column (Thermo Aquasil, 50 
× 2.1 mm, 190 Å) and a gradient of 10–30% solvent B over 20 min at a flow rate of 0.3 
ml/min. All solvents used were HPLC grade.  
 
RP-HPLC and MALDI-TOF Mass Spectrometry.  
Both analytical and semi-preparative RP-HPLC was performed using a Shimadzu 
Prominence HPLC system with the column at room temperature (~21–22°C). Peptide 
mass was determined using matrix-assisted laser desorption/ionisation time-of-flight 
(MALDI-TOF) MS using a Model 4700 Proteomics Analyzer (Applied Biosystems, Foster 
City, CA, USA) collected in both positive reflector and linear mode. All masses reported 
are M+H+. Fractions were mixed (1:1, v/v) with α-cyano-4-hydroxycinnamic acid matrix (7 
mg/mL in 50% acetonitrile in H2O). To obtain a sequence tag of the peptide the reductive 
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matrix 1,5-diaminonaphthalene (1,5-DAN) was used50. The active fractions were mixed 
(1:1, v/v) with 1,5-DAN (10 mg/ml in 50% acetonitrile, 0.1% formic acid in H2O). 
 
Peptide Sequencing 
The pure peptide was reduced with 2-mercaptoethanol and alkylated by 4-vinyl-pyridine 
then sequenced via N-terminal Edman degradation (477A, Applied Biosystems, Foster 
City, CA, USA). Sequence homologies were determined using sequences obtained from a 
search of non-redundant protein databases via the BLAST server and Arachnoserver 
(www.arachnoserver.org/)30. Sequence alignments and percentages of similarity were 
calculated using BLASTP51. 
 
Production of Recombinant Hm3a 
Recombinant Hm3a was produced using the bacterial periplasmic expression system as 
described for PcTx131-32. The synthetic gene encoding PcTx1 was cloned into the pLicC-
MBP expression vector, then mutated using standard PCR protocols52 to produce a vector 
encoding Hm3a. The fusion protein was expressed in E. coli BL21 (λDE3) and grown in 
Luria-Bertani broth medium to an OD600 of 0.8–1.0. The culture was then cooled to 16°C 
and induced with 0.5 mM IPTG for 16 hours. Cells were pelleted by centrifugation at 5000 
g then lysed via mechanical lysis at 28 kPa. The fusion protein was purified from the cell 
lysate via affinity chromatography using Ni-NTA Superflow resin (QIAGEN, Valencia, CA, 
USA). The peptide was cleaved from the fusion protein using TEV protease and purified by 
RP-HPLC on a C4 semi-preparative column (Phenomenex Jupiter, 250 x 10 mm, 300 Å). 
Peptide purity was verified using analytical RP-HPLC on a C18 column (Thermo Aquasil, 
50 x 2.1 mm, 190 Å) and gradient of 10–50 % solvent B over 40 min, at a flow rate of 0.25 
ml/min. Masses of the eluted peptides were obtained using MALDI-TOF MS.  
 
Electrophysiology 
Peptide activity was assessed using TEVC electrophysiology on Xenopus laevis 
oocytes. Oocytes preparation, cDNA/cRNA preparation and injections were performed as 
described4, 32. Stage V–VI oocyte were injected with 20–40 ng of ion channel cDNA/cRNA 
(Nanoject 2000; WPI, Sarasota, FL, USA). Currents were recorded 1–6 days after injection 
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under voltage-clamp using two standard glass microelectrodes of 0.5–2 MΩ resistance 
when filled with 3 M KCl solution. Oocytes were clamped at −60 mV (OC-725C oocyte 
clamp; Warner Instruments, Hamden, CT, USA). Currents were elicited by a drop in pH 
from 7.45 to 6.0 or 5.0 using a gravity–driven microperfusion system (consisting of 60 mL 
syringe connected to an IV flow regulator) to allow controlled to allow rapid solution 
exchange (~1.5 ml/min) at room temperature. HEPES was replaced by MES in buffers 
with pH below 6.8. A series of control currents were taken to account for the tachyphylaxis 
effect of ASICs in response to repeated pH stimulation prior to peptide application. Data 
was acquired (2000 Hz and filtered at 0.01 Hz) and analysis was performed using 
pCLAMP software Version 10 (Axon Instruments, Sunnyvale, CA, USA). Peptides were 
prepared by serial dilutions in ND96 (96 mM NaCl, 1.8 mM CaCl2, 2 mM KCl, 2 mM MgCl2, 
5 mM HEPES) solution supplemented with 0.1 % bovine serum albumin (BSA, fatty acid 
free) to minimize adsorption to plastic surfaces.  
 
Stability Assays 
Thermal stability was assessed by dissolving Hm3a, PcTx1 or oxytocin in 10 mM 
phosphate buffer pH 7.4 to a final concentration of 25 mM. Samples were incubated at 55 
°C and triplicate samples were taken at t = 0, 2, 4, 8, 24, 48, and 72 h, quenched with 5% 
TFA solution, centrifuged at 17 000 g for 25 minutes and analyzed using RP-HPLC. The 
peak corresponding to intact peptide was identified by comparison to an untreated sample 
and mass determination via MALDI-TOF MS. Levels of peptide were quantified by 
integration of the peak area recorded at 214 nm, and plotted as a percentage of the peak 
area at t = 0 for each respective sample. 
Serum stability was performed using male AB human serum (Sigman-Aldrich) and 
cerebrospinal fluid (CSF) stability using pooled human CSF collected from healthy 
volunteers (acquired from The Macquaire Motor Neurone Disease Research Centre, 
Macquarie University, NSW, 2109, Australia). Both serum and CSF were pre-warmed to 
37 °C for 15 minutes and added to lyophilized Hm3a, PcTx1, human atrial naturetic 
peptide, or oxytocin to a final concentration of 50 mM. Triplicate samples were taken at t = 
0, 1, 2, 4, 8, 12, 24, and 48 h, quenched with 20% TFA solution, and stored at 4 °C for 15 
minutes to precipitate serum or CSF proteins. Samples were centrifuged at 17 000 g for 25 
minutes and analyzed using RP-HPLC. The peak corresponding to intact peptide was 
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identified by comparison to an untreated sample and mass determination via MALDI-TOF 
MS. Levels of peptide were quantified as described above. 
 
Deposition of Protein and cDNA Sequence Information. 
Peptide sequence information derived for Hm3a has been submitted to the publicly 
accessible ArachnoServer spider-toxin database30. The ArachnoServer accession 
numbers for Hm3a is AS002366. Toxin records can be accessed directly using the final 
four digits of the accession number. 
 
Materials 
Chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA, via Sigma 
Australia, Castle Hill, NSW, Australia), with the exceptions of IPTG (Bioline, Alexandria, 
NSW, Australia) and TFA (Auspep Tullamarine, VIC, Australia). Recombinant TEV 
protease was produced in-house using a previously described protocol 53. 
 
Animal Welfare and Ethics Statement. 
Oocyte studies complied with the Australian code of practice for care and use of 
animals for scientific purposes, 8th Ed. 2013. The protocol was approved by The University 
of Queensland Animal Ethics Committee (Approval No. QBI/059/13/ARC/NHMRC). 
Xenopus laevis oocytes were obtained via recovery surgery performed under tricaine 
methanesulfonate anaesthesia (animals bathed in 1.3 mg/ml). The minimum time between 
surgeries on the same animal was 3 months. All studies involving animals are reported in 
accordance with the ARRIVE guidelines for reporting experiments involving animals 54-55. 
 
Data Analysis and Statistical Procedures 
Data were normalized to a series of control current (I/Icontrol) elicited by a drop in pH (6.0–
5.0) with only sample buffer and analyzed with the software Graphpad Prism 7 (La Jolla, 
CA, USA). The half-maximal response (IC50, EC50 or pH50) and Hill coefficient (nH) was 
obtained through a non-linear fit to the data of a four parameter logistic equation 
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("sigmoidal dose-response”). Half-life (t1/2) was obtained through a non-linear fit to the data 
of a “dissociation – one phase exponential decay” equation. Results are reported, in the 
text or on the figures, as means ± SEM. They represent the mean of n individual 
measurements on different oocytes. Statistical analysis and comparison between three or 
more groups were performed with one-way ANOVA and Tukey’s Test whilst comparison 
between two groups was performed using Student’s t-test. 
  




Steady-state desensitization curves of rASIC1a chimeras 
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Elucidating the pharmacokinetics and biodistribution of PcTx1 
following intravenous and intranasal administration 
 
4.1 Introduction 
Until recently, toxinology research was mainly focused on negating the adverse effects 
of venoms (e.g., via the development of anti-venoms). However, deepened 
understanding of the molecular basis of channelopathies and neurological disorders had 
sparked an interest in the development of venom-derived ion channel ligands as 
therapeutics and diagnostics tools226-228. Spiders, in particular, are a rich source of ion 
channel modulators. Peptides from spider venom, fine-tuned over million of years of 
evolution, are able to target various ion channels with incredible potency and specificity. 
To our advantage, these highly potent venom peptides have proven to be useful 
pharmacological tools as well as leads for agrochemical10 and pharmaceutical229 
applications. In particular, PcTx1, an ASIC1a modulator, is a valuable research tool and 
possible therapeutic lead molecule for several neurological diseases where gaining 
access to the CNS is crucial for its use in in vivo studies (as detailed in Chapters 1 and 
3). However, achieving an effective dose of PcTx1 in the brain is challenging as the 
brain is enveloped by the blood-brain barrier.  
 
The BBB is responsible for maintaining delicate homeostasis in the brain and it prevents 
the influx of unwanted molecules, which unfortunately includes most drugs and drug 
leads172, 230. In general, only compounds with a molecular weight less than 400–600 Da, 
a polar surface <70 Å2 and an octanol-to-water partition coefficient close to 3.4 have the 
potential to cross the BBB by passive diffusion231. As such, PcTx1 (~4.8 kDa) is unlikely 
to reach the brain via conventional parenteral routes such as IV administration. Indeed, 
intracerebroventricular administration, but not IV, administration of “PcTx1 venom” and 
PcTx1 provided neuroprotection in rat model for stroke141-142. Interestingly, IN 
administration of “PcTx1 venom” did result in substantial neuroprotective effects in a 
rodent model of stroke141, indicating that IN administration of PcTx1 may be able viable 
route to bypass the BBB and reach the brain. However, as PcTx1 constitutes only 
~0.4% of P. cambridgei venom142, it remains unclear if the neuroprotection following IN 
administration of “PcTX1 venom” was due to PcTx1 inhibition of ASIC1a or from other 
bioactive molecules present in the venom. Thus, we are interested in understanding the 
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therapeutic efficacy of pure PcTx1 and differences in its pharmacokinetics following IN 
and IV administration.  
 
An understanding of a molecule’s pharmacokinetic properties is critical to the 
development and assessment of new therapeutic agents. Detailed analysis of 
absorption, distribution, metabolism, and excretion (ADME) is required by regulatory 
agencies that govern the approval process230. Traditional pharmacokinetic and 
biodistribution studies for pharmaceutical agents involve blood and tissue sampling at 
various time-points to determine local concentrations and serum half-life232. Non-
invasive in vivo imaging techniques such as positron emission tomography (PET), 
optical imaging, X-ray computed tomography (CT) and magnetic resonance imaging 
(MRI) are increasingly being used to investigate the biodistribution and 
pharmacokinetics of drugs as opposed to conventional tissue biodistribution (ex vivo) 
studies233. A distinct advantage of in vivo imaging is the ability to perform repeated, 
serial imaging on the same animal, thereby reducing the number of animals required 
and providing finer time resolution. 
 
Amongst the in vivo imaging techniques, PET and optical imaging are regarded as 
quantitative or semi-quantitative imaging modes234 due to their superior detection 
sensitivity, whereas CT and MRI are normally used for anatomical imaging purposes as 
they provide better spatial resolution235-236. As summarised in Table 4.1, each imaging 
technique has advantages and limitations. Hence, combinations of complementary 
imaging modes (i.e. PET/CT or PET/MRI) are used to provide high sensitivity and 
enhanced anatomical localisation of the molecule in question237-238. 
 
PET imaging allows quantitative in vivo biodistribution studies of molecules labelled with 
PET tracers (positron-emitting radionuclides) with unparalleled sensitivity. PET tracers 
undergo radioactive decay resulting in emission of positrons (an anti-electron)239. The 
positron travels for 1–2 mm before colliding with an electron, resulting in annihilation 
and emission of two 511 keV photons that move in opposite (180o) directions. These 
photons are sensed by the gamma detector and their source location computationally 
calculated. Thus, the detection of two 511 kEV photons can be directly translated to the 
frequency of annihilation events and distribution of the PET-labelled molecule239. PET 
tracers such as carbon-11, oxygen-15, fluorine-18, gallium-68, copper-64, and bromine-
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76 have half-lives ranging from 20 min to 16 h 234. Long-lived PET tracers such as 
zirconium-89 and iodine-124 with half-lives of 3.2 days and 4.2 days are also 
available234. The use of PET imaging in the drug development process can be directly 
translated from animals to humans as it is a clinically relevant imaging technique240. 
However, PET imaging has several drawbacks, including the exposure to ionising 
radiation, and thus requires a high level of technical expertise. It is also limited by the 
half-lives of radionuclides, high cost of radionuclide production, and the generation of 
radioactive waste.  
 
Compared to PET imaging, optical imaging using near-infrared (NIR) probes provides a 
simpler, non-ionising and relatively sensitive method for in vivo imaging. The use of 
probes at NIR wavelengths (750–900 nm) enables clearer discrimination between the 
signal from the probe and background autofluorescence (i.e., better signal-to-noise 
ratio). Biological materials such as hemoglobin have λmax <600 nm while water has λmax 
>1150 nm; thus, in the NIR spectral range, absorbance by biological materials is 
minimised, allowing deeper penetration of NIR wavelengths (several centimeters) 
through biological tissues241. However, NIR probes are often large, organic molecules, 
which may also confound the pharmacokinetics and biodistribution of the molecule 
being studied242.  
 
A major caveat of PET and NIR optical imaging is their relatively lower spatial resolution 
as compared to CT or MRI237-238. To circumvent this issue, multimodal imaging 
approaches, such as PET/CT237 and, more recently, PET/MRI243 enables imaging with 
both high sensitivity and high anatomical resolution. In CT imaging, X-rays are used to 
generate image contrast based on differences in absorptivity of X-ray in different 
tissues. Multiple X-ray slices are taken then computationally assembled and 
reconstructed into 3D images. 
 
In comparison, MRI provides better contrast in soft tissues such as the brain, using the 
intrinsic properties of protons in different tissues (such as water or fat) to generate 
contrast244. The magnetic dipole moment of protons are aligned with the external 
magnetic field of an MRI machine. Radiofrequency (rf) pulses are then used to disrupt 
the alignment. When protons return to their initial alignment (i.e. aligned with the 
external magnetic field) via a process known as relaxation, they lose energy by emitting 
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rf radiation that is detected by a receiver coil. Thus, image contrast is based on the 
differences in relaxation properties and density of protons, which influence the signal 
intensity obtained. Tissues with higher water content (slow relaxation) have different 
signal intensity as compared to tissue with higher fat content (fast relaxation)245.  
 
Table 4.1: Comparison of PET, MRI and NIR imaging235, 237-238, 241. 
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In order to evaluate the efficiency of IN administration as a method for CNS delivery of 
venom peptides, we decided to use PcTx1 as a model peptide. PcTx1 is a highly potent 
ASIC1a inhibitor which had been used extensively in in vivo studies with no reports of 
toxicity141. Moreover, there have been extensive structure-activity relationship (SAR) 
studies undertaken on PcTx1, providing a clear understanding of the epitopes important 
for activity, and sites that can be manipulated without affecting its inherent function. 
Most importantly, neuroprotection of the brain was observed with IN administration of 
P. cambridgei venom in a mouse model of stroke, strongly that IN administration is a 
plausible method for delivering PcTx1 to the CNS. Hence, we decided to combine in 
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vivo imaging techniques and traditional ex vivo tissue sampling to study the uptake of 
PcTx1 in the brain following IN administration.  
 
Given that one single imaging mode is unlikely to be sufficient to completely understand 
the pharmacokinetics and biodistribution of PcTx1, we employed different labelling 
strategies to allow use of different methods of in vivo imaging of PcTx1. This chapter 
describes the production and characterisation of PcTx1 analogues and studies of their 
pharmacokinetics and biodistribution using PET, MRI and NIRF imaging. 
 
4.2 Materials and Methods 
4.2.1 Recombinant expression and purification of PcTx1 and TyrN_PcTx1 
Recombinant PcTx1 (wild-type) and the variant TyrN_PcTx1 (i.e., PcTx1 with an 
additional N-terminal Tyr residue) were produced using the E. coli periplasmic system 
described in Chapters 2 and 3. The non-native tyrosine in TyrN_PcTx1 was introduced 
via site-directed mutagenesis of the WT PcTx1 plasmid using standard PCR 
protocols246.  
 
4.2.2 Solid-Phase Peptide Synthesis of AHA-PcTx1 (azPcTx1) 
In order to achieve site-specific coupling through azide-alkyne Huisgen cycloaddition, a 
variant of PcTx1 (azPcTx1) containing L-azidohomoalanine (AHA) was synthesised by 
Mr Zoltan Dekan (IMB, University of Queensland, Australia). The peptide was produced 
using standard solid-phase peptide synthesis (SPPS) protocol with 9-
fluorenylmethyloxycarbonyl (Fmoc) as the α-amino protecting group. The side-chain 
protecting groups were Arg(Pbf), Asn(Trt), Asp(OtBu), Cys(Trt), Glu(OtBu), His(Trt), 
Lys(Boc), Ser(tBu), Thr(tBu) and Trp(Boc) (Chem-Impex International, Illinois, USA) 
 
The peptide was synthesised (0.1 nmol scale) using a Symphony Automated Peptide 
Synthesiser (Protein Technologies Inc. Arizona, USA) on Fmoc-Thr(tBu)-Wang 
polystyrene resin (loading 0.68 nmol/g) (Peptides International Inc., Kentucky, USA). 
Chain assembly was performed following an established in situ neutralisation 
method247. Briefly, Fmoc deprotections were achieved using 30% piperidine in 
dimethylformamide (DMF) (1 x 1.5 min, then 1 x 4 min). Amino acid couplings (2 x 20 
min) were performed in DMF using five equivalents of Fmoc-amino acid/2-(1H-
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Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU)/diisopropylethylamine (DIEA), at 1:1:1 ratio, relative to resin loading capacity. 
After assembly of the peptide chain, the resin was rinsed with 50% methanol (MeOH) 
and dichloromethane (DCM) then dried under vacuum.  
 
Cleavage from resin and removal of side-chain protecting groups was achieved by 
treatment with 50 mL of 95% TFA/2.5% triisopropylsilane (TIPS)/2.5% H2O at room 
temperature for 2 h. After most of the cleavage solution was evaporated under a stream 
of N2, the products were precipitated and washed twice with cold diethyl ether (Et2O) 
and lyophilised from 50% MeCN/0.1% TFA/H2O. Electrospray ionisation mass 
spectrometry (m/z): calculated (average) [calc. (avg.)] [M+4H]4+ = 1206.4, observed = 
1206.3. 
 
The purified linear peptide was oxidised as follows: peptide (50 mg), reduced 
glutathione (100 equiv.) and oxidised glutathione (10 equiv.) were dissolved in 50 mL of 
8 M urea then added to a 450 mL of 5 M NH4OAc (pH 8.0) and stirred for 3 days at 4°C 
with exposure to air. The refolding was monitored using analytical RP-HPLC. 
 
4.2.3 Synthesis of alkyne DOTA (1,4,7,10-tetraazacyclododecanetetraacetic 
acid) tags 
DOTA-propargylgylcine (1xDOTA) and 4xDOTA-DBCO (4xDOTA) were manually 
assembled (0.1 mmol scale) on a Fmoc-propargylglycine (Boc)-Rink polystyrene resin 
(loading 0.62 mmol/g). Amino acid or DOTA side-chains were protected as follows; 
propargylglycine(Fmoc), Lys(Boc), Lys(Fmoc), DOTA(tBu).  
 
The synthesis strategies for 1xDOTA and 4xDOTA are shown in Fig. 4.3. Fmoc 
deprotections were achieved using 50% piperidine/DMF (1 x 2 min, then 1 x 4 min). 
Couplings were performed in DMF using four equivalents of Fmoc-amino acid/HATU (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate)/DIEA (1:1:1) relative to resin loading for 1 x 20 min. Overnight 
coupling of DOTA-tri-t-Bu-ester was performed in DMF using 1.5 equivalents of t-Bu-
DOTA/HATU/DIEA (1:1:1). Cleavage from the resin and removal of side-chain 
protecting groups was achieved by treatment with 95% TFA/2.5% TIPS/2.5 % H2O at 
room temperature for 4 h. The cleavage solution was evaporated under a stream of N2, 
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the products were precipitated and washed with cold Et2O then lyophilised from 50% 
MeCN/0.1% TFA/H2O. 
 
Derivatisation of the 4xDOTA with a dibenzocyclooctyne (DBCO) functional group was 
achieved by incubating 3 equiv. of 4xDOTA with 1 equiv. of dibenzocyclooctyne-N-
hydroxysuccinimidyl ester (DBCO-NHS ester) in 0.1 M sodium phosphate, pH 7.6 for 4 
h. The product was purified using RP-HPLC and quantified based on UV absorbance at 
309 nm (ε309 DBCO = 12,000 M-1.L.cm-1). ESI MS (m/z): calculated (average) 499.5 
[M+H]1+, found 499.4 (1xDOTA); MALDI-TOF MS (m/z): calculated 2362 [M+H]1+, found 
2365.9 (4xDOTA). 
4.2.4 Azide-alkyne Huisgen cycloaddition   
Coupling between azPcTx1 and the alkyne imaging moiety was achieved using Cu(I)-
catalysed azide/alkyne cycloaddition (CuAAC)248 using one equiv. of azPcTx1 with two 
equiv. of alkyne. The reaction was carried out in 50 mM MES, pH 6 buffer containing 
0.5 mM copper(II) sulphate, 2.5 mM Tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA), and 6.3 mM aminoguanidine hydrochloride. The reaction was initiated by 
addition of 6.3 mM sodium ascorbate then the mixture was incubated overnight at room 
temperature with gentle mixing. Due to the possibility of copper chelation by DOTA, the 
1xDOTA tag was preloaded with gadolinium by incubating it with 10 equiv. of 
gadolinium chloride (GdCl3) in 50 mM MES buffer at pH 6 for > 12 h. 
 
A copper-free click chemistry was used for coupling of azPcTx1 and the 4xDOTA tag 
using Strain-Promoted [3 + 2] Azide−Alkyne Cycloaddition (SPAAC)249. The reaction 
mixture contained 1 equiv. of azPcTx1 and 1.5 equiv. of 4xDOTA tag in 50 mM MES, 
pH 6 buffer. The 4xDOTA tag was also chelated with 40 equiv. of GdCl3 concurrently in 
the same reaction vessel. The mixture was incubated for > 12 h and purified using RP-
HPLC. 
 
4.2.5 Relaxation studies of DOTA-labelled peptides  
Data and image acquisition for MR relaxation studies of aqueous azPcTx1, Gd-DOTA-
PcTx1 and 4x-Gd-DOTA-azPcTx1 solutions (20, 50 and 150 µM) were acquired on a 
Bruker Biospec 9.4 T small animal imaging spectrometer (Ettlingen, Germany) by Dr 
Yas Tesiram (CAI, University of Queensland). Longitudinal relaxation times (T1) for 
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these samples were measured using a saturation recovery with a spin echo data 
acquisition scheme. In this experiment the echo time  (TE) was kept constant at 7 ms, 
and the repetition time (TR) was varied (TR = 988–10000 ms). For the images, the field 
of view (FOV) was 12 × 12 mm, matrix = 96 × 96, slice thickness = 0.5 mm, and number 
of averages = 2. Transverse relaxation times (T2) were measured using a multi-slice 
multi-echo (MSME) sequence with 128 echoes. The experimental parameters were TR = 
10000 ms, TE = 0.06–0.768 s, FOV = 12 × 12 mm, matrix = 96 × 96, slice thickness = 
0.5 mm. 
 
MR images were analysed using ImageJ250 and mean signal intensity calculated from 
circular regions of interest (ROI) of the samples (Fig. 4.6A,B) to obtain plots of signal 
intensity against TR or TE (Fig. 4.6C,E). The recovery curves for T1 and T2 time 
estimation, were fitted to a non-linear, least square fit, based on a “one-phase decay” 
equation, using the software Prism 6.0 (La Jolla, USA). The longitudinal relaxivity (r1) 
and transverse relaxivity (r2) of the compounds were calculated from the slopes of the 
plots of 1/T1 and 1/T2 versus the sample concentrations. All curve fitting and statistical 
analysis were performed using Prism 6.0 (La Jolla, USA). 
 
4.2.6 Iodination of TyrN_PcTx1  
TyrN_PcTx1 was iodinated using chloramine-T251. Briefly, 7.5 µl of 0.1 M sodium iodide 
(7.5 nmol) was added to TyrN_PcTx1 (7.5 nmol) in 135 µl of 0.1 M phosphate buffer, pH 
7.5. The reaction was initiated by adding 15 µl of 3 mM chloramine T (15 nmol) with 
gentle mixing. The mixture was incubated for 1 min at room temperature, then diluted to 
0.5 mL with Solvent A. Separation of unlabelled, mono-iodinated, and di-iodinated 
PcTx1 was performed using analytical C18 RP-HPLC and isolated products confirmed 
using mass spectrometry.  
 
4.2.7 Two-electrode voltage clamp electrophysiology (TEVC)   
The ASIC1a inhibitory activity of PcTx1 variants (modified with different imaging 
moieties) was assessed using TEVC electrophysiology on X. laevis oocytes. Oocyte 
digestion, cDNA/cRNA preparation, injections and data analysis were performed as 
described in Chapter 3.  
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4.2.8 Thermal, serum and cerebrospinal fluid stability assay  
The thermal and metabolic stability of PcTx1 was assessed at 55oC using human serum 
or human CSF as described in Chapter 3.  
 
4.2.9 Iodine-124 iodination and TLC purification 
Iodination of TyrN_PcTx1 and TLC purification of iodinated products was performed by 
Dr Rajiv Bhalla (CAI, University of Queensland). Lyophilised TyrN_PcTx1 (200 µg) was 
reconstituted in 300 µL of 0.1 M phosphate buffer pH 7.45, and added to an iodogen 
tube (Thermo Scientific, Australia). Then, iodine-124 (124I, produced in-house as sodium 
iodide at CAI), dissolved in 100 µL of 0.05 M NaOH, was added to the same iodogen 
tube. The tube was capped and gently agitated then incubated at room temperature for 
~35 min. The labelling efficiency and radiochemical purity were determined using	instant 
thin-layer chromatography strips (iTLC) (Agilent Technologies, Australia) using saline as 
the mobile phase. The result from iTLC was verified with RP-HPLC on a C18 column 
(Agilent ZORBAX Eclipse Plus, 150 x 4.6 mm x 5 µm, 95 Å) using a gradient of 15–35 
% Solvent B over 20 min. 
 
4.2.10 in vivo PET/CT imaging  
PET/CT data were acquired using an Inveon multimodality PET/CT imaging scanner 
(Siemens, Australia). Animal preparation, peptides administration, PET/CT data 
acquisition, organs harvesting, gamma counting, data acquisition and image analyses 
were performed by Dr Karine Mardon (CAI) and/or Ms Xin Song (CAI). Briefly, mice 
were anaesthetised with isoflurane (IsoFlo, Abbott Laboratories) at a dose of 2% in a 
closed anaesthetic induction chamber. Mice were monitored using ocular and pedal 
reflexes to ensure deep anaesthesia. Once the mouse was deeply anesthetised, it was 
placed on an appropriate animal bed, where the anaesthetic air mixture (1%) was 
delivered to its nose and mouth through a nose cone. Physiological monitoring 
(respiration using a sensor probe) was achieved throughout all experiments using an 
animal monitoring system (BioVetTM system, m2m Imaging, Australia). The radiolabelled 
124I-PcTx1 was administered intravenously (1.5–2.0 MBq) through the tail vein or via the 
intranasal route (0.5–0.3 MBq).  
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For IV administration, the injection syringe was filled with the radioisotope solution 
(approximately 150 µL in 0.1 M phosphate buffer, pH 7.45) and the activity in the 
syringe was measured using a dose calibrator (Capintec CRC-25, USA). The activity left 
in the syringe after the tail vein injection was measured using the same dose calibrator 
and the total volume injected into each mouse was calculated. For IN administration, 
mice were first placed in a supine position, then a 2.5–5 µL droplet of 124I-PcTx1 was 
pipetted into the nostril. The process was repeated several times using alternating 
nostrils until the required dosage was achieved. The maximum volume administered 
was 20 µL per mouse. 
 
Following injection of the radiotracer, PET Images were acquired for 90 min (dynamic 
acquisitions) or 30–60 min (static acquisitions) following IV or IN administration, 
respectively. PET Images were reconstructed using an ordered-subset expectation 
maximisation (OSEM2D) algorithm and analysed using the Inveon Research Workplace 
software (IRW 4.1) (Siemens). Immediately after PET acquisition, CT scans were 
acquired for anatomical co-registration. The CT images of the mice were acquired 
through an X-ray source with the voltage set to 80 kV and the current set to 500 µA. 
The scans were performed using 360° rotation via 120 rotation steps with a low 
magnification and a binning factor of four. The exposure time was 230 ms with an 
effective pixel size of 106 µm. The total CT scanning process took approximately 15 
min. The CT images were reconstructed using Feldkamp reconstruction software 
(Siemens).  
 
Following CT imaging, fusion of CT and PET images and definition of regions of interest 
(ROIs) were performed using IRW 4.1. CT and PET datasets of each individual animal 
were aligned using IRW software (Siemens) to ensure good overlap of the organs of 
interest. Three-dimensional ROIs were placed within the whole body, as well as all the 
organs of interest, using morphologic CT information to delineate organs. Activity per 
voxel was converted to nci/cc using a conversion factor obtained by scanning a 
cylindrical phantom filled with a known activity of 124I to account for PET scanner 
efficiency. Activity concentrations were then expressed as percent of the decay-
corrected injected activity per cm3 of tissue that can be approximated as percentage 
injected dose/g (%ID/g). The dynamic tracer uptake was calculated post reconstruction 
of PET data sets into 35 frames. 
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4.2.11 Post mortem biodistribution study   
At various time points after administration of the radiotracer, tissue samples were 
collected for gamma counting in a collaborative effort with Dr Karine Mardon and Ms Xin 
Song (CAI) in order to determine peptide biodistribution. Mice were injected in a group 
of four at t = 0 and sacrificed at different time points after injection of 124I-PcTx1. For IN 
administration, mice were given a dose of approximately 0.30–1.00 MBq in a maximum 
volume of 20 uL. Anesthetised mice were sacrificed by cervical dislocation and organs 
including, heart, lung, liver, spleen, kidney, stomach, gut, muscle, nose and brain were 
surgically removed, weighed and placed in tubes. The brains were further dissected into 
different regions including medulla pons, cerebellum, midbrain, hypothalamus, 
hippocampus, striatum, frontal cortex, posterior cortex and olfactory bulb. Radioactivity 
was counted using a gamma counter (Wizard 2480, Perkin Elmer). Tissue uptake was 
obtained based on the specific activity of 124I-labelled TyrN_PcTx1 (determined from 
standards sampled from the dose solution), counts per minute in the tissue following 
subtraction of background radioactivity, and tissue weight in grams. Radioactivity 
concentrations were then expressed as percent of the decay-corrected injected activity 
per g of tissue that can be approximated as percentage injected dose/g (%ID/g). Dose-
normalised concentrations in brain from intranasal experiments were calculated and 
expressed in nmol/L (assuming a density of 1 g/mL).  
 
4.2.12 Reversed-phase high performance liquid chromatography  
Unless otherwise stated, RP-HPLC fractionations were performed as described. 
Preparative RP-HPLC was performed with a C8 column (Grace Vydac, 250 x 22 mm) 
attached to a Ultimate 3000 LC system (Dionex, Sunnyvale, USA). Semi-preparative or 
analytical RP-HPLC was performed on a Prominence HPLC system (Shimadzu, Kyoto, 
Japan) with a C4 semi-preparative column (Phenomenex Jupiter, 250 x 10 mm x 10 µm, 
300 Å) at 5 mL/min; C18 analytical column (Phenomenex Kinetex, 250 x 4.6 mm x 5 µm, 
100 Å) at 1 mL/min; C18 narrow-bore column (Thermo Hypersil, 100 x 2.1 mm x 5 µm, 
180 Å) at 0.3 mL/min. Fractions were separated using a gradient of Solvent A (0.05% 
TFA in H2O) and Solvent B (0.043% TFA, 90% MeCN in H2O). Fractions were manually 
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4.2.13 Mass determination  
Peptide masses were obtained using electrospray ionisation mass spectrometry (ESI-
MS; (LCMS-2020 Shimadzu, Kyoto, Japan) or matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) using a Model 
4700 Proteomics Bioanalyser (Applied Biosystems, Carlsbad, USA). For MALDI-TOF 
MS, samples were spotted 1:1 (v/v) with α-cyano-4 hydroxycinnamic acid matrix 
(CHCA) (7 mg/mL in 50% acetonitrile/1% formic acid in H2O). Observed masses are 
reported as monoisotopic m/z or average mass.  
4.2.14 Animals  
Male wild-type (C57BL6) mice, ~12–15 weeks old, weighing 25–30g, were obtained 
from local breeding colonies (University of Queensland Biological Resources, Australia). 
Mice were maintained under standard conditions in clean holding facilities on a 12 h 
light–dark cycle with ad libitum access to food and water. All procedures for X. laevis 
oocytes electrophysiology studies and mice PET/CT biodistribution studies were in 
compliance with the Australian code of practice for care and use of animals for scientific 
purposes and approved by The University of Queensland Animal Ethics Committee 
(Approval number QBI/059/13/ARC/NHMRC and CAI/398/14/NHMRC). Oocytes were 
obtained by trained personnel via recovery surgery performed on mice under tricaine 
methanesulfonate anaesthesia. The minimum time between surgeries on the same 




4.3.1 Recombinant expression and purification of PcTx1 variants 
Recombinant TyrN_PcTx1 was produced using the E. coli periplasmic expression 
system (Fig. 4.1A) described in Chapter 2. Fig. 4.1B shows an SDS-PAGE gel 
illustrating various stages in the expression and purification of TyrN_PcTx1. Following 
IPTG induction, the His6-MBP-PcTx1 fusion protein (~43 kDa) was the major cellular 
protein produced (Fig. 4.1B, compare lanes 2 and 3). The majority of the fusion protein 
was soluble with a small amount in the insoluble fraction (Fig. 4.1B, compare lanes 4 
and 5). Following Ni-NTA purification, the soluble fusion protein was obtained in high 
purity as indicated by a single protein band at 43 kDa (Fig. 4.1B, lanes 6–8). The 
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peptide was liberated from the fusion protein using TEV protease as indicated by a ~4.5 
kDa shift of the protein band on SDS-PAGE  (Fig. 4.1B, compare lanes 9 and 10). The 
cleavage mixture containing TyrN_PcTx1 was purified using semi-preparative C4 RP-
HPLC (Fig. 4.1C), then further purified to >95% purity as judged by the elution of a 
single peak on analytical C18 RP-HPLC (Fig. 4.1D). The observed monoisotopic mass 
for recombinant TyrN_PcTx1 (4774.29) is in agreement with the theoretical 
monoisotopic mass of 4774.21 (Fig. 4.1D inset).  
 
 
Figure 4.1. (A) Top panel: Schematic representation of the coding region of the pLic-MBP expression 
vector. This IPTG-inducible plasmid contains genetic components encoding the MalESS-His6-MBP-peptide 
fusion protein with a TEV protease recognition site between the MBP and toxin coding regions and an 
IPTG-inducible Lac operon. Bottom panel: An illustration of the E. coli periplasmic expression system. 
The fusion protein is expressed within the cytoplasm. The MalE signal sequence directs the translocation 
of the fusion protein to the periplasm via the SecYEG translocase system. The Dsb machinery in the 
periplasm catalyses the formation of disulfide bonds. (B) SDS-PAGE gel showing various steps in the 
expression and purification of TyrN_PcTx1. The lanes (from left to right) are as follows: (1) molecular 
weight markers; (2) whole-cell extract before IPTG induction; (3) whole-cell extract after IPTG induction; 
(4) insoluble fraction after lysis of induced cells; (5) soluble fraction after lysis of induced cells; (6) flow-
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through from loading of soluble cell fraction onto Ni-NTA column; (7) eluate from wash of Ni-NTA column 
with 5 mM imidazole; (8) eluate from wash of Ni-NTA column with 250 mM imidazole; (9) eluted His6-
MBP- TyrN_PcTx1 fusion protein prior to TEV protease cleavage; (10) His6-MBP-TyrN_PcTx1 fusion 
protein sample after TEV protease cleavage. (C) RP-HPLC chromatogram showing purification of 
TyrN_PcTx1 from the TEV protease cleavage mixture. (D) RP-HPLC chromatograms showing final 
purification of TyrN_PcTx1 using an analytical C18 column. Inset shows a MALDI-TOF mass spectrum of 
the purified peptide. Asterisk denotes peaks with mass corresponding to the theoretical mass of 
TyrN_PcTx1. 
 
4.3.2 Chemical synthesis of azPcTx1 
Synthesis of azPcTx1 at 0.1 mmole scale resulted in approximately 430 mg of crude 
material. The m/z (1206.3) of the crude material is in agreement with the theoretical 
value of 1206.4 ([M+4H]4+). The crude product was purified using preparative RP-HPLC 
to give 110 mg of hexathiol azPcTx1. After refolding (50 mg of crude material), the 
single major product (Fig. 4.2, left panel), was obtained with a final yield of ~22% (11 
mg of folded peptide). The observed m/z (1204.7), matched the calculated value of 
1204.9 ([M+4H]4+) (Fig. 4.2, right panel), of the folded peptide. The IC50 of ~1.2 nM 
obtained for inhibition of rASIC1a by azPcTx1 (data not shown) is in agreement with 
published values for PcTx1 (IC50 ~1 nM)103-104, indicating that peptide activity is 
unaffected by the azide modification. 
 
 
Figure 4.2 Purification of azPcTx1 (Experiment performed by Mr Zoltan Dekan). Right: RP-HPLC 
chromatogram showing purification of azPcTx1 from folding reaction mixture. Left: ESI mass spectrum of 
purified folded azPcTx1. 
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4.3.3 Synthesis, derivatisation and bioconjugation of imaging moieties  
Alkyne DOTA tags were synthesised from DOTA-tri-tBu-ester (MacrocyclicsTM, TX, 
USA) as illustrated in Figure 4.3. Following removal of the protecting group (tBu), the 
observed m/z of the product (499.1 for the [M+H+] ion) is in agreement with the 
calculated molecular weight (MW) (498.5 Da) (Fig. 4.3 inset). The 4xDOTA tag was 
assembled with Fmoc-protected lysines for the incorporation of four DOTA groups and 
DBCO-NHS. The average m/z of the product (2365.99, in linear mode) is in agreement 
with the calculated MW (2362.67 Da) (Fig. 4.3 inset). 
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Figure 4.3. Schematic of 1xDOTA (synthesised by Mr Zoltan Dekan) and 4xDOTA synthesis using Fmoc 
SPPS. Inset shows mass spectra obtained using ESI and MALDI-TOF MS of the crude products after 
ether precipitation.  
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Prior to CuAAC, the 1xDOTA tag was chelated with Gd3+ to prevent chelation of Cu(I) 
by DOTA. Following CuAAC, a single product (Gd-DOTA-azPcTx1) was obtained as 
judged by RP-HPLC (Fig. 4.4A). The average m/z (5471.24) is in agreement with the 
calculated MW (5468.3 Da), which corresponds to the combined mass of azPcTx1 
(MW: 4815.6 Da), 1xDOTA (MW: 498.5 Da) and Gd3+ ion (MW: 154.3 Da) (Fig. 4.4A 
inset).  
 
The 4xDOTA tag was conjugated to azPcTx1 via SPAAC and chelated with Gd3+ 
concurrently. As shown using RP-HPLC, the reaction was highly specific and efficient 
with a single product obtained (4x-Gd-DOTA-azPcTx1) (Fig. 4.4B). The observed 
average isotopic mass (m/z 7796.3) from MALDI is in good agreement with the 
calculated MW (7795.7 Da), which corresponds to the combined mass of azPcTx1 
(MW: 4815.6 Da) coupled with the 4xDOTA tag (2362.7 Da) coordinated with four Gd3+ 
ions (617.0 Da) (Fig. 4.4B inset). 
 
 
Figure 4.4. Labelling of azPcTx1 with various imaging moieties. (A) RP-HPLC of Gd-DOTA-azPcTx1. 
Inset shows MALDI mass spectrum of product with an average m/z of 5471.24 Da. (B) RP-HPLC of 4x-
Gd-DOTA-azPcTx1. Inset shows the MALDI mass spectrum of product with average m/z of 7796.31 Da. 
 
4.3.4 Iodination of PcTx1 
Prior to radiolabelling of TyrN_PcTx1 with 124I for PET imaging, a trial iodination trial was 
performed in order to test the effect of the modification on PcTx1 activity as well as to 
obtain a standard for subsequent radiolabelling. As indicated in Fig. 4.5, iodination of 
TyrN_PcTx1 using chloramine T and sodium iodide resulted in the production of non-, 
mono- and di-iodinated variants that were easily separated using RP-HPLC. The 
observed m/z of non-, mono- and di-iodinated variants are as indicated (Fig 4.5 insets). 
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The mass increment of 125.91 Da and 251.97 Da is indicative of iodination of the tyrosyl 
group. The activity of TyrN_PcTx1 and its iodinated version was assessed using TEVC 
studies on X. laevis oocytes expressing rASIC1a. As compared to WT PcTx1 (IC50 = 0. 
47 nM), the addition of an N-terminal Tyr resulted in a ~3-fold decrease in activity (IC50 
= 1.83 nM). The activity decreased further by 4- and 8-fold with the addition of one (IC50 
= 8.37 nM) and two iodines (IC50 = 15.03 nM), respectively (Table 4.2). Nevertheless, 
all of the iodinated derivatives are potent inhibitors of rASIC1a. 
 
 
Figure 4.5. RP-HPLC chromatograms showing purification of PcTx1_TyrN before iodination (dashed, 
purple) and after iodination (black). Peaks corresponding to the mass of the mono-iodinated (Mono) and 
di-iodinated (Di) TyrN_PcTx1 are as indicated. Inset shows MALDI-TOF mass spectra of corresponding 
peaks with monoisotopic M+H+ of 4936.86 (TyrN_PcTx1), 5062.77 (mono-iodinated) and 5188.83 (di-
iodinated).  
 
Table 4.2. IC50 values for inhibition of rASIC1a by PcTx1 and TyrN_PcTx1 (mean ± SEM; n = 4). The 
modification in the TyrN_PcTx1 sequence is highlighted in red. 
PcTx1 variant Sequence IC50 (nM) 
PcTx1 SEDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT 0.47 ± 0.05 
TyrN_PcTx1 
SYEDCIPKWKGCVNRHGDCCEGLECWRRRRSFEVCVPKTPKT 
1.83 ± 0.47 
TyrN_mono_PcTx1 8.37 ± 3.00 
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4.3.5 Longitudinal and transverse  relaxation of Gd3+ loaded DOTA-azPcTx1 
Longitudinal (T1) and transverse (T2) relaxation profiles  (Fig. 4.6A,B,C,E) and relaxivity  
(Fig. 4.6D,F) for azPcTx1, Gd-DOTA-azPcTx1 and 4x-Gd-DOTA-azPcTx1 were 
determined at a magnetic field strength of 9.4 T. As summarised in Table 4.2, there 
were no significant differences in the longitudinal or transverse relaxation rates of 
azPcTx1 over the concentration range 20–150 µM. In comparison, both Gd-DOTA-
azPcTx1 and 4x-Gd-DOTA-azPcTx1 displayed concentration-dependent enhancement 
in longitudinal  (~2–3 fold) and transverse (~1.5–2.4 folds) relaxation rates. The 
calculated longitudinal relaxivities (r1) for 1xDOTA-Gd-azPcTx1 and 4xDOTA-Gd-
azPcTx1 were 4.60 ± 0.24 mM-1s-1 and 9.40 ± 0.86 mM-1s-1, respectively, a considerable 
enhancement compared to the relaxivity of azPcTx1 (–0.13 mM-1s-1). Similarly, both 
compounds were shown to enhance transverse relaxivity (r2) as compared to azPcTx1 
(0.67 ± 0.49 mM-1s-1). The calculated transverse relaxivity for Gd-DOTA-azPCTx1 and 
4x-Gd-DOTA-azPcTx1 is 11.63 ± 0.36 mM-1s-1 is 40.72 ± 0.18 mM-1s-1, respectively.  
 
Table 4.3: Summary of the longitudinal and transverse relaxation times (T1 and T2), rates (R1 and R2) and 
relaxivity (r1 and r2) of PcTx1, 1xDOTA-Gd-PcTx1 and 4xDOTA-Gd-PcTx1  
  azPcTx1 Gd-DOTA-azPcTx1 4x-Gd-DOTA-azPcTx1 
Concentration (µM) 20 50 150 20 50 150 20 50 150 
T1 (sec) 2.646 2.663 2.773 2.050 1.521 0.913 1.563 0.965 0.527 
R1 (1/T1) 0.378 0.376 0.361 0.488 0.658 1.096 0.640 1.036 1.897 
r1 (mM-1 s-1) –0.137 ± 0.013 4.60 ± 0.24  9.40 ± 0.86 
T2 (sec) 0.335 0.341 0.328 0.307 0.281 0.211 0.266 0.200 0.110 
R2 (1/T2) 2.982 2.937 3.049 3.254 3.555 4.751 3.767 5.013 9.066 
r2 (mM-1 s-1) 0.67 ± 0.49 11.63 ± 0.36 40.72 ± 0.18 
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Figure 4.6: Nuclear relaxation of PcTx1 and variants at 9.4 T (MR images acquired by Dr Yas Tesiram). 
(A) Signal intensities of the various samples in a T1-weighted MRI (1x = Gd-DOTA-azPcTx1, 4x = 4x-Gd-
DOTA-azPcTx1 and Az = azPcTx1) at a specific repetition time. (B) Signal intensities of the various 
samples in a T2-weighted MRI at a specific repetition time. (C) Plot of mean signal intensity versus 
repetition time (TR). (E) Plot of mean signal intensity versus echo time (TE) for T2 relaxation.	(D and F) 
Relaxivity of Gd3+-loaded DOTA PcTx1 obtained by plotting the T1 and T2 relaxation rates against peptide 
concentrations.  
 
4.3.6 Activity of labelled PcTx1 variants on rASIC1a and hASIC1a 
The activity of labelled PcTx1 variants were assessed on both rASIC1a and hASIC1a 
using TEVC. Addition of an azide group or imaging moieties ranging from 31 Da 
(terminal azide group) to ~2.3 kDa (4xDOTA-Gd), resulted in a slight reduction in 
potency (< 7 fold) on both human and rat ASIC1a (Fig. 4.7). The largest effect was 
observed for the fluorescently-labelled PcTx1 (AF488_azPcTx1 and CF680R_azPcTx1) 
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and the 4x-Gd-DOTA-azPcTx1 where there was ~7-fold decrease in the inhibitory 
activity.  
 












CF680R_azPcTx1 : IC50 = 3.17 ± 0.51 nM
Cy5_azPcTx1 : IC50 = 2.33 ± 0.60 nM
AF488_azPcTx1  : IC50 = 3.41 ± 0.33 nM
PcTx1 : IC50 = 0.47 ± 0.05 nM
Tyr_PcTx1 IC50 = 1.83 ± 0.47 nM
Gd-DOTA-azPcTx1: IC50 = 1.38 ± 0.13 nM
Gd-4xDOTA-azPcTx1 : IC50 = 3.00 ± 0.87 nM











azPcTx1 : IC50 = 19.11 ± 2.48 nM
CF680R_azPcTx1 : IC50 = 35.91 ± 3.15 nM
Cy5_azPcTx1 : IC50 = 36.48 ± 3.89 nM
PcTx1 : IC50 = 27.96 ± 1.24 nM
Gd-DOTA-azPcTx1: IC50 = 33.87 ± 3.21 nM
AF488-azPcTx1: IC50 = 35.23 ± 4.83 nM
4x-Gd-DOTA-azPcTx1: IC50 = 27.26 ± 2.36 nM
_	
 
Figure 4.7. Concentration-effect curves for inhibition of rASIC1a (top panel) and hASIC1a (bottom 
panel) by various PcTx1 analogues. Data points are mean ± SEM; n = 4−6. 
 
4.3.7 Stability profile of PcTx1   
PcTx1 was assessed for thermal stability at 55oC (at pH 7.4), and biological stability in 
human serum and human CSF as shown in Fig. 3.6 of Chapter 3. 
 
4.3.8 Interaction between PcTx1 and serum albumin  
We used isothermal calorimetry (ITC) and NMR chemical shift mapping (NMR-CSM) to 
determine whether PcTx1 interacts with serum albumin. ITC revealed a clear interaction  
between PcTx1 and bovine serum albumin (BSA), with the negative deflections in the  
raw data (Fig. 4.8, left panel) indicating that the interaction is exothermic as less 
energy is required to heat the sample cell. Fitting of a sigmoidal model to the binding 
isotherm (Fig. 4.8, right panel) yielded a dissociation constant (Kd) of 9.96 µM and a 
stoichiometry (n) of 0.29, indicating that up to three PcTx1 molecules may bind to a 
single BSA protein.  
  




Figure 4.8. Left panel: Raw ITC data showing the exothermic response (negative deflections) obtained 
when PcTx1 was added to monomeric BSA. Right panel: Binding isotherm obtained by integrating the 
peaks in the left panel and plotting against the molar ratio of PcTx1:BSA. Fitting of sigmoidal curve to the 
data yielded a Kd of ~ 9.96 µM. 
 
NMR-CSM is commonly used to map residues involved in protein-protein interactions. 
Typically, one protein is 15N-labelled while the interacting partner is unlabelled. Titration 
of the unlabelled partner into a solution of the 15N-labelled protein leads to an 
observable perturbation of the NMR chemical shift and/or intensity of residues at the 
protein-protein interface. Here we titrated BSA into a solution of 15N-labelled PcTx1 and 
acquired 2D 1H-15N HSQC spectra as a function of increasing BSA concentration 
(Fig. 4.9). These HSQC spectra revealed a decrease in intensity for peaks from Trp7, 
Lys25, Arg26, Arg27, Arg28, Ser29, Val32 upon addition of BSA. The signal decay 
constant (K) was obtained by fitting a one-phase decay curve to a plot of signal intensity 
versus BSA concentration, and this is shown as function of residue number in Fig. 4.10, 
left panel. The signals from residues R26, R27 and V32 experienced the highest decay 
rates. Interestingly, these residues are located in the β-hairpin loop that contains the 
majority of residues that mediate the interaction of PcTx1 with ASIC1a [add references 
here to support this statement] (Fig. 4.10, right panel). 
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Figure 4.9. Overlay of 2D 1H-15N HSQC spectra of 50 µM 15N-labelled PcTx1 in the absence (red) and 
presence of 25 µM (green), 50 µM (orange) or 150 µM (blue) BSA. Residues R26, R27 and V32 undergo 
the greatest intensity perturbation as peaks corresponding to these residues became broadened beyond 
recognition upon addition of 25 µM BSA. (Spectra were collected at the IMB by Dr Carus Lau, who is now 




Figure 4.10. Left panel: Rate of signal decay (K) as a function of residue position when PcTx1 was 
titrated with BSA. The greatest diminution in peak intensity was observed for R26, R27 and V32. Right 
panel: Surface representation of PcTx1 (PDB: 2KNI) with residues most affected by the addition of 
albumin highlighted in orange. NMR CSM experiments were performed and analysed by Dr Carus Lau.  
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4.3.9 Radiolabelling of TyrN_PcTx1 
TyrN_PcTx1 (~200 µg of peptide) was labelled with 124I using iodogen tubes. The 
radiochemical purity (RCP) of the product was >96% as indicated using both thin layer 
chromatography (TLC) (Fig. 4.11, left panel) and RP-HPLC (Fig. 4.11, right panel). 
The final radiolabelled product, 124I-PcTx1, was reconstituted in phosphate-buffered 
saline (PBS) to a final concentration of 0.5 µg/µL. The iodination was highly efficient and 
resulted in mainly mono-iodinated product as indicated by the single peak obtained in 
the RP-HPLC chromatogram (Fig. 4.11, right panel). 
 
Figure 4.11. Labelling efficiency and radiochemical purity of iodinated TyrN_PcTx1. Left: TLC trace of 
crude product after iodination. Right: RP-HPLC chromatograms of iodinated (red) and non-iodinated 
(blue) TyrN_PcTx1 eluted over a gradient of 15–35% Solvent B (90% CH3CN/0.01% TFA in water) in 20 
min (Radioiodination, HPLC and data acquisition were performed by Dr Rajiv Bhalla, Centre for Advanced 
Imaging, University of Queensland, Australia.) 
 
4.3.10  Pharmacokinetics of 124I-PcTx1 after intravenous administration 
The uptake of intravenously administered 124I-PcTx1 (1.6–2.1 MBq, ~9–25 µg) was 
monitored using PET/CT imaging (Fig. 4.12A). Radioactivity in various organs was 
measured and calculated over a time course of 90 min to obtain time–activity curves 
(TACs) (Fig. 4.12B). A biodistribution study of 124I-PcTx1 was also performed in various 
organs at different time points after intravenous injection (IV) of the radiotracer. Data is 
shown in Fig. 4.12C. 
 
The dynamic PET imaging (Fig. 4.12B) revealed a brief initial peak (0–1.75 min) of 124I-
PcTx1 in the heart and liver, as expected from a transient increase in blood-pool activity 
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following IV administration. A peak uptake of 9.9 %ID/g was observed in the heart 
(surrogate for blood concentration) at 1.75 min after administration which then declined 
rapidly to ~50% after 6.5 min. The concentration subsequently remained largely 
unchanged at ~3.5 %ID/g for up to 90 min. Similarly, a rapid increase in 124I-PcTx1 
concentration (6.2 %ID/g) was observed in the liver at 1.75 min which then gradually 
increased to 8.9%ID/g over 90 min. A large proportion of the 124I-PcTx1 accumulated in 
the kidneys, increasing from 6.8 %ID/g at 1.75 min to 16.8 %ID/g at 27.5 min, then 
slowly decreased to 11.2 %ID/g at 87.5 min. Increasing uptake was also observed in the 
thyroid (2.3–5.7 %ID/g) from 1.75–8.75 min. There was also increasing accumulation of 
124I-PcTx1 in the bladder over the 90 min time course. The low observed uptake (0.7 
%ID/g) in the brain indicates that the peptide is unlikely to cross the BBB in any 
appreciable amount.  
 
The uptake of 124I-PcTx1 in different organs at different time points after injection of the 
radiotracer was assessed using PET is shown in Fig. 4.12C. The uptake of 124I-PcTx1 
in the heart remained largely consistent from 15–240 min. Similarly, liver uptakes were 
consistent between 15–120 min, followed by a rapid decline from 120–240 min. In the 
kidneys, there was a high initial accumulation followed by a gradual decline. In 
agreement with this observation, there was also a gradual accumulation of radioactivity 
in the bladder which increased over time, indicating that the peptide is eliminated via 
renal clearance. Low uptake in the brain was observed across all time points, further 
highlighting that 124I-PcTx1 is unlikely to cross the BBB. Accumulation of 124I-PcTx1 was 
also observed in the thyroid and stomach. However, this is likely a result of 
dehalogenation and iodide sequestration in these organs and not peptide uptake.  
 
The results obtained from the PET imaging data were supported by ex vivo 
biodistribution studies using gamma counting of the dissected tissues. As summarised 
in Figure 4.12D, the average uptakes (90 min, 120 min, 150 min, 240 min and 270 min) 
in various tissues were largely consistent, in the blood (4.1 ± 0.5 %ID/g), heart (1.7 ± 
0.3 %ID/g), lungs (3.6 ± 0.8 %ID/g), spleen (2.2 ± 0.7 %ID/g) and brain (0.18 ± 0.04 
%ID/g). The high amount of 124I-PcTx1 measured in the kidneys indicates that renal 
clearance is the main route of elimination of the radiotracer.  
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Figure 4.12 Pharmacokinetics of 124I-PcTx1 following IV administration. (A) Representative whole-body 
PET/CT images of C57BL6 mice showing peptide distribution after IV administration at various time 
points. (B) Time-activity curves (TACs) of 124I-PcTx1 in various tissues over 90 min. (C) The in vivo 
distribution of 124I-PcTx1 assessed using PET/CT imaging (paired t-test, p = 0.5824, n.s.).. (D) Ex vivo 
biodistribution of 124I-PcTx1 determined using gamma counting of dissected tissues (paired t-test, p = 
0.8460, n.s.). Data for PET/CT images are measured using ROI–based analysis in mice. All uptake 
values are expressed as %ID/g. (Data are mean ± S.D., n = 1–4). PET/CT images, time activity curves 
and biodistribution studies were performed by Dr Karine Mardon.  
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4.3.11  Pharmacokinetics of 124I-PcTx1 after IN administration 
We studied the pharmacokinetics of intranasally administered 124I-PcTx1 (~0.3 MBq, 
~5 µg) using PET imaging (Fig. 4.13A,B) and biodistribution at 30 min, 110 min and 
220 min after injection of the radiotracer (Fig. 4.13C,D). Static PET images were taken 
90 min and 180 min after administration (Fig. 4.13A). There was no significant 
difference in the biodistribution at 90 min or 180 min post intranasal administration (p = 
0.3335, n.s.). The majority of the peptide appears to be still in the nasal cavity at 90 min 
(133. 5 %ID/g) and 180 min (~30.48 %ID/g) post-injection of 124I-PcTx1. Systemic 
uptake is evident as indicated by radioactivity in the whole body, heart and lungs. 
Interestingly, CNS uptake was also observed with ~2.8 and ~1.9 %ID/g in the brain at 
90 min and 180 min, respectively. Similar to IV administration of 124I-PcTx1, renal 
clearance is likely the main route of elimination as indicated by accumulation of peptide 
in the bladder at 90 min (16.0 %ID/g) and 180 min (44.8 %ID/g) (Fig. 4.13B).  
 
The results from static PET imaging were supported by the data obtained with the in 
vivo biodistribution studies of 124I-PcTx1 at 30 min, 110 min and 220 min post IN 
administration (Fig. 4.13C,D). Similarly, there was no significant difference in the 
distribution of 124I-PcTx1 in various organs over time (p = 0.4091, n.s.). A large 
proportion of the peptide remained in the nasal cavity as indicated by the high 
radioactivity at 30 min, 110 min and 220 min, with an average %ID/g of 14.8 ± 7.0. In 
good agreement with PET imaging, systemic exposure of 124I-PcTx1 is evident based 
on the average uptake over time (30, 110 and 220 min) in the blood (2.7 ± 0.2 %ID/g) 
and peripheral organs including the heart (1.3 ± 0.3 %ID/g), lungs (1.6 ± 0.4 %ID/g), 
spleen (1.6 ± 0.9 %ID/g), liver (0.9 ± 0.2 %ID/g), gastrointestinal tract (guts) (3.1 ± 1.0 
%ID/g), and muscle (0.9 ± 0.6 %ID/g) (Fig. 4.13C). The brain was further dissected to 
characterise the distribution of peptide within the brain (Fig. 4.13D). There was no 
significant difference in the distribution of 124I-PcTx1 in different regions of the brain over 
time (p = 0.2522, n.s.). In comparison to IV, higher brain uptake was observed following 
IN with the highest concentrations found in the olfactory bulb in all three groups (1.12 ± 
0.66 %ID/g). Radioactivity was also detected in other parts of the brain including the 
medulla/pons, cerebellum, frontal cortex, and posterior cortex; the however, the uptake 
values for these brain regions were similar to the level of whole-brain uptake observed 
with IV administration. 
 
  



































































































90 min 180 min
  
Figure 4.13. Uptake (%ID/g) of 124I-PcTx1 after IN administration. (A) Example PET/CT image of mice at 
90 min and 180 min post IN administration of 124I-PcTx1. (B) In vivo PET imaging data at 90 min and 180 
min after IN administration. Measurements were obtained using ROI–based analysis of PET data sets in 
mice (paired t-test, p = 0.3335, n.s.). .Ex vivo biodistribution data of (C) organs (one-way ANOVA, p = 
0.4091, n.s.) and (D) brain section (one-way ANOVA, p = 0.2522, n.s.) at 30 min, 110 min, 220 min after 
injection. All uptake values are expressed as % ID/g. Data are mean ± S.D, n= 3–4. PET/CT images, time 
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4.4 Discussion  
4.4.1 Production and characterisation of labelled PcTx1 variants for PET, MRI 
and fluorescence imaging 
In the present study, variants of PcTx1 labelled with different imaging moieties were 
produced and characterised. These peptides were produced to facilitate 
pharmacokinetic and biodistribution studies of PcTx1 as a model SVP. Labelled PcTx1 
variants were obtained through two main approaches: recombinant production of a 
tyrosine-containing mutant for iodination, and chemical synthesis of an azide-
functionalised mutant (azPcTx1) for bioconjugation with different alkyne-functionalised 
imaging moieties. These labelled peptides were made for complementary PET, MR and 
fluorescence imaging to enable visualisation of the peptide in vivo.  
 
PET has unrivalled sensitivity (at pM range) compared to other imaging modalities (µM 
to mM range), thus making it a method of choice for molecular imaging in drug 
development studies. In a typical PET study, the compound (in this case, TyrN_PcTx1) 
is labelled with a PET tracer (radioisotope) for visualisation. Due to the uncertainty in 
the pharmacokinetic properties of PcTx1 (i.e. clearance rates), 124I was chosen as the 
tracer due to its relatively long half-life of ~4.2 days, thereby allowing an extended 
period of study, if needed. In comparison, the half-life of 18F (another common PET 
tracer) is ~110 min, restricting the length of the study to only several hours252. 
Moreover, 124I-labelled peptides can be produced through iodination of tyrosine (and to 
a lesser extent, histidine) without the need for modification with large functional groups 
that might have affect the peptide's physicochemical properties. 
 
Iodination of tyrosine residue is a commonly used method for radiolabelling peptides or 
proteins251. Although PcTx1 contains a histidine residue that could potentially be 
iodinated, the reaction is 30–100 times slower than with tyrosine, requiring harsher 
conditions, longer reaction times, and excessive iodine253. Due to the lack of tyrosine in 
the sequence of PcTx1, a variant containing a non-native tyrosine was produced, based 
on the success of this approach for radioligand binding assays where the authors 
demonstrated that incorporating a tyrosine residue at either N- or C-terminus and 
iodination of PcTx1 had minimal effects on its ability to inhibit ASIC1a108. Moreover, our 
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lab has conducted extensive structure-activity relationship studies showing that the N-
terminal region of PcTx1 is not involved in its interaction with ASIC1a104, 110.  
 
The potency of TyrN_PcTx1 was assessed using TEVC on X. laevis oocytes expressing 
rASIC1a. TyrN_PcTx1 was slightly less potent than WT PcTx1 on rASIC1a. The decline 
in potency was more pronounced for iodinated variants of the peptide (3–8 fold 
decrease), suggesting that additions to the N-terminus may affect peptide activity, 
contrary to co-crystal structures and MD studies showing that the N-terminus points 
away from the channel, and does not engage in channel interactions104. Moreover, 
electrophysiology experiments of other labelled PcTx1 variants with bulkier additions at 
the N-terminus were more potent than iodinated TyrN_PcTx1. Given these observations, 
it is possible that the stock concentration of the iodinated variants might have been 
overestimated based on UV absorbance. In support of this presumption, a positive 
correlation was observed in the absorptivity of tyrosine (at 280 nm) with increasing 
iodination254. This may have contributed to the erroneous quantification of the iodinated 
TyrN_PcTx1, thereby resulting in the subsequent underestimation of peptide activity. 
Nevertheless the iodinated TyrN_PcTx1 still potently inhibited ASIC1a, with an IC50 in 
the low nanomolar range.  
 
azPcTx1 was synthesised for site-specific N-terminal labelling with alternative imaging 
moieties via click chemistry. The triazole formed between an azide and alkyne is 
irreversible and chemically inert to reactive conditions (e.g. oxidation, reduction, and 
hydrolysis) thus ensuring the stability of the complex in an in vivo environment. As 
verified using mass spectrometry and TEVC, the various alkyne-activated imaging 
moieties (up to 2.3 kDa) were successfully attached to the azPcTx1 via CuAAC or 
SPAAC with minimal effects on its ASIC1a inhibitory activity. Electrophysiology 
experiments performed on both rASIC1a  and hASIC1a showed that all variants 
inhibited ASIC1a with low nanomolar potency. 
 
As an alternative to radioiodination, DOTA-conjugated variants of PcTx1 were produced 
to facilitate chelation of radiometals as PET tracers or lanthanides for magnetic 
resonance imaging. DOTA consists of a macrocyclic ring structure that functions as an 
octadentate ligand for chelating metal ions (especially lanthanide ions, Ln3+) through its 
four amine and carboxylate groups forming highly stable complexes with extraordinary 
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thermodynamic stability and kinetic inertness255. Peptide-DOTA complexes are 
commonly used in magnetic resonance imaging (gadolinium), nuclear imaging (indium-
111, gallium-68, copper-64/67), and as therapeutic radiopharmaceuticals (yttrium-90, 
lutetium-177)255. In an attempt to improve the sensitivity of PET or MR imaging, two 
azide-reactive DOTA tags were synthesised which could coordinate either one or four 
metal ions. The syntheses were achieved with high yield and purity. The DOTA tags 
were shown to coordinate one (Gd-DOTA) or four (4x-Gd-DOTA) gadolinium ions 
respectively, as verified using mass spectrometry.  
 
MRI was also explored as a potential complement to PET imaging, as it provides 
greater spatial resolution. Contrast in MRI is largely generated based on differences in 
proton (mainly water) relaxation. Gadolinium complexes are clinically used to enhance 
contrast in T1-weighted MRI by altering 1H relaxation properties, causing regions with 
higher concentration of the gadolinium complex to appear brighter. We hypothesised 
that the interaction with DOTA-Gd-azPcTx1 conjugates may also induce changes in 
relaxation properties in regions with higher peptide concentration, particularly in areas 
with high ASIC1a expression (e.g. brain), thus providing information regarding peptide 
uptake, localisation, as well as the distribution/relative expression levels of ASIC1a. 
There was an overall marked enhancement in r1 and r2 relativity of the DOTA-Gd-
azPcTx1 complexes as compared to azPcTx1. Moreover, the metallated PcTx1-DOTA 
complexes have higher r1 values (4.6–9.4 mM-1s-1) than clinically used MRI T1 contrast 
agents such as DOTAREM® (Gadoterate meglumine, Gd-DOTA, r1 of 3.9 mM-1s-1), and 
Magnevist® (Gadopentetate Dimeglumine, Gd-DPTA [diethylenetriaminepentaacetic 
acid], r1 of 4.1 mM-1s-1 at 9.4 T)256. However, the inherently low sensitivity of MRI 
(requiring high µM to mM concentrations for contrast), made the use of MR imaging for 
pharmacokinetics and biodistribution study impractical at this stage due to the high 
quantities of peptide conjugates necessary for statistical significance.  
 
4.4.2 Stability of PcTx1 
Assessment of thermal and metabolic stability is imperative prior to radiolabelling and in 
vivo experiments. As such, PcTx1 was incubated at high temperature (55oC) and in 
human serum or CSF to establish its stability profile under these conditions (Chapter 3). 
Oxytocin, a nonapeptide containing a single disulfide bond, was used as a comparison 
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as it is known to be relatively heat labile257. The thermal stability observed for oxytocin 
at 55oC (~40% remaining at 48 h) was in good agreement with published data258.  
 
The ICK scaffold is regularly claimed to provide high thermal stability and resistance to 
proteolytic degradation10, 13 and this has been demonstrated for several spider-venom 
ICK peptides12, 259. Surprisingly, PcTx1 was less stable than expected. A plausible 
explanation could be the highly dynamic and cationic nature of the β-hairpin loop of 
PcTx1104, which might enhance susceptibility to serum and CSF proteases. Curiously, 
Hm3a (a close homolog of PcTx1, described in Chapter 3), was more stable than 
PcTx1, with ~90% peptide intact after 48 h at 55oC. Based on sequence homology, it 
can be presumed that Hm3a has similar structural features such as the flexible β-hairpin 
loop. Thus, there may be other factors accounting for the differences in thermal stability. 
From an inspection of the amino acid sequences, a possible degradation-contributing 
site could be Asp2 of PcTx1, which is replaced by a proline in Hm3a. Aspartate is highly 
susceptible to isomerisation, forming intermediates such as isoaspartate (β-Asp). In 
support of this hypothesis, degradation products containing β-Asp were observed 
following incubation of the growth hormone–releasing hormone (GHRH) at 55oC in 
acidic solution260. Thus, at high temperature, the accelerated isomerisation of Asp2 in 
PcTx1 could result in the formation of side products, accounting for the loss of native 
peptide as observed on RP-HPLC. 
 
Metabolic stability is an important factor that affects a peptide's efficacy in vivo as there 
are a multitude of proteases and peptidases in plasma that could lead to degradation of 
the peptide261. Compared to thermal stress, PcTx1 was more resistant to metabolic 
degradation when incubated in human serum and CSF, with >76% of peptide remaining 
intact even after 48 h. Thus, it can be safely predicted that PcTx1 would remain largely 
intact throughout the course of the imaging study.  
 
4.4.3 Interaction with serum albumin  
It is common practice in in vitro functional studies to include some kind of protein in the 
physiological saline solutions in order to minimise adsorptive losses of peptide to plastic 
surfaces. Indeed, when PcTx1 is assayed using TEVC, the presence or absence of 
BSA has a dramatic effect on inhibition of rASIC1a at pH 7.45 (Supp. Fig. 4.1). In the 
context of understanding the pharmacokinetics of a drug lead, serum binding is an 
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Supplementary Figure. 4.1. Influence of BSA on PcTx1 inhibition of rASIC1a when tested at pH 7.45 (p 
< 0.001, F = 28.85). 
 
Serum albumin (66.5 kDa) is a monomeric, globular protein that is synthesised in the 
liver. It constitutes about 50% of serum proteins (35–50 g/L) and has an average serum 
half-life of ~19 days. Serum albumin is a multifunctional protein that is involved in the 
maintenance of oncotic pressure (type of osmotic pressure contributed by proteins), 
plasma pH, and transport of hydrophobic molecules such as hormones and fatty acids. 
Albumin is able to bind a wide variety of molecules via interactions with many different 
amino acid side chains262. Hence, it also binds to numerous drugs and metal ions and 
can act as a depot and transport vehicle for these molecules in the blood. Thus, albumin 
binding can be an important determinant of the pharmacokinetics of a drug as it 
influences the amount of “free” molecule that reaches its intended target263. It also has 
implications for the clearance of a drug from the blood264. In rats, IV administered 
analogs of the 39-residue anti-diabetic drug exenatide that contain albumin-binding 
domains (Kd of 8.2–18.3 nM for rat albumin) have extended plasma half-lives of 11–16 h 
as compared to 30 min for the wild-type peptide drug264. 
 
ITC experiments indicated that PcTx1 binds to BSA with a Kd of 9.96 µM. The 
interaction site on PcTx1 was mapped using NMR-CSM, which showed a massive 
diminution in the peak intensity of resonances from Arg26, Arg27 and Val32 with 
increasing BSA concentration. Changes in peak intensity, as opposed to chemical shift 
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perturbations, are typical for interactions with moderate affinity (µM range)265, which is 
consistent with the ITC results. Curiously, these residues are part of the pharmacophore 
of PcTx1 involved in its interaction with ASIC1a (Fig. 4.14). However, as PcTx1 binds to 
ASIC1a with low nanomolar affinity (Kd ~0.20–0.37 nM)108, the interaction between 
PcTx1 and BSA is unlikely to affect its intrinsic activity on the channel, as seen in TEVC 
experiments. However, the interaction of PcTx1 with serum albumin may improve its 
pharmacokinetic properties by extending its plasma half-life, reducing glomerular 
filtration and renal clearance263. 
 
 
Figure 4.14. Interaction between residues of the PcTx1 pharmacophore ((W7, W24, R26, R27 and F30) 
and Helix 5 of cASIC1 (figure from Saez et. al., 2015110). 
 
4.4.5 Pharmacokinetics of PcTx1 
A combined PET imaging and conventional ex vivo tissue sampling approach was 
undertaken to compare the pharmacokinetics and biodistribution of PcTx1 after IV and 
IN administration. Following IV administration, PcTx1 was largely eliminated through 
glomerular filtration based on the observed accumulation of peptide in the kidney and 
bladder. High radioactivity was also observed in the stomach, liver and thyroid. 
However, this is likely due to the dehalogenation and the high expression of the sodium-
iodide symporter (NIS) in these organs, resulting in the sequestration and accumulation 
of 124I (Ref. 266-267). The interaction between PcTx1 and serum albumin, as we observed 
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using ITC and NMR-CSM, may have contributed to its relatively long blood half-life 
(3.54 ± 0.22 %ID/g) and kidney half-life (5.28 ± 2.21 %ID/g). IV administration of PcTx1, 
even at a high dose of ~0.5 mg/kg, caused no obvious adverse side-effects (e.g., no 
sedation, paralysis or neurological symptoms), indicating that the peptide is likely to be 
well-tolerated with minimal toxicity issues. However, an important observation relevant 
to development of PcTx1 as a neuroprotective agent was that the peptide did not cross 
the BBB following IV administration, at least in healthy animals. 
 
IN administration of PcTx1 resulted in higher uptake in the brain as compared to IV 
administration.. The highest concentration of 124I-PcTx1 was found in the olfactory bulb, 
medulla and pons, corresponding to the entry points for the olfactory and trigeminal 
nerves, respectively. This indicates that the peptide is likely to travel along the olfactory 
and trigeminal nerve pathways to the brain following IN administration as previously 
discussed in Section 1.18 and illustrated in Figs 1.6 and 1.7. Although the level of 
brain uptake was quite low, the high potency of PcTx1 and its lack of systemic toxicity 
suggests that IN administration is a promising strategy for disorders in which brain 
ASIC1a is implicated, such as ischemic stroke. However, it remains to e determine 
whether IN administration of PcTx1 would provide sufficient peptide to the infarcted 
partial region of the brain to be therapeutically useful after stroke. Future imaging and 
biodistribution studies will be helpful in dissecting the uptake of IN administered PcTx1 
after ischemic stroke in which the BBB is also known comprised176. 
 
Based on the highest average uptake observed in the olfactory bulb (2.885 %ID/g or 
0.026 %ID/organ) with 5 µg of peptide administered via IN, the amount of the PcTx1 in 
the olfactory bulb will be ~1.3 ng. McCarthy et al. found that a single dose of PcTx1 at 
1 ng/kg administered ICV at 2 h post-stroke reduced brain infarct size in rats by 
~70%142; this roughly equates to 30 pg of PcTx1 needed for a 30 g mouse to achieve 
similar results. Hence, IN administration of 5 µg of peptide would be more than sufficient 
to induce similar therapeutic effects. Curiously, IN administration of crude “PcTx1 
venom” was shown to elicit ~50% reduction in infarct size when given to mice at 1–4 h 
post stroke141. In this latter study, 25 ng of “PcTx1 venom” was administered 
intranasally in mice141. Given that PcTx1 constitutes ~0.4 % of venom142, the amount of 
PcTx1 administered via IN (based on our results) would be ~0.1 ng, equating to 
~0.026 pg of peptide in the olfactory bulb, considerably less than the amount 
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administered via ICV. This indicates that the neuroprotective effect observed by 
Pignataro et al.141 was more likely due to a combined effect from other unknown 
components in the venom and not PcTx1 alone.  
 
Intranasal administration is a promising method for CNS drug delivery of peptidic 
molecules such as PcTx1. However, adsorption across the nasal epithelium is a major 
caveat for IN, severely limiting the uptake of drugs to the target site. Based on this 
study, only a small percentage (maximum of 2.83 %ID/g) was able to reach the target 
whilst most of the peptide remained in the nasal cavity even after extended periods of 
time (up to 220 min). There are numerous limiting factors that can influence nasal 
absorption. These include the presence of nasal mucociliary clearance mechanisms, 
metabolising enzymes, efflux transporters, and reduced availability due to absorption in 
to the circulation instead of the nasal epithelium268. In order to improve the low 
absorptivity across the nasal epithelium, several formulation strategies have been 
assessed (Table 4.5) 268. Such formulation strategies could be explored to improve 
uptake of PcTx1 (and other peptidic drug leads) to the CNS following IN administration.  
 
Table 4.4. Formulation strategies for improving absorption across the nasal epithelium268. 
Strategy Mechanism 
Nasal permeation enhancers 
• cyclodextrin 
• fusidic acid derivatives 
• Phosphatidylcholines 
• microspheres and liposomes 
• bile salts and surfactants 
• Increase in the membrane fluidity 
• Create transient hydrophilic pores, decreasing 
the viscosity of mucous layer  
• Opening of tight junctions in the epithelium 
Mucoadhesive 
• Mucoadhesive polymers (e.g. polyacrylic 
acid, carbopol, and carboxymethycellulose)  
• Mucoadhesive gel formulation  
• Enhances the nasal residence time of the drug 
molecule and hence enhances absorption and 
bioavailability 
Enzyme inhibitors 
• Various peptidease and protease inhibitors 
• Increase bioavailability of drug by reducing 
enzymatic degradation 
Particulate drug delivery system 
• Microspheres, nanoparticles, and liposome 
• Formulation with nasal permeation enhancers or 
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4.5 Conclusion 
This chapter described the development, production and characterisation of PcTx1 
variants with attached imaging moieties for complementary pharmacokinetics and 
biodistribution studies using advanced imaging techniques such as PET, NIRF and MRI. 
An azPcTx1 analog was synthesised and ligated with various imaging moieties via click 
chemistry methods. A recombinant TyrN_PcTx1 analog was successfully produced and 
radioiodinated. Based on TEVC characterisation of the PcTx1 variants, the various N-
terminal modifications had minimal effect on the intrinsic activity of PcTx1 on both rat 
and human ASIC1a. PcTx1 is moderately stable at high temperature, and in human 
serum and human CSF. PcTx1 also interacts with serum albumin with moderate affinity 
as demonstrated using ITC and NMR-CSM. 
 
We studied the pharmacokinetics and biodistribution of 124I-PcTx1 following IV and IN 
administration using PET/CT imaging. Rapid renal clearance, typical for small peptides, 
was observed following IV administration with the highest PET signal coming from the 
liver, kidneys and bladder. Uptake in the brain was low, as expected due to restricted 
access across the BBB. Significantly increased brain uptake of PcTx1 was achieved 
following IN administration as evident from PET/CT imaging and biodistribution studies. 
Radioactivity from the labelled peptide was observed in multiple parts of the brain, 
particularly the olfactory bulb and medulla pons, corresponding to the proposed uptake 
routes associated with the olfactory and trigeminal nerves. Radioactivity was also 
detected in several other parts of the brain including the frontal cortex, posterior cortex 
and cerebellum indicating possible wide spread distribution in the brain. Accumulation of 
the peptide in blood and peripheral organs also suggest systemic uptake.  
 
To the best of our knowledge, this chapter describes the first pharmacokinetic and 
biodistribution studies undertaken for a spider-venom peptide using a multimodal 
imaging approach. The information from this study will be valuable for the development 
of spider venom peptides as therapeutics. In particular, we have shown that IN 
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Final conclusion and future directions 
The ultimate aim of this thesis was to characterise spider venom peptides that could be 
developed as eco-friendly bioinsecticides or as therapeutic leads targeting ASIC1a.  
 
Development of OAIPs as bioinsecticides 
OAIP3 is one of five insecticidal peptides that were previously discovered through assay-
guided fractionation200. The insecticidal activity observed when the peptides were injected 
or fed has garnered commercial interest in their development as bioinsecticides. However, 
only OAIP1 had been characterised thus far; moreover, it was produced via chemical 
synthesis which is less pragmatic for commercialisation due to its high cost and limited 
scalability. In this work, I used a bacterial expression system for production of recombinant 
OAIP3 in sufficient yield and purity for further characterisation of the peptide. 
Heteronuclear NMR studies revealed that OAIP3 has a canonical ICK fold, which indicates 
that it is likely to be stable under stressful environmental conditions such as high 
temperature and the protease-rich gut environment of targeted insect pests. However, 
recombinant OAIP3 is less potent than WT OAIP3 when injected into mealworms which I 
attribute to the lack of C-terminal amidation in the recombinant peptide. Hence, production 
of amidated OAIP3 will be imperative for functional characterisation in future experiments. 
The peptide should also be tested against different target and non-target insect species 
from various orders such as Lepidoptera, Diptera and Hymenoptera to determine its 
phyletic specificity. It is also imperative to study its effect on vertebrates to identify 
potential toxicity liabilities as this is a major concern for insecticide development.  
 
From a biotechnology standpoint, the need for post-translational modification of a bioactive 
peptide would grossly increase the complexity and cost of production, rendering the 
compound less commercially viable. This is especially important for development of field-
applied insecticides given the large quantities required. Thus, methods to functionally 
mimic critical post-translation modifications should be explored, as previously described for 
mimicry of the C-terminal amidation in µ-TRTX-Hh2a224, in order to enhance the 
commercial viability of OAIP3 as a bioinsecticide. 
 
The establishment of an efficient method for production of recombinant OAIPs paves the 
way for future characterisation of other OAIPs, including deciphering their molecular 
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target(s). Whilst my initial study indicates that OAIP3 is not a good candidate for 
insecticide development, OAIP2, OAIP4 and OAIP5 remained to be characterised.  
 
Development of spider venom peptides as therapeutics 
Hm3a is a close homolog of PcTx1, sharing similar pharmacological profiles on ASICs and 
most likely having a very similar 3D structure. Despite these similarities, Hm3a is markedly 
more stable at high temperature and in the protease-rich environment of human serum. 
Through analysis of the peptide sequences, we hypothesised that the difference in stability 
might be due to the Asp to Pro mutation at position 2, removal of lysines, and incorporation 
of Pro at the C-terminal of Hm3a. Thus, future work should include mutagenesis of the 
aforementioned residues in PcTx1 to examine their influence on peptide stability. 
Comparing the structure of Hm3a and PcTx1 will also aid in the development of other 
therapeutically-relevant peptide analogues to improve their inherent stability.  
 
Despite the immense potential of spider venom peptides as therapeutics, particularly those 
with an ICK fold, very few studies have been undertaken to elucidate their 
pharmacokinetics and biodistribution properties. In this work, we used advance imaging 
and traditional tissue sampling to address this lack of information. In the interest of 
developing SVPs as therapeutics for stroke or other CNS diseases, we demonstrated a 
direct nose–to–brain delivery of PcTx1 via IN administration, bypassing the BBB. In 
contrast, minimal brain uptake was observed following IV administration, indicating that 
PcTx1 is unable to cross the BBB in healthy mice. The knowledge gained from this study 
is likely to be applicable to delivery of other venom-derived peptides targeting the CNS. 
 
The high potency of many SVPs make them well suited for IN administration. Although 
only modest brain uptake was observed following IN administration, an effective dose 
could be achieved relatively easily given the nanomolar potency of SVPs such as PcTx1. 
Notably, the majority of the IN-administered peptide remained in the nasal cavity and 
therefore it should be beneficial to explore formulation strategies designed to improve 
uptake of molecules across the nasal epithelium. 
 
A major caveat of PET or MR imaging is cost and the need for high technical expertise. 
Moreover, in the current PET study, high radioactivity was detected in the thyroid and 
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stomach, which is commonly associated with dehalogenation and sequestration of iodide 
in these organs, which could confound the biodistribution study. Thus, it will be crucial to 
determine the metabolic stability of the iodinated or labelled peptides for future 
experiments. From our study of PcTx1, clearance of peptide was evident within several 
hours. Thus, short-lived radioisotopes such as 18F instead of 124I might be more suitable for 
PET imaging of peptides for biodistribution studies.  
 
Overall, this thesis has demonstrated that spider venoms provide a huge source of 
bioactive peptides with biotechnological potential that could potentially be utilised for the 
development of novel agrochemical or therapeutic compounds. 
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